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The cardiovascular system
The circulation of blood was one of the landmark discoveries in medical history. Sir William 
Harvey (1578-1657) might be considered the founder of modern day cardiovascular 
physiology. He was the first to describe the circulation of blood following the contracting 
motion of the heart in the Exercitatio anatomica de motu cordis et sanguinis in animalibus 
(‘Concerning the motion of the heart and blood’, commonly known as De Motu Cordis).1 
Interestingly, Harvey’s ideas were introduced in a scientific era dominated by the church, 
where it was ‘believed’ for over 1,400 years that blood was produced in the liver and heart, 
being consumed in the muscles. His research and experiments laid the foundation of modern 
day knowledge on the cardiovascular system. The cardiovascular system consists of the 
heart and the blood vessels, and is responsible for the distribution of nutrients and oxygen 
throughout the body. During normal circulation, the heart contracts, resulting in the emission 
of blood out of the heart into the arterial blood vessels. After delivering nutrients and oxygen 
to the periphery, the deoxygenated blood, which now contains waste products and CO2, is 
transferred back to the heart, where it is re-oxygenated in the pulmonary circulation, before 
repeating its original circulation.
 
Atherosclerosis and the endothelium
Cardiovascular disease and morbidity are responsible for 45% of all deaths annually (more 
than 4 million people), being the leading cause of death in Europe.2 The principal contributor 
to the progression of cardiovascular disease is the process of atherosclerosis.3 It is of key 
importance to understand the development of atherosclerosis, which may be realised 
through exploring the artery wall itself. The wall of the artery consists of multiple layers; the 
intima (inner), media, and outer adventitial layer. Atherosclerosis represents the pathologic 
change, initially affecting the intima of arteries, that is characterized by the focal thickening 
of the sub-intimal space, often due to lipid accumulation.4 More specifically, when the arterial 
wall is damaged or dysfunctional, an inflammatory response occurs.3 Through continuous 
exposure to potentially detrimental stimuli, this response can become excessive, resulting 
in abnormal accumulation of white blood cells (leukocytes, foam-cells and macrophages), 
cholesterol and vascular smooth muscle cells in the sub-intima.5, 6 This subsequently can 
ultimately lead to pathologic narrowing and inadequate blood supply to the distal tissue. 
The earliest atherosclerotic lesions are commonly seen in the intima of major vessels in 
childhood or adolescence.7 Several known risk factors contribute to the development of 
accelerated atherosclerosis, such as hypertension, hypercholesterolemia, diabetes, smoking, 
and inactivity.5, 6, 8-18
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Endothelial function and dysfunction
The inner layer of the vascular wall is lined with endothelial cells. Whilst the endothelium 
plays several physiological roles, maintenance of the adhesive properties (i.e. platelet 
activation and inhibition) and vascular tone (i.e. by maintenance of blood flow) are of most 
clinical interest.5, 6, 19 Furchgott and Zawadzki demonstrated that endothelial cells were 
responsible for the production of an endothelium-derived relaxing factor (EDRF).20 This 
Nobel prize winning research eventually resulted in the identification of endothelium-derived 
nitric oxide (NO),21 an important contributor to several physiological processes, including 
maintenance of the vascular tone.20, 22, 23 The release of NO depends on a variety of stimuli, 
including increased blood flow and consequent shear stress, which transduces vasodilation 
mediated by vascular smooth muscle cell relaxation.23-26 When the endothelium dysfunctions, 
the vascular tone and adhesive properties can be disrupted. This may predispose arteries 
to enhanced responses to vasoconstrictor substances, platelet aggregation to the vascular 
wall and, eventually, the process of plaque formation.22, 23 Endothelial dysfunction is an early 
manifestation of atherosclerosis, which precedes structural signs of vascular alteration.3, 6, 27 
This makes the endothelial dysfunction an important target for early intervention in efforts 
focussed on CVD prevention.14 
Whilst the process of atherosclerosis occurs throughout the body, the coronary circulation is 
particularly susceptible to the development of endothelium dysfunction. Studies have shown 
that intracoronary infusion of acetylcholine, a potent endothelium-dependent vasodilator, 
can induce paradoxical vasoconstriction in the coronary arteries, implying the presence of 
endothelial dysfunction.28-31 Such constriction occurs in patients with established CVD, but 
also in individuals with angiographic ‘normal’ coronary arteries who may be at high risk 
of future atherogenic development. Indeed, coronary artery responses to acetylcholine 
strongly predict the occurrence of future CV events. These findings highlight the key role of 
the endothelium in atherogenesis and CVD progression. 
Measuring vascular function and health in humans
Developing and validating reliable techniques to measure vascular health with strong, 
independent, predictive capacity for future cardiovascular disease, represent the Holy Grail.19 
In the past, several tests have been developed and tested. Some of the most commonly used 
tests will be discussed below (Table 1). 
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Table 1. Advantages and disadvantages of different vascular tests
Technique Vascular bed Advantages Disadvantages Stimulus
Coronary 
angiography
Epicardial 
conduit arteries
•  Direct assessment of 
coronary vascular bed
• Invasive Acetylcholine
•  Functional and 
structural assessment
• Time consuming Cold pressor 
test
• Golden standard • Expensive
  • Difficulty in 
performance
 
Intima-media 
thickness
Peripheral 
conduit 
arteries, often 
carotid or aorta
• Non-invasive • Structural assessment
•  Surrogacy of coronary 
structure
• Dependent on plaque
• Easy to perform •  Added clinical value 
unknown
  • Quick test  
Pulse-wave 
velocity
Aorta and 
peripheral 
arteries (e.g. 
radial artery)
• Non-invasive •  Limited evidence in 
periphery
propagation 
of systolic 
wave
•  Surrogacy for coronary 
function (aorta)
• Reliability uncertain
• Functional assessment
Flow-
mediated 
dilation
Peripheral 
conduit 
arteries, often 
brachial artery
• Non-invasive • Technically challenging NO-release
•  Surrogacy of peripheral 
arteries for coronaries
•  Large between-study 
variability
Shear
•  Inconsistency in FMD 
value
Carotid artery 
reactivity
Carotid artery • Non-invasive • Physiology unknown Cold pressor 
test
•  Surrogacy for coronary 
function
•  literature reliant on 
coronaries
• Easy to perform
  • Quick test  
Adapted from Flammer et al.32
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Coronary structure. In examining coronary artery disease (CAD), especially in the suspicion of 
(partial) stenosis, direct assessment of coronary artery structure is the commonly adopted 
approach. Serendipitously, Mason Sones Jr. was the first to perform coronary catheterization. 
Whilst attempting to perform cardiac catheterization, but mistakenly inserted the catheter 
in the right coronary artery.33 Together with the findings of Drs. Judkins34 and Amplatz,35 
radiologists who gained access to the left ventricle through percutaneous techniques via the 
femoral artery, Sones laid the foundation for the current coronary angiography technique. 
Coronary angiography uses the infusion of contrast dye following coronary catheterization, 
with simultaneous X-ray pictures to visualise the coronary arteries. This allows for the 
detection of blockages in the coronary circulation that are the result of lesions and 
atherosclerotic plaques. This procedure is regarded as the gold standard in assessment of 
the coronary anatomy, as it accurately defines the extent of coronary luminal obstruction.36 
However, using coronary angiography as a ‘screening tool’ is not prudent, nor cost-effective 
in clinical populations.36, 37 Additionally, coronary angiography is limited in its ability to define 
the aetiology of the obstruction,36 and lacks representation of the coronary functionality. 
Coronary function. When the invasive coronary angiography technique is combined with 
infusion of different substances (e.g. acetylcholine, a potent endothelium-dependent 
vasodilator, or adenosine, nitroglycerin, or papaverine, all endothelium-independent 
dilators), functionality of the coronary endothelium can be assessed.38-41 This procedure 
is commonly regarded as the gold standard technique to examine coronary endothelial 
function, since it independently predicts acute CV events in patients both with and without 
CAD, providing strong prognostic value.38, 41-43 Nonetheless, the potential limitation associated 
with coronary infusion is the increased risk for complications, involving bleeding, infections, 
and blood vessel damage. Using coronary infusion on a large scale to assess the risk for CVD 
is ill-advised, due to its invasiveness, costs, difficulty in performance and it is time consuming. 
Peripheral structure (intima-media thickness). Based on the invasive nature of intra-coronary 
drug infusion and the difficulty of measuring coronary artery function, several studies 
have explored the potential clinical value of measuring peripheral conduit artery function 
and structure.7, 44 Previous studies have shown a good agreement between peripheral and 
coronary arteries, and, therefore, peripheral arteries have be used as a surrogate for coronary 
arteries.25, 44-46 
In 1986, Pignoli was the first to describe the possibility of non-invasively imaging atherosclerotic 
lesions in peripheral arteries (e.g. the common carotid artery and the aorta) using B-mode 
imaging.47 Since then, numerous studies have demonstrated that the common carotid artery 
intima-media thickness (cIMT) is a strong predictor for future cardiovascular events,48-50 and 
that it relates to the development of coronary artery disease.51-53 Unfortunately, measuring 
the cIMT relies heavily on the presence of carotid plaques, and according to recent studies, 
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plaque measurements alone add to CVD risk prediction, and are independent of IMT 
measurements.54, 55 Accordingly, it remains unclear to what extent the cIMT measurement 
is of added clinical value to risk stratification in individuals free from CVD.56-59 Nonetheless, 
this easy, quick, non-invasive test remains a popular test in studies on cardiovascular health. 
Peripheral structure/function (aortic stiffness and pulse-wave velocity). Other tests to 
examine peripheral vascular health relate to the stiffening of the arteries. Stiffening of the 
larger arteries is believed to reflect both structural characteristics of the vessel wall, but also 
functional aspects of artery health. Stiffness of the cardiovascular system can be assessed 
locally in an individual artery (i.e. stiffness) or across a vascular bed (i.e. pulse wave velocity). 
Assessment of stiffness entails measuring the arterial diameter across the cardiac cycle (i.e. 
difference between systole and diastole), which is related to the pulse pressure, leading to 
an arterial diameter change for a given increase in (blood) pressure.60 The aorta is of great 
interest in determination of regional stiffness, since the aorta makes the largest contribution 
to the arterial buffering function. The buffering capacity of the aorta is an independent 
predictor of outcome in a variety of populations, such as hypertensive patients and patients 
with higher cardiovascular risk.61-63 
Pulse-wave velocity is the most common and generally accepted measurement of arterial 
stiffness, a measurement based on the velocity of blood from the heart to a peripheral 
artery.61 When the heart contracts, the systolic blood wave propagates through the aorta 
into the periphery, transitioning from large elastic vessels to the smaller muscular periphery. 
When the vasculature becomes stiffer, blood will travel faster through arteries as the vessels 
are less able to dampen down the kinetic energy from the pressure wave. This is measured 
using the pulse-wave velocity (PWV), a non-invasive test.64 It was suggested that measuring 
vascular health of the aorta and larger vessels could function as a surrogate for early 
detection of coronary artery dysfunction.65 PWV is associated with CV mortality, and predicts 
future development of CVD, in both patients at risk for CVD and the general population.66-71 
Unfortunately, the pulse wave velocity is relatively often studied in the aorta, despite the 
importance of measuring PWV along the entire arterial tree.72 Additionally, several risk 
factors, such as age and an increased heart rate,72, 73 can influence PWV measurements. There 
is still uncertainty regarding the reliability of PWV assessment in treatment evaluation and 
risk prediction,72, 74 but PWV may indeed add predictive capacity.66 The role of PWV remains 
to be further elucidated. 
Peripheral function (flow-mediated dilation). Functional alterations in the vascular 
endothelium precede structural changes, which denotes the protective role of a functionally 
intact endothelium.6 Several studies have elucidated the importance of functionally intact 
endothelium in vasomotor responses to increases in flow and shear.25, 26 Functional intact 
endothelium results in vasodilatory responses of coronary arteries following an increase 
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in blood flow, whilst the presence of atherosclerosis or risk factors impair flow-mediated 
responses in the coronary circulation.31, 75, 76 In 1992, Celermajer et al. introduced the flow-
mediated dilation (FMD), which encompasses non-invasive ultrasound imaging of the brachial 
artery in response to hyperaemic flow following a brief period of limb occlusion.7 This reactive 
hyperaemic flow triggers endothelial cells to produce NO, which in turn results in relaxation 
of the smooth muscle cells in the vessel wall, causing dilation.77 In case of endothelial 
dysfunction, NO production and/or bioavailability becomes impaired, resulting in an impaired 
dilation in those at risk for cardiovascular disease.7 Based on these early observations of the 
presence of vasodilation following elevation in endothelium-dependent flow in both coronary 
and the brachial artery,25, 44-46 studies have explored whether peripheral artery responses can 
be used as a surrogate for coronary vessels. Takase et al. examined the possible surrogacy 
of the brachial artery, by directly evaluating coronary (following coronary angiography) and 
brachial artery responses to a similar stimulus (i.e. increase in blood flow and shear stress), 
demonstrating a strong relation between both arteries,46 similar to others.44 The past 25 
years, the FMD has become a popular technique to examine vascular function in clinical 
studies.  Numerous studies indicate that FMD provides independent prognostic information, 
exceeding the predictive value of traditional risk factors,78-84 whilst a more modest association 
is found in asymptomatic subjects.83, 85 Nevertheless, a recent comparison of different tests 
for vascular health in a large cohort of patients at intermediated risk, showed that FMD failed 
to improve discrimination and risk classification, while FMD reproducibility was quite low in 
this specific study.86 Minor adjustments in methodology can critically impact the variation and 
reproducibility, and whilst clear, stringent methodology and guidelines for valid assessment 
are available,19, 84, 87 variation in FMD remains. Therefore, a final judgement on the potential 
prognostic value of the FMD remains unclear.
Peripheral function (carotid artery reactivity). Whilst the FMD is strongly linked to blood flow 
(e.g. shear stress) mediated changes in artery diameter, several other stimuli are known to 
impact the vasculature. One example is activation of the sympathetic nervous system (SNS).41, 
88 The coronary circulation is highly responsive to sympathetic activation (e.g. following a 
cold pressor test, the immersion of a limb in an ice-bath, CPT), leading to either vasodilation 
or vasoconstriction, presumably dependent on the integrity of the endothelium.28, 31 
More specifically, vasodilation is typically observed in healthy arteries, whilst paradoxical 
vasoconstriction is found in irregular arteries with clear presence of atherosclerosis.28, 89-92 
Interestingly, following the cold-pressor test, the coronary arteries behave similarly to the 
intra-coronary infusion of acetylcholine, the gold standard for coronary artery function.28, 
31 Schächinger et al. demonstrated in 147 patients undergoing routine diagnostic following 
chest pains, that in accordance with the acetylcholine induced coronary responsiveness, the 
CPT-induced response of the coronary arteries holds strong independent predictive value for 
future cardiovascular disease.40, 87 
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Several studies have explored the response of the peripheral vasculature to SNS activation, 
resulting in conflicting observations without clear evidence that the peripheral arteries are 
highly responsive to SNS stimulation.93-98 This suggests poor agreement between peripheral 
and coronary arteries in response to the CPT. In 2000, Rubenfire et al. studied patients at 
risk for CAD and patients with established CAD, and the vasomotor responses following 
CPT, whilst measuring the carotid artery. Interestingly, the carotid artery, a easily accessible 
artery, demonstrated marked vasomotor responses to SNS activation.99 More specifically, it 
was demonstrated that the carotid artery, similar to the coronary arteries, dilates in healthy 
volunteers, whilst this dilation was absent or even reversed into constriction in the presence 
of coronary artery risk factors and/or disease. To date, no previous study explored the possible 
agreement of coronary and carotid artery responses to the CPT, nor was the potential clinical 
value of the carotid artery reactivity to assess coronary risk examined. 
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Outline of this thesis
Aim of the present studies
Measurement of the endothelial function of coronary arteries is a strong predictor for future 
cardiovascular events. Several studies have explored strategies to measure (peripheral) 
vascular health to understand the process of development of CVD, but also for early detection 
of endothelial dysfunction and identification of increased risk for future CVD. The overall aim 
of my thesis is to explore and improve measures of vascular endothelial function. First, I 
explored sources of variation in the FMD test. This work was performed to improve current 
guidelines. Secondly, I focussed on developing an alternative method of measuring endothelial 
function, the carotid artery reactivity (CAR). This work includes exploring the agreement of 
the CAR with coronary artery function, the underlying mechanisms and potential prognostic 
value.
In part one of this thesis, I specifically focus on measuring the endothelial function with 
brachial artery flow-mediated dilation. Although the FMD has been used frequently, the 
measurement is susceptible to a variety of subject-related and methodological factors 
influencing its variability. While previous studies have set a specific set of guidelines for the 
measurement,84, 87 minor changes in methodological approach may critically impact the 
variability and reproducibility of the measurement. 
Chapter 2 describes the identification of subject- and methodology related factors that 
contribute to the variation of the brachial artery FMD in a large group of individuals. 
Accounting for these factors improves reproducibility of the FMD, providing a more accurate 
measurement of vascular function, reducing measurement error and increasing the power 
of studies that adopt the FMD. To further explore the importance of adherence to expert 
guidelines to assess the FMD, Chapter 3A depicts the relation between adherence to the 
current guidelines and reproducibility of the FMD. Furthermore, we examined which subject- 
and/or methodology-related factors were associated with the reproducibility of the flow-
mediated dilation measurement. Chapter 3B demonstrates the methods of data acquisition 
for this study, while in Chapter 3C we provide additional support for our statistical analyses. 
As impairment of coronary artery blood flow and endothelial function characterizes the 
development of cardiovascular disease, early detection of endothelial dysfunction remains of 
utmost importance. A strong prognostic stimulus in assessing coronary function is activation of 
the sympathetic nervous system. Sympathetic activation can result in either a vasoconstrictive 
or vasodilatory response of coronary arteries, presumably dependent on the integrity of the 
endothelium. Part two of this thesis focusses on developing and validating a new test, which 
serves as a surrogate for coronary artery responses to sympathetic stimulation. I explore the 
potential value of the carotid artery reactivity (CAR) test. The carotid artery demonstrates 
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similarity with coronary artery responses to a sympathetic stimulus (i.e. a cold pressor 
test), with a clear vasodilation in both arteries in healthy subjects, whilst this reverses to 
constriction in those with CV risk factors and/or disease. This similarity in response to the 
cold pressor test between coronary and carotid arteries is further examined in Chapter 4. 
Furthermore, in this chapter we also assess the relation between the CAR and cardiovascular 
risk factors. In Chapter 5 we continue to explore the CAR and we specifically focus on the 
potential underlying mechanisms mediating the CAR test. First, we explore the responses of 
the carotid artery to different types of sympathetic stimuli (i.e. the cold pressor test and the 
lower body negative pressure test). We also examine the underlying mechanisms mediating 
the vasomotor response by pharmaceutically blocking the α1 receptors, which are believed 
to be responsible for vasoconstriction during sympathetic activation. In addition, potential 
similarity between the carotid and coronary artery responses to both stimuli, are examined. 
Finally, in Chapter 6 we investigate the potential clinical value by examining prognostic value 
of the CAR in patients with peripheral arterial disease for the 1-year development of CV 
events and progression of disease.
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Methods applied in this thesis
To examine endothelial function of both the peripheral and central arteries (the brachial, and 
the carotid and coronary arteries, respectively), vascular structure and different sympathetic 
stimulation tests, we used different techniques. These different methods will be explained in 
this section. In accordance with previous set guidelines for vascular ultrasound assessment, 
all participants attended our measurements in fasted (>6 hours) state, and were instructed 
to abstain from products high on vitamin C, caffeine, and alcohol (>18 hours), and to not 
perform strenuous exercise for at least 24 hours.
Brachial artery flow-mediated dilation (FMD). Participants were asked to extend the scanned 
arm at an angle of ~80 degrees from the torso, following a short (10-15 minutes) resting 
period in supine position. A rapid inflation and deflation pneumatic cuff (Hokanson, Bellevue 
(Washington), USA) was positioned on the forearm of the imaged arm distal to the olecranon 
process to provide a stimulus of forearm ischemia. With an ultrasound system, B-mode 
images of the brachial artery in the distal third of the upper arm (above the antecubital fossa 
in the longitudinal plane) were made. When an optimal image was obtained, the ultrasound 
probe was held stable (manually or by using a clamp) and ultrasound parameters were set 
to optimise the longitudinal B-mode image. At least one minute of baseline diameter was 
recorded, after which the pneumatic cuff was inflated to at least 50 mmHg above systolic 
pressure to occlude arterial inflow for 5 minutes of occlusion. Subsequent cuff deflation 
induced a brief high-flow (hyperaemic) state that increased wall-shear stress at the brachial 
artery, causing it to dilate. To assess flow velocity, a mid-artery pulsed Doppler signal was 
obtained during the protocol. 
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Figure 1. FMD set-up
Panel A shows FMD set-up, with occlusion cuff  on the lower arm, and conti nuous assessment of brachial 
artery diameter and velocity. Panel B demonstrates the wall-tracking soft ware. The red bars represent 
the calibrati on bars. The yellow boxes indicate the region of interest, and the edge-detecti on feedback. 
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Carotid artery intima-media thickness (cIMT). Carotid artery intima-media thickness (cIMT) is 
assessed after a 15 minute rest in supine position. We assessed the baseline resting diameter 
and wall thickness of the left common carotid artery, approximately 2 cm proximal to the 
bulbus. The images were optimized by using contrast controls on an ultrasound machine 
(T3000, Terason, Burlington (Massachusetts), USA), and parameters were set to optimize the 
B-mode images of the lumen-arterial wall interface. We recorded the IMT continuously for 10 
seconds, in 2 different perpendicular planes (differing 90°).  From the 2 measurements wall 
thickness was calculated. 
Carotid artery reactivity (CAR). Participants were positioned with the neck extended to 
allow for assessment of the left common carotid artery. Diameter and red blood cell velocity 
were recorded continuously during baseline and the sympathetic test with a 10-MHz linear 
array handheld probe attached to a high resolution ultrasound machine (T3000, Terason, 
Burlington (Massachusetts), USA). When an optimal image was found, the probe was held 
stable and the ultrasound parameters were set to optimise the longitudinal, B-mode image 
of the lumen-arterial wall interface. Continuous pulsed wave Doppler velocity assessments 
were also obtained and were collected at the lowest possible insonation angle (always <60º). 
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Figure 2. CAR set-up
Panel A demonstrates the CAR set-up, with concomitant echo-Doppler assessment of the caroti d artery 
and a left  hand cold pressor test (ice-slush ≤4ºC). Panel B shows the conti nuous assessment of the 
caroti d artery, using wall-tracking and edge-detecti on soft ware. Panel C shows a dilatory response 
during 1; the baseline assessment, and 2; 3-mintues of CPT test. 
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Coronary artery responses. Before and during sympathetic stimulation, the left anterior 
descending (LAD, cm) coronary artery velocity was examined using transthoracic ultrasound. 
This assessment was performed simultaneously with the assessment of the common carotid 
artery diameter and velocity responses. All echocardiographic measurements were collected 
by trained sonographers on a commercially available ultrasound system using a transducer 
(Chapter 4; Vivid Q, GE Medical, Horten, Norway, with a 4 MHz phased array and Chapter 
5; Vivid E9; GE, Fairfield, CT, with a broadband M5S 5 MHz or a 3V 3D-array transducer). 
Participants assumed a left lateral position to allow for data collection. The LAD was imaged 
using a modified parasternal short axis view from the fourth or fifth left intercostal space, and 
was assessed using pulsed-wave Doppler. The transducer was positioned such that a 2- to 
3-mm segment of the LAD was imaged along the long axis, taking care to align the pulse-wave 
cursor with the length of the vessel. With a sample volume (2.0 mm) positioned over the 
colour Doppler signal in the LAD, measurements of the LAD velocity were collected during 
the sympathetic tests.
Sympathetic stimulation - cold pressor test. The cold pressor test (CPT) consisted of a 3-minute 
immersion of the left hand in a bucket of ice slush (~4.0 ºC). The participant was positioned 
supine on a comfortable bed, facilitating arm movement of the left hand into the bucket 
of ice slush without significant movement of the neck to enable assessment of the carotid 
artery. After a 1-minute baseline period, the participant immersed the hand up to the wrist in 
the ice slush for 3 minutes. The participant was instructed not to speak and breathe normally 
(to prevent hyperventilation) when the hand was submerged into the ice slush.
Sympathetic stimulation - lower body negative pressure test. The participant was positioned 
in the supine position on a tilt bed, and strapped into a custom-made airtight, lower-body 
suction chamber at the level of the iliac crest.100 The lower body negative pressure (LBNP) 
chamber was then moved from supine position into a left lateral position (~25-30°) to ensure 
concurrent adequate coronary imaging. The LBNP test consisted of a 5-minute baseline, 
followed by progressive 2-minute stages, using increments of -10 mmHg, to -80 mmHg 
or until pre-syncope.  LBNP was terminated when a) pre-syncope, defined by a sustained 
drop in systolic blood pressure <80 mmHg for more than 10 seconds,101 occurred, or b) on 
participants request due to the onset of subjective symptoms (e.g. feelings of dizziness, 
nausea, faintness). 
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Flow-mediated dilation
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Abstract
Objectives. Brachial artery flow-mediated dilation is a popular technique to examine 
endothelial function in humans. Identifying subject- and methodological factors related 
to variation in flow-mediated dilation is important to improve measurement accuracy and 
applicability.
Methods. Subject- and methodology-related parameters were collected in 672 subjects from 
8 affiliated centres world-wide who underwent repeated measures of flow-mediated dilation. 
All centres adopted contemporary expert-consensus guidelines for flow-mediated dilation 
assessment. After calculating the coefficient of variation (%) of the flow-mediated dilation 
for each individual, we constructed quartiles (n=168 per quartile). Based on 2 regression 
models (1.Subject-related factors, 2.Methodology-related factors), statistically significant 
components of these two models were added to a final regression model (calculated as 
β-coefficient and R2). This allowed us to identify factors that independently contributed to 
the variation in flow-mediated dilation%. 
Results. Median coefficient of variation was 17.5%, with healthy volunteers demonstrating 
a coefficient of variation of 9.3%. Regression models revealed age (β=0.248, P<0.001), 
hypertension (β=0.104, P<0.001), dyslipidaemia (β=0.331,P<0.001), time between 
measurements (β=0.318, P<0.001), lab experience (β=-0.133, P<0.001) and baseline flow-
mediated dilation% (β=0.082, P<0.05) as contributors to the coefficient of variation. After 
including all significant factors in the final model, we found that time between measurements, 
hypertension, baseline flow-mediated dilation%, and lab experience with flow-mediated 
dilation independently predicted brachial artery variability (total R2=0.202). 
Conclusions. Whilst flow-mediated dilation% showed good reproducibility, larger variation 
was observed in conditions with longer time between measurements, hypertension, less 
experience and lower baseline flow-mediated dilation%. Accounting for these factors may 
improve flow-mediated dilation% variability.
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Introduction
Cardiovascular disease remains the world’s leading cause of morbidity and mortality. 
Previous studies have provided convincing evidence that endothelial dysfunction is an early 
manifestation of cardiovascular disease,1, 2 contributing to development and/or acceleration 
of the atherosclerotic process. Based on the detrimental role of endothelial dysfunction in 
this common disease process, studies have attempted to develop and validate (non-invasive) 
methods and biomarkers to assess endothelial function in humans. The conceptual idea 
is that identification of endothelial dysfunction, in symptomatic as well as asymptomatic 
subjects, is related to increased risk for future development of cardiovascular events.3, 4
A frequently-used, non-invasive technique to examine endothelial function in humans in vivo 
is flow-mediated dilation (FMD).5 This measurement adopts high resolution ultrasonography 
to measure the conduit artery diameter dilatation in response to marked elevation in blood 
flow (and therefore shear stress) after a 5-minute period of distal limb ischemia.6 Studies have 
provided evidence that the FMD-response is endothelium-dependent7 and largely mediated 
by nitric oxide,8 an important and potent vasodilator and anti-atherogenic molecule. The 
measurement of endothelial function using FMD has become popular in clinically-orientated 
studies, likely because of its non-invasive nature, ability to predict cardiovascular events4, 9-11 
and correlation to coronary artery endothelial function.2, 12 
Despite its valid conceptual basis, a number of factors influence the variability of FMD.13, 
14 Previous studies found that FMD is influenced by lifestyle factors (e.g. smoking, physical 
activity), methodology (e.g. cuff placement, duration of ischemia), intake of food and 
beverages, hormonal changes, and method of analysis.8, 11 Although many of these factors are 
currently being controlled for through adopting expert-consensus guidelines,11, 15 variation in 
FMD remains. These sources of variation may be subject-and/or methodology-dependent, 
but this has not yet been systematically studied. Identification of such factors will contribute 
to the control of measurement error, which will help to appropriately power studies and aid 
in the construction of rigorous and standardized guidelines.11, 16
The purpose of this study was to identify subject- and methodology-related factors that 
contribute to FMD variation in humans.  To this end, we combined data from previous studies 
(from 8 research centres) that performed repeated measurements within-subjects of brachial 
artery FMD in a total of 672 individuals. All included studies were performed according to 
expert-consensus guidelines.11 Subsequently, we assessed subject- and methodology-related 
factors that contributed to brachial artery FMD variability.  
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Methods
Study population 
The International Working Group on Flow-Mediated Dilation (IWG-FMD) originates from eight 
different research groups in four different countries. All groups provided written consent to 
contribute their data. We compiled subject-level data from all participating research centres 
(see supplementary list), including a total of 19 different studies. All affiliated researchers 
provided details on methodology of included studies in a specifically designed questionnaire. 
These details were cross-checked with earlier published and/or unpublished data. All centres 
received an outline of the datasheet, to enhance sufficient and complete data collection. A 
total of 84 parameters were explored. Data from a total of 672 individuals with measurement 
of the brachial artery FMD, assessed on at least two separate occasions, obtained by B-mode 
ultrasound systems were available for data analyses. When studies included more than 
one repeated measurement, only the first and second measurement were included prior 
to statistical analyses. All subsequent repeated measurements were rejected, to prevent 
distortion included parameters. 
Brachial artery flow mediated dilation measurements: methodological considerations
We included data from participants whose FMD data were collected on 2 separate occasions 
without an intervention between both measurements. These measurements were limited 
to the brachial artery (measurements of e.g. the radial-, femoral or popliteal arteries were 
excluded), in either the right or left arm (consistent for both measurements). To examine 
brachial artery FMD, participants extend the scanned arm following a short (10-15 minutes) 
resting period in the supine position. A rapid inflation and deflation pneumatic cuff was 
positioned on the forearm of the imaged arm distal to the olecranon process to provide a 
stimulus of forearm ischemia.11, 15 With an ultrasound system, B-mode images of the brachial 
artery in the distal third of the upper arm (above the antecubital fossa in the longitudinal 
plane) were made. When an optimal image was obtained, the ultrasound probe was held 
stable (manually or by using a clamp) and ultrasound parameters were set to optimise the 
longitudinal B-mode image. At least one minute of baseline diameter was recorded, after 
which the pneumatic cuff was inflated to at least 50 mmHg above systolic pressure to 
occlude arterial inflow for a standardised length of time (i.e. standardised time of 5 minutes 
of occlusion). Subsequent cuff deflation induced a brief high-flow (hyperaemic) state that 
increased wall-shear stress at the brachial artery, causing it to dilate. To assess flow velocity, 
a mid-artery pulsed Doppler signal was obtained during the protocol.11, 15 Whilst all study 
centres used slightly different protocols to collect the repeated FMD measurements, all 
followed the above described expert-consensus guidelines.
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Different types of ultrasound systems were used across the different centres, including; 
TerasonT3000 (Terason, Aloka, United Kingdom; 10-MHz multifrequency linear array 
transducer, n=136), Sonos 5500 (Hewlett-Packard, 7.5-MHz linear array transducer, n=20), 
ESAOTEMyLab25 (ESAOTE, Florence, Italy; 10-MHz linear array transducer, n=54), ESAOTE 
Picus Just 4D (ESAOTE, Maastricht, the Netherlands, 7.5-MHz linear array transducer, 
n=60), ESAOTE MyLabTM70 (ESAOTE, Maastricht, the Netherlands; 7.5-MHz linear array 
transducer, n=51), VIVID E9 (VIVID E9, General Electric, Waukesha, WI, USA, 15-MHz linear 
array transducer, n=109), AU5 Armonic system (ESAOTE, Florence, Italy; 7.0-MHz linear array 
transducer, n=136). One included study is a multi-centre study consisting of 7 sub-studies, 
which used a range of devices (ESAOTE, Philips, Siemens and General Electric, 7.5-10 MHz 
linear array transducer, n=110). 
All studies used (semi)automatic analysis software. However, different software was used 
across the centres:(1) Custom made MyFMD software, V2012.2, Prof. A.P.G. Hoeks, Department 
of Biomedical Engineering, Maastricht University, Maastricht, the Netherlands (n=130); (2) 
Custom made software,17 Pisa, Italy (n=135); (3) Custom made DICOM software for edge-
detection (n=135)18, 19; and (4) FMD Studio, Cardiovascular Suite, ClinicalPhysiology, National 
ResearchCouncil, Pisa, Italy (n=272).20, 21 All centres collected continuous measurements of 
the diameter and recorded these (on either VCR or digitally) for post-study analyses. No study 
used fixed time points for diameter estimation.
Sources of variation
Our primary outcome parameter was the variation between both FMD measurements, 
for which we calculated the coefficient of variation (CV) for each individual’s repeated 
measurements, calculated as [(sdFMD/meanFMD)*100]. Furthermore, we recorded FMD 
(%), baseline diameter (cm), maximal diameter (cm), and time between measurements 
(categorized in <24h, 1-7 days, 8-14 days, 2-4 weeks, or >4 weeks). 
Measurement of subject-related factors. We included the following subject-related factors, 
that were all presented using a continuous scale; age (inclusion ≥18 years, range 18-82 years); 
weight (range 45-171 kg); height (range 1.55-1.94 m); body mass index (calculated as weight 
(kg)/ height2(m), range 17.6-55.8kg/m2); systolic- and diastolic blood pressure (in mmHg) 
and calculated mean arterial pressure [MAP, calculated as (2*diastolic pressure + systolic 
pressure) / 3, range 64-139 mmHg]; and blood-specific parameters (i.e. total cholesterol; high 
density lipoprotein, HDL; low density lipoprotein, LDL; triglycerides; glucose; all in mmol/L). 
All original parameters were rescaled to the same metric or most frequently used units (i.e. 
cholesterol and glucose values converted from mg/dL to mmol/L).22
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We also presented subject-related factors using categorical scales: sex (male/female); 
presence of hypertension (conform current guidelines defined as: systolic pressure ≥140 
mmHg and/or diastolic pressure ≥90 mmHg, or using blood pressure-lowering drugs, yes/
no); the presence of diabetes (type 1 or type 2); smoking status (yes/no/history of smoking); 
presence of dyslipidaemia (yes/no, as specified by each contributing centre), and history and/
or presence of cardiovascular disease (CVD). 
Measurement of methodology-related parameters. All assessments followed the expert-
consensus FMD guidelines, ensuring that the protocol involved cuff placement around the 
forearm, occlusion for 5-minutes and cuff inflation ≥50 mmHg above systolic pressure. 
Furthermore, we assessed the following factors; use of a probe holder (yes/no); lab experience 
(total number of peer-reviewed publications that included measurement of FMD from 
contributing principal investigator through a Pubmed-based search using the search term 
“[author] AND flow mediated dilation”); mention of the laboratory’s own reported coefficient 
of variation (mentioned as CV% reported); use of continuous and/or ECG-gated diameter 
recording; measurement of artery diameter across the cardiac cycle; and the time between 
measurements (<24h, 1-7 days, 8-14 days, 2-4 weeks, and >4 weeks). The Supplementary 
material provides details of the questionnaire used to assess these factors.
Missing values
Since missing data were present for all of the 82 individual parameters, we used multiple 
imputation chained equations to impute parameters. We performed this procedure with a 
maximum up to 30%, as previously described.23, 24 Parameters for which 31% or more was 
data were missing, were excluded from analyses and are not further mentioned. A more 
detailed outline of the imputation model can be found in the Supplementary material. 
Statistical analysis
All data are presented as N(%) or mean ± standard deviation unless stated otherwise. The 
main outcome measure for the reproducibility of the FMD is the coefficient of variation (CV) 
calculated for the mean difference between both FMD measurements. All descriptive data 
were examined in the pooled dataset and in quartiles of variation in FMD (i.e. CV). Based on 
the CV, we qualified the reproducibility as excellent (0-10%), good (10-20%), moderate (20-
30%) or poor (>30%).25 In multiple linear regression analyses we used the (log transformed) 
FMD CV as the dependent variable to identify factors that independently contributed to the 
variability of the FMD measurement, using backward regression analysis. A total of 4 models 
were constructed; Model 1a - Subject-related factors (continuous scale), Model 1b–Subject-
related factors (categorical scale, i.e. presence of hypertension), Model 2–Methodology-
related factors, and Model 3–Significant factors from previous models 1a-1b-2. Details of all 
regression models are given in the Supplemental information. All statistical analyses were 
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performed using the Statistical Package for Social Sciences, version 20.0 (SPSS, INC. Chicago, 
IL, USA).
Results
A median CV of 17.5% was observed for the entire population of 672 subjects, whilst 
a median CV of 9.3% was observed for volunteers without CV risk factors (n=109). We 
observed substantial variation between subjects regarding the individual CV for the FMD% 
(Figure 1). When dividing subjects into 4 quartiles, we calculated the CV for each quartile 
(Mean CV 29.9±46.5, range 0.14-745.33; Median CV Quartile-1 3.25%; Quartile-2 11.74%; 
Quartile-3 24.76%; Quartile-4 61.03%). We found an excellent, good or moderate CV in 33% 
(n=221), 22% (n=147), and 14% (n=94) of the sample, respectively. A poor CV was observed 
in 31% of the cases (n=210).
Figure 1. Individual reproducibility in Brachial artery FMD
Data of all subjects (n=672) relating to the individual reproducibility of the brachial artery FMD across 
2 repeated measurements.
Subject-related factors
Age, BMI, total cholesterol, and glucose levels showed a gradual increase across quartiles, 
with Q3 and Q4 (i.e. large variation in FMD) showing significantly higher values than Q1 (Table 
1). Systolic, diastolic and mean blood pressure were highest in Q2-3, whilst this difference 
was lost in Q4 (Table 1). When subject-related factors were presented using a categorical 
scale, hypertension and dyslipidaemia had significant impact on the reproducibility of the 
FMD (presence of hypertension Q1 15.5%, Q2 30.4%, Q3 32.1% and Q4 21.4%, diabetes 
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Q1 0%, Q2 0%, Q3 1.2% and Q4 0.6%, both P<0.001), but not sex, smoking status, diabetes 
mellitus and CVD.
Methodology-related factors
FMD% and baseline diameter were significantly different across quartiles of the CV (Table 2). 
Subject in Q4 had a lower FMD and a larger baseline diameter (Table 2). We found that all 
factors related to the practical performance of the FMD, except the use of a probe holder, 
were significantly different between quartiles (Table 2). Larger variation in CV FMD% (i.e. Q3-
4) was associated with absence of ECG-gated recording, no measurement of the diameter 
across the cardiac cycle, longer time between tests, less experience of the research centre 
in FMD measurements, and absence of reporting the CV of the laboratory in manuscripts 
(Table 2).
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Regression analyses
Model 1a – Subject-related factors (continuous). After including all subject-related factors 
that significantly differed across quartiles, this model showed an R2=0.087 and adjusted 
R2=0.086. We found that only age predicted variation in FMD%CV (β=0.248, ratio of 28.1%, 
CI[0.020-0.035], p-value <0.001). 
Model 1b–Subject-related factors (categorical). Including all subject-related factors that 
differed across quartiles, we found an R2=0.112 and adjusted R2=0.108. We identified 
hypertension (β=0.104, ratio of 11%, CI [0.095-0.533], p-value 0.005), dyslipidaemia (β=0.331, 
ratio of 39.2%, CI [0.813-1.275], p-value <0.001) and sex (β=-0.069, ratio of -6.7%, CI[-0.390-
0.010], p-value 0.063) as significant predictors for the reproducibility of the FMD%.
Model 2–Methodology-related factors. This model showed an R2=0.198 and adjusted 
R2=0.184 when including methodology-related factors that differed across quartiles. The 
model identified time between measurements (β=0.318, ratio of 37.5%,CI[0.179-0.298], 
p-value <0.001), FMD% at baseline (β=-0.124, ratio of -11.7%, CI [-0.098--0.021], p-value 
0.002), baseline diameter (β=0.082, ratio of 8.6%, CI[0.007-0.270], p-value 0.039) and 
lab experience (β=-0.133, ratio of -12.4%, CI [-0.011--0.003], p-value 0.001) as significant 
contributors to the variation in FMD% CV. 
Model 3 - Overall model Factors identified by models 1a, 1b and 2 were included in the overall 
model which resulted in an R2=0.208 and adjusted R2=0.202. Backward linear regression 
analysis identified time between measurements (β=0.291, ratio of 33.8%, CI [0.156-
0.273], p-value <0.001), hypertension (β=0.096, ratio of 10.1%, CI[0.068-0.501], p-value 
0.010), baseline FMD% (β=-0.142, ratio of -13.3%, CI [-0.105--0.030], p-value <0.001) and 
lab experience (β=-0.131, ratio of -12.3%, CI [-0.012--0.003], p-value 0.001) as significant 
contributors to the variation in FMD% across 2 repeated measurements (Figure 2). Baseline 
diameter demonstrated a borderline significant association with FMD% reproducibility 
(β=0.070, ratio of 7.2%, CI [-0.015-0.242], p-value 0.084).
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Figure 2. Regression analysis
Plot for regression coeffi  cient β for the coeffi  cient of variati on (CV) of the fl ow mediated 
dilati on (FMD). * implies a stati sti cal signifi cant contributi on in fi nal model
Discussion
This study included 672 repeated measurement of the brachial artery FMD, involving data 
from diff erent research centres and various populati ons. This allowed us to comprehensively 
explore factors contributi ng to the within-subject variability of brachial artery FMD%, when 
measured according contemporary guidelines.11 We present the following observati ons. 
First, the majority of the measurements showed an excellent-to-good reproducibility. 
For asymptomati c subjects, the median CV was 9.3%. This demonstrates that FMD is a 
reproducible tool to assess endothelial functi on in vivo. Secondly, we also found substanti al 
variati on between individuals in the CV of FMD%. In parti cular, the presence of hypertension 
contributed to a larger variati on in FMD%, independent of other factors. Third, we found that 
a poorer reproducibility of the FMD was associated with the presence of a lower baseline 
FMD%, a higher baseline brachial artery diameter, a longer ti me period between repeated 
measurements, and less experience of the laboratory with the FMD measurement. Taking 
these factors into considerati on for sample size calculati ons in future studies will help to 
decrease chances of type II errors.
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Subject-related factors
Several previous studies have explored and described reproducibility of brachial artery 
FMD and presented mixed results, ranging from an excellent to poor reproducibility.13, 26, 27 
The overall median CV% in our analysis of 17.5% in the whole study population, and 9.3% 
in subjects without CV risk/disease, are in line with findings of most previous studies that 
reported a good reproducibility.14, 16, 28-30 An important strength of our analysis is the large 
number of repeated measurements, which allowed us to identify between-subject and –
laboratory related factors contributing to the variation in brachial artery FMD% within an 
individual. Interestingly, we found that older age, dyslipidaemia and presence of hypertension 
were related to larger variation in FMD%. This suggests, in agreement with previous work,28 
that reproducibility of the FMD may be lower in populations with clinical symptoms than in 
healthy, young subjects. 
An explanation for the larger variation in clinical populations could be the presence of a lower 
baseline FMD% that is typically observed in older subjects31 and in those with hypertension,32 
CVD33 or dyslipidaemia.14 Indeed, we found that baseline FMD% is a strong and independent 
predictor for larger variability. Therefore, baseline FMD% was added to the statistical model 
to explore its impact on variability in FMD% independent of older age, hypertension and 
dyslipidaemia. Interestingly, in this model the impact of age and dyslipidaemia disappeared, 
suggesting that the lower baseline FMD% in older subjects is at least partly responsible for 
the larger variation with increasing age. In contrast, the impact of hypertension remained 
significant, indicating that other factors play a role in the larger variation in repeated 
measurements of brachial artery FMD%. Possibly, this poorer reproducibility may relate 
to higher stiffness of the vessels in clinical populations, compared to healthy volunteers.34 
Craiem et al. also found that subjects with CVD, despite comparable baseline FMD% values, 
demonstrate a larger coefficient of variation compared to healthy controls.28
Methodology-related factors
Identification of methodology-related factors that contribute to the variation in FMD is highly 
relevant because such factors can potentially be controlled for. Several previous studies have 
highlighted the importance of methodological factors, which formed the basis for the FMD 
expert consensus guidelines.11 The present study identified time between measurements 
and lab experience as independent determinants of the variation in FMD%, with more 
time between FMD measurements leading to a higher CV. Most studies that explored FMD 
reproducibility included fixed time points between measurements, which makes direct 
comparisons of the duration between testing difficult. Interestingly, Charakida et al. explored 
FMD reproducibility after a few hours, 2 day, 3 months and 9 month.35 In agreement with 
our findings, this study also demonstrate a poorer CV with increased time between re-
testing. In contrast, Sorensen et al. found no difference in reproducibility when FMD was 
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repeated after 1-2 days, 1-2 weeks or 2-4 months.27 However, this study did not apply FMD 
measurements according to current guidelines, which may have affected the results. Whilst 
longer time between repeated measures may be associated with increased variability due to 
purely methodological variation, it is also likely that true biological variability is greater under 
circumstances where the repeated measure is more distant in time. 
Laboratories that provided data for this analysis adopted expert consensus guidelines to 
perform and analyse FMD. This makes it difficult to explore the importance, for reproducibility, 
of the individual aspects within these guidelines. Nonetheless, our analysis showed that 
laboratory experience with FMD measurements independently contributes to the variation in 
FMD measurement. More specifically, the greater the experience of a laboratory with the FMD 
technique, the smaller the variation between repeated FMD measurements. This somewhat 
self-evident finding is nonetheless important, as it should guide laboratories who adopt the 
technique in attaining the level of practice and experience required before robust measures 
can be assumed. Nonetheless, limited experience of FMD did not completely invalidate 
assessment: the subgroup of healthy subjects without CV risk/disease that showed a CV of 
9.3±19% (n=109) included data from both experienced and less experienced laboratories, 
demonstrating the feasibility of a low CV in FMD measurements. This is in accordance with 
previous multi-centre studies.16 These data demonstrate the importance of adherence to the 
expert-consensus guidelines in addition to a priori practice and experience with the FMD-
technique.
Practical relevance. This study demonstrates that, in addition to adopting current guidelines, 
some factors should be considered that might affect the variation of the FMD. For example, 
larger FMD reproducibility is observed when the time between measurements increases and/
or in the presence of hypertension, and low resting FMD%. These factors should be taken 
into consideration when performing a sample size calculation and in the design of the study. 
Furthermore, the data of this study also emphasise that, in addition to fair reproducibility of 
the FMD in less experienced laboratories, training and gaining more experience is likely to 
minimise measurement error of the FMD-technique.
Limitations. One limitation of our study is that it was not prospectively designed to address 
FMD reproducibility. This may have introduced some error, especially relating to controlling 
physical activity and/or dietary instructions for the time between testing. However, all data 
was collected as in a ‘real world’ study rather than being set-up as a reproducibility study. 
Therefore, our study possesses ecological validity and can be extrapolated to various research 
settings. Another limitation is that all data in our analysis derive from laboratories adopting 
current guidelines for FMD measurement. Therefore, we were unable to address the relative 
importance of individual aspects included in these guidelines. In addition, whilst all centres 
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indicated they adhered to the expert-consensus guidelines, we have no specific data on the 
internal control of adherence and/or small variation within these guidelines between centres 
(e.g. differences in analysis software, ultrasound machines). Such differences may in part 
contribute to the inherent variability of the FMD.
In conclusion, we have shown in a large dataset of repeated measurements that the majority of 
FMD measurements show an excellent-to-moderate reproducibility. Despite adopting expert 
consensus guidelines, several subject and methodology-related factors have independent 
impact on the variation in FMD% between two measurements. These include the presence 
of hypertension, a lower resting FMD%, a larger baseline artery diameter, a longer time 
between subsequent measurements, and less laboratory experience with the measurement. 
Future studies should take these subject- and methodology-related factors into consideration 
to improve sample size calculation. Such procedures will importantly decrease variability of 
the FMD and, consequently, decrease chances for type II errors in studies that rely on FMD as 
their primary outcome parameter. 
517976-L-bw-van Mil
Processed on: 14-3-2018 PDF page: 52
52
Chapter 2
References
1. Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction: Testing and clinical 
relevance. Circulation. 2007;115:1285-1295
2. Takase B, Uehata A, Akima T, Nagai T, Nishioka T, Hamabe A, Satomura K, Ohsuzu F, Kurita A. 
Endothelium-dependent flow-mediated vasodilation in coronary and brachial arteries in suspected 
coronary artery disease. Am J Cardiol. 1998;82:1535-1539, A1537-1538
3. Green DJ, Dawson EA, Groenewoud HM, Jones H, Thijssen DH. Is flow-mediated dilation nitric oxide 
mediated?: A meta-analysis. Hypertension. 2014;63:376-382
4. Ras RT, Streppel MT, Draijer R, Zock PL. Flow-mediated dilation and cardiovascular risk prediction: A 
systematic review with meta-analysis. International journal of cardiology. 2013;168:344-351
5. Anderson TJ. Prognostic significance of brachial flow-mediated vasodilation. Circulation. 
2007;115:2373-2375
6. Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, Lloyd JK, Deanfield JE. 
Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. 
Lancet. 1992;340:1111-1115
7. Dawson EA, Rathore S, Cable NT, Wright DJ, Morris JL, Green DJ. Impact of introducer sheath coating 
on endothelial function in humans after transradial coronary procedures. Circ Cardiovasc Interv. 
2010;3:148-156
8. Green DJ, Jones H, Thijssen D, Cable NT, Atkinson G. Flow-mediated dilation and cardiovascular 
event prediction: Does nitric oxide matter? Hypertension. 2011;57:363-369
9. Inaba Y, Chen JA, Bergmann SR. Prediction of future cardiovascular outcomes by flow-mediated 
vasodilatation of brachial artery: A meta-analysis. Int J Cardiovasc Imaging. 2010;26:631-640
10. Vita JA, Keaney JF, Jr. Endothelial function: A barometer for cardiovascular risk? Circulation. 
2002;106:640-642
11. Thijssen DH, Black MA, Pyke KE, Padilla J, Atkinson G, Harris RA, Parker B, Widlansky ME, Tschakovsky 
ME, Green DJ. Assessment of flow-mediated dilation in humans: A methodological and physiological 
guideline. Am J Physiol Heart Circ Physiol. 2011;300:H2-12
12. Anderson TJ, Uehata A, Gerhard MD, Meredith IT, Knab S, Delagrange D, Lieberman EH, Ganz P, 
Creager MA, Yeung AC, Selwyn AP. Close relation of endothelial function in the human coronary 
and peripheral circulations. J Am Coll Cardiol. 1995;26:1235-1241
13. De Roos NM, Bots ML, Schouten EG, Katan MB. Within-subject variability of flow-mediated 
vasodilation of the brachial artery in healthy men and women: Implications for experimental 
studies. Ultrasound in Medicine & Biology. 2003;29:401-406
14. Donald AE, Halcox JP, Charakida M, Storry C, Wallace SM, Cole TJ, Friberg P, Deanfield JE. 
Methodological approaches to optimize reproducibility and power in clinical studies of flow-
mediated dilation. J Am Coll Cardiol. 2008;51:1959-1964
15. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, Deanfield J, 
Drexler H, Gerhard-Herman M, Herrington D, Vallance P, Vita J, Vogel R, International Brachial 
517976-L-bw-van Mil
Processed on: 14-3-2018 PDF page: 53
53
RepRoducibility of Repeated measuRments of fmd
2
Artery Reactivity Task F. Guidelines for the ultrasound assessment of endothelial-dependent flow-
mediated vasodilation of the brachial artery: A report of the international brachial artery reactivity 
task force. J Am Coll Cardiol. 2002;39:257-265
16. Ghiadoni L, Faita F, Salvetti M, Cordiano C, Biggi A, Puato M, Di Monaco A, De Siati L, Volpe M, 
Ambrosio G, Gemignani V, Muiesan ML, Taddei S, Lanza GA, Cosentino F. Assessment of flow-
mediated dilation reproducibility: A nationwide multicenter study. Journal of hypertension. 
2012;30:1399-1405
17. Beux F, Carmassi S, Salvetti MV, Ghiadoni L, Huang Y, Taddei S, Salvetti A. Automatic evaluation of 
arterial diameter variation from vascular echographic images. Ultrasound Med Biol. 2001;27:1621-
1629
18. Black MA, Cable NT, Thijssen DH, Green DJ. Importance of measuring the time course of flow-
mediated dilatation in humans. Hypertension. 2008;51:203-210
19. Woodman RJ, Playford DA, Watts GF, Cheetham C, Reed C, Taylor RR, Puddey IB, Beilin LJ, Burke V, 
Mori TA, Green D. Improved analysis of brachial artery ultrasound using a novel edge-detection 
software system. Journal of applied physiology. 2001;91:929-937
20. Gemignani V, Bianchini E, Faita F, Giannarelli C, Plantinga Y, Ghiadoni L, Demi M. Ultrasound 
measurement of the brachial artery flow-mediated dilation without ecg gating. Ultrasound Med 
Biol. 2008;34:385-391
21. Gemignani V, Faita F, Ghiadoni L, Poggianti E, Demi M. A system for real-time measurement of 
the brachial artery diameter in b-mode ultrasound images. IEEE transactions on medical imaging. 
2007;26:393-404
22. Erasmus MC. Conversiefactoren 2010
23. Engelen L, Ferreira I, Stehouwer CD, Boutouyrie P, Laurent S, Reference Values for Arterial 
Measurements C. Reference intervals for common carotid intima-media thickness measured with 
echotracking: Relation with risk factors. Eur Heart J. 2013;34:2368-2380
24. Sterne JA, White IR, Carlin JB, Spratt M, Royston P, Kenward MG, Wood AM, Carpenter JR. Multiple 
imputation for missing data in epidemiological and clinical research: Potential and pitfalls. Bmj. 
2009;338:b2393
25. Thijssen DH, Bleeker MW, Smits P, Hopman MT. Reproducibility of blood flow and post-occlusive 
reactive hyperaemia as measured by venous occlusion plethysmography. Clin Sci (Lond). 
2005;108:151-157
26. Hardie KL, Kinlay S, Hardy DB, Wlodarczyk J, Silberberg JS, Fletcher PJ. Reproducibility of brachial 
ultrasonography and flow-mediated dilatation (fmd) for assessing endothelial function. Australian 
and New Zealand journal of medicine. 1997;27:649-652
27. Sorensen KE, Celermajer DS, Spiegelhalter DJ, Georgakopoulos D, Robinson J, Thomas O, Deanfield 
JE. Non-invasive measurement of human endothelium dependent arterial responses: Accuracy 
and reproducibility. Br Heart J. 1995;74:247-253.
517976-L-bw-van Mil
Processed on: 14-3-2018 PDF page: 54
54
Chapter 2
28. Craiem D, Chironi G, Gariepy J, Miranda-Lacet J, Levenson J, Simon A. New monitoring software 
for larger clinical application of brachial artery flow-mediated vasodilatation measurements. J 
Hypertens. 2007;25:133-140
29. Donald AE, Charakida M, Cole TJ, Friberg P, Chowienczyk PJ, Millasseau SC, Deanfield JE, Halcox 
JP. Non-invasive assessment of endothelial function: Which technique? J Am Coll Cardiol. 
2006;48:1846-1850
30. Welsch MA, Allen JD, Geaghan JP. Stability and reproducibility of brachial artery flow-mediated 
dilation. Med Sci Sports Exerc. 2002;34:960-965
31. Herrington DM, Fan L, Drum M, Riley WA, Pusser BE, Crouse JR, Burke GL, McBurnie MA, Morgan 
TM, Espeland MA. Brachial flow-mediated vasodilator responses in population-based research: 
Methods, reproducibility and effects of age, gender and baseline diameter. Journal of cardiovascular 
risk. 2001;8:319-328
32. Simova I, Nossikoff A, Denchev S. Interobserver and intraobserver variability of flow-mediated 
vasodilatation of the brachial artery. Echocardiography. 2008;25:77-83
33. Onkelinx S, Cornelissen V, Goetschalckx K, Thomaes T, Verhamme P, Vanhees L. Reproducibility of 
different methods to measure the endothelial function. Vascular medicine (London, England). 
2012;17:79-84
34. Witte DR, van der Graaf Y, Grobbee DE, Bots ML, Group SS. Measurement of flow-mediated 
dilatation of the brachial artery is affected by local elastic vessel wall properties in high-risk 
patients. Atherosclerosis. 2005;182:323-330
35. Charakida M, de Groot E, Loukogeorgakis SP, Khan T, Luscher T, Kastelein JJ, Gasser T, Deanfield JE. 
Variability and reproducibility of flow-mediated dilatation in a multicentre clinical trial. European 
heart journal. 2013;34:3501-3507
517976-L-bw-van Mil
Processed on: 14-3-2018 PDF page: 55
55
RepRoducibility of Repeated measuRments of fmd
2
Supplementary data – Study contributions
All included studies involved in the van Mil et al. are listed below, grouped per country on 
alphabetical order, with contributing author(s). 
Australia   University of Western Australia - prof. Daniel Green
 1 study  dr. Ceri Atkinson, dr. Louise Naylor and dr. Howard Carter
Italy     Università di Pisa - prof. Lorenzo Ghiadoni
 3 studies  dr. Rosa Maria Bruno
The Netherlands  Maastricht University - prof. Ronald Mensink & dr. Koen Reesink
 1 study  dr. Frank van Bussel and dr. Yvo Kusters (CARIM)
 1 study  dr. Peter Joris (NUTRIM)
    Radboudumc Nijmegen - prof. Dick Thijssen
 2 studies  dr. Tim Schreuder
 1 study  drs. Joost Seeger
 1 study  dr. Constatijn Wouters
 1 study  prof. Dick Thijssen
    Unilever - dr. Peter Zock
 2 studies  dr. Arno Greyling
    Wageningen University - prof. Marianne Gelijnse
 1 study  dr. Lieke Gijsbers
 1 study  dr. James Dower
The United Kingdom   Liverpool John Moore’s University - prof. Dick Thijssen and    
 prof. Daniel Green
 2 studies  dr. Gurpreet Birk
 2 studies  dr. Tom Bailey
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Supplementary data - questionnaire
This Supplementary data contains the methodological questionnaire we asked all contributing 
centres (and authors) to fill in, to acquire the necessary methodological information. 
Study name :                
Number of subjects included in the study:                
1. Investigators
Please provide below the names and e-mail addresses of all investigators responsible for your study 
who should be mentioned as co-authors in this project
Name E-mail address
1. Study information
Please give a short description of the study population below (e.g. apparently healthy, specific age 
range, obese individuals, hypertensive individuals, etc.)
               
Please list all inclusion and exclusion criteria for the study below
               
Please list all references to publications containing results of this study below
               
1. Diameter/Flow Mediated Dilation measurements of the brachial artery
Please give a short description of the subject preparation prior to the FMD measurement protocol 
below (i.e. resting, refrained from smoking/alcohol/exercise or not, vasoactive medications 
withheld or not, position of the participant, etc.)
Please give a short description of the post occlusive reactive hyperemia protocol below (i.e. brachial 
artery occluded distal or proximal to the ultrasound probe, occlusion cuff pressure, duration of 
occlusion, etc.) 
Which device was used for obtaining B-mode images of the brachial artery (i.e. name, version, type 
& frequency of probe, etc.)
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(Semi)Automated analysis using edge detection and wall tracking 
software?
If yes, please provide details of the system used (i.e. name, version, 
software version, etc.)
Yes:     No:  
Continuous measurement of diameter?
If yes, what was the size of the time bins (sec)?
Yes:       No:   
Diameter measured at fixed time points?
If yes, at which time points?
Yes:       No:    
Were diameter measurements ECG-gated? Yes:       No:    
Were diameter measurements averaged over the cardiac cycle? Yes:       No:    
Were FMD measurements centrally analyzed? Yes:       No:    
Simultaneous acquisition of pulse-wave Doppler velocity signal for 
quantification of shear stimulus?
If yes, what was the insonation angle and how was the shear stimulus 
defined?
Yes:       No:    
Was a stereotactic probe-holder used Yes:       No:    
What was the time duration between repeated measurements?
What was the CV of the lab for %FMD at the time of the study?
What was the level of the sonographer’s experience at the time of the study? (i.e. number of years/
number of measurements conducted)
Was endothelium-independent dilation measured?
If yes, please provide details of the protocol used (i.e. dose of GTN, 
duration of measurement, etc.)
Yes:       No:    
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Supplementary data – imputation model
This Supplementary data provides a more detailed description of the imputation model 
used to impute missing values. Parameters for which 31% or more was data were missing, 
were excluded from analyses and are not further mentioned. This model was developed 
in collaboration with dr. Lian van Engelen, who had previous experience with related data 
assessments. All analyses were done in SPSS 20.0, as described earlier. 
MULTIPLE IMPUTATION weight height BMI SBP DBP MAP t_chol ldl_chol hdl_chol diabetes 
glucose lntrig 
    lnage lnFMD_CV hypertension_control mean_FMD stdev_FMD time dyslipidaemia 
smoking_1 smoking_2 
    smoking_3 smoking 
  /IMPUTE METHOD=AUTO NIMPUTATIONS=10 MAXPCTMISSING=NONE  MAXCASEDRAWS=50 
MAXPARAMDRAWS=2
  /CONSTRAINTS weight( MIN=40.0 MAX=175.0)
  /CONSTRAINTS height( MIN=1.45 MAX=2.1)
  /CONSTRAINTS BMI( MIN=15.0 MAX=57.0)
  /CONSTRAINTS SBP( MIN=80.0 MAX=200.0)
  /CONSTRAINTS DBP( MIN=40.0 MAX=120.0)
  /CONSTRAINTS MAP( MIN=60.0 MAX=145.0)
  /CONSTRAINTS t_chol( MIN=0 MAX=12)
  /CONSTRAINTS ldl_chol( MIN=0.0 MAX=10.0)
  /CONSTRAINTS hdl_chol( MIN=0.0 MAX=5.0)
  /CONSTRAINTS glucose( MIN=0.0 MAX=12.0)
  /CONSTRAINTS lntrig( MIN=-2.0 MAX=3.0)
  /CONSTRAINTS lnage( ROLE=IND)
  /CONSTRAINTS lnFMD_CV( ROLE=IND)
  /CONSTRAINTS hypertension_control( ROLE=IND)
  /CONSTRAINTS mean_FMD( ROLE=IND)
  /CONSTRAINTS stdev_FMD( ROLE=IND)
  /CONSTRAINTS time( ROLE=IND)
  /CONSTRAINTS smoking_1( ROLE=IND)
  /CONSTRAINTS smoking_2( ROLE=IND)
  /CONSTRAINTS smoking_3( ROLE=IND)
  /MISSINGSUMMARIES NONE 
  /IMPUTATIONSUMMARIES MODELS DESCRIPTIVES 
  /OUTFILE IMPUTATIONS=IWG_imputation_total .
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To briefly elaborate on the model above, we imputed missing data for; weight, height, BMI, 
SBP, DBP, MAP, t_chol, ldl_chol, hdl_chol, diabetes, glucose, and lntrig. To provide for enough 
possible data points, we used; lnage, lnFMD_CV, hypertension_control, mean_FMD, stdev_
FMD, time, dyslipidaemia, smoking_1, smoking_2, and smoking_3 as independent predictors 
(ROLE=IND). 
For all imputed data we set constraints on reasonable values, to assure that the imputations 
would be possible within the normal distributional range.
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Abstract
Background. Brachial artery FMD is widely used as a non-invasive measure of endothelial 
function. Adherence to expert guidelines is believed to be of vital importance to obtain 
reproducible measurements. We conducted a systematic review of studies reporting on the 
reproducibility of the FMD in order to determine the relation between adherence to current 
expert guidelines for FMD measurement and its reproducibility.
Methods. Medline-database was searched through July 2015 and 458 records were screened 
for FMD reproducibility studies reporting the mean difference and variance of repeated FMD 
measurements. An adherence score was assigned to each of the included studies based on 
reported adherence to published guidelines on the assessment of brachial artery FMD. A 
Typical Error Estimate (TEE) of the FMD was calculated for each included study. The relation 
between the FMD TEE and the adherence score was investigated by means of Pearson 
correlation coefficients and multiple linear regression analysis.
Results. Twenty-seven studies involving 48 study groups and 1,537 subjects were included in 
the analyses. The adherence score ranged from 2.4 to 9.2 (out of a maximum of 10) and was 
strongly and inversely correlated with FMD TEE (adjusted R2=0.36, P<0.01). Use of automated 
edge-detection software, continuous diameter measurement, true peak diameter for %FMD 
calculation, a stereotactic probe holder, and higher age emerged as factors associated with 
a lower FMD TEE.
Conclusions. These data demonstrate that adherence to current expert consensus guidelines 
and applying contemporary techniques for measuring brachial artery FMD decreases its 
measurement error.
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Introduction 
The endothelium is a key regulator of vascular homeostasis and endothelial dysfunction 
is an early manifestation of atherosclerosis.1 Currently, the most widely used technique to 
study endothelial function in vivo is the flow-mediated dilation (FMD) of the brachial artery. 
This is a non-invasive, ultrasound-based method which correlates with endothelial function 
of the coronary arteries2, 3 and independently predicts cardiovascular disease (CVD).4, 5 The 
technique is attractive as a surrogate end-point, especially since changes in FMD can be 
detected across a relatively short timeframe.6 Despite its popularity, minor changes in the 
methodological approach may critically impact variability and decrease reproducibility of the 
FMD response.7-9
Previous expert consensus guidelines have made important contributions to standardize the 
technical approach and to set minimum standard requirements for FMD measurements.10, 11 
However, not all studies on FMD apply these recommendations, or only in part. The impact 
of adherence to these guidelines on the reproducibility of FMD measurements is currently 
unclear, but may importantly contribute to the measurement error of the FMD technique 
Furthermore, little is known about the relative importance of the individual aspects of 
the expert-consensus guidelines to contribute to the reproducibility of the FMD. Better 
quantitative data on this matter can help reduce variation within and between studies, which 
will increase the statistical power of studies on FMD to detect changes and, subsequently, 
decrease chances for type II errors.
In light of these considerations, we hypothesized that adherence to expert consensus 
guidelines is related to better reproducibility of FMD measurements.10, 11 Therefore, we 
performed a systematic search for published studies that reported data on reproducibility 
of FMD measurements, and investigated the relation between (full or partial) adherence to 
current expert consensus guidelines and reproducibility of the FMD. Secondly, we explored 
which subject- and methodology-related factors were related to FMD reproducibility.
Methods
Search Strategy
The MEDLINE bibliographic database was searched (January 2000 through July 2015) for 
studies that assessed the reproducibility of the FMD using the following search terms: 
“flow mediated dilation”, “flow mediated dilatation”, “flow mediated vasodilation”, “flow 
mediated vasodilatation”, “endothelial function”, “endothelial dysfunction”, “FMD”, “FMV”, 
“brachial artery”, “reproducibility”, “reliability”, “repeatability”, “coefficient of variation”, 
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“CV”, and “variance”. The search was limited to studies in human adults published in the 
English language. Additi onally, we supplemented the search by hand-searching references of 
included studies and relevant reviews and meta-analyses on this topic.
Selecti on of Studies
Included studies were identi fi ed by means of a two-step selecti on process. During the fi rst 
step, two reviewers (ACCMvM, AG) independently screened ti tles, abstracts and keywords 
of publicati ons to identi fy potenti ally eligible studies. Studies were included if the mean 
diff erence and variance of repeated FMD measurements of the brachial artery were reported. 
During step 2 of the selecti on, both reviewers examined the full text of these publicati ons to 
gauge eligibility based on two additi onal inclusion criteria: FMD was determined through 
non-invasive ultrasound imaging, and a reacti ve hyperaemia protocol (with an ischemia 
durati on of 4 to 5 minutes) was used to elicit the shear stress sti mulus required for FMD. 
Thus, studies that adopted (ischemic) hand-grip exercise, passive movement and/or skin 
warming protocols to elicit (brachial) artery dilati on were not included in our analysis. In 
cases of discrepancy between the reviewers, eligibility was discussed along with a third 
reviewer (DHJT) unti l consensus was reached.
	Figure 1. Flow diagram of the study selecti on procedure.
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Data extraction 
Study and subject characteristics: A standardized data collection sheet was used to extract 
general publication details (author, year of publication, country) and specific study- and 
subject characteristics: number of subjects, mean age (in years); CVD risk status of the study 
population (defined as presence of diagnosed CVD, hypertension or diabetes); baseline 
brachial artery diameter (in mm); % brachial artery FMD and its associated variance for 
each repeated measurement; and the mean absolute difference between repeated FMD 
measurements and its associated variance. 
Adherence to guidelines. We extracted information from the methods sections of the 
individual papers to assess the adherence to current expert-consensus guidelines. Based on 
recent guidelines,11 we scored each individual study on the reporting of 19 different factors 
which were divided over 4 categories. The categories were related to: 1. Subject preparation 
(10 items), 2. Image acquisition (4 items), 3. Data analysis (3 items), and 4. Laboratory (2 
items). Before performing the systematic literature search, values were assigned to each 
factor proportional to its perceived importance for valid assessment of the FMD. This was 
done through expert consensus discussion within the Working Group (AG, LG and DHJT).12 The 
“Adherence Score” that could be assigned to a study ranged from 0 to 10 points, depending 
on how many of the 19 different factors that were reported. In addition, we counted the 
number of previous studies on FMD published by the principal author of each study included 
in the systematic review. This number served as a measure of the perceived experience in 
FMD measurements for each centre at the time of publication of the reproducibility data 
included here.
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Table 1. General characteristics of the FMD reproducibility studies included in the systematic review.
Source Health  
status
Number 
of 
subjects
Age 
(years)
Mean 
baseline 
FMD  
(%)
Mean 
baseline 
diameter 
(mm)
Time between 
measurements*
TEE
Kanahara 201414 Healthy 32 40 7.90 3.83 14 1.28
Charakida 201315 CVD, 
Diabetes
67 61 4.10 4.55 2 0.94
Charakida 2013 67 61 4.10 4.60 90 1.04
Charakida 2013 67 61 4.10 4.65 270 1.47
Ghiadoni 201216 Healthy 135 32 6.52 3.53 1 hour 0.83
Ghiadoni 2012 135 32 6.52 3.55 30 1.15
Onkelinx 201217 CVD 18 68 6.80 3.92 0.5 hour 0.94
Onkelinx 2012 18 68 7.13 3.91 2 0.88
Lima 201018 Healthy 31 25 13.17 3.57 2 2.91
Thijssen 200919 Healthy 10 24 6.83 4.28 0.5 hour 0.89
Donald 200820 Healthy 32 43 8.10 3.70 6 hours 0.79
Donald 2008γ 34 43 7.50 3.70 7 0.79
Donald 2008γ 37 43 8.10 3.75 30 0.53
Donald 2008γ 35 43 7.80 3.80 90 0.74
Donald 2008γ 32 43 7.30 3.70 6 hours 1.08
Donald 2008** 34 43 6.70 3.70 7 0.95
Donald 2008** 37 43 7.50 3.75 30 0.63
Donald 2008** 35 43 7.10 3.80 90 0.87
Simova 200821 CVD, 
Hypertension
40 62 6.05 3.84 0.25 hour 0.85
Craiem 200722 Healthy 10 32 7.60 3.95 1 hour 0.80
Craiem 2007 10 32 8.10 3.89 7 0.91
Craiem 2007 CVD 26 44 6.98 3.97 1 hour 1.34
Craiem 2007 26 44 5.66 4.15 30 0.96
Harris 200723 Healthy 9 57 7.80 4.11 2 1.32
Meirelles 200724 Healthy 10 33 19.90 3.50 1.5 hours 2.70
Meirelles 2007 13 33 16.50 3.55 3 2.50
Donald 200625 Healthy 16 28 7.30 3.55 1 1.63
Harris 200626 Healthy 16 23 9.88 3.74 2 hours 0.71
Leeson 200627 Healthy 17 32 4.74 4.05 20 1.22
Elsen 200528 Healthy 15 23 4.61 4.04 1 0.63
Sejda 200529 Healthy 18 28 5.95 4.04 7 3.89
Sejda 2005 18 28 4.23 4.15 7 1.63
Stoner 200430 Healthy 9 23 10.20 3.90 2 3.26
West 200431 Diabetes 18 55 5.57 4.01 7 0.81
West 2004 18 55 5.57 4.01 14 1.07
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Source Health  
status
Number 
of 
subjects
Age 
(years)
Mean 
baseline 
FMD  
(%)
Mean 
baseline 
diameter 
(mm)
Time between 
measurements*
TEE
Sidhu 200232 Healthy 12 36 5.38 3.94 20 0.37
Sidhu 2002 CVD 12 62 1.80 4.29 20 0.33
Beux 200133 Healthy 38 44 6.62 4.41 1 hour 1.97
Beux 2001 38 44 4.32 4.41 1 hour 1.22
De Roos 200134 Healthy 34 27 4.13 3.90 25 2.01
Herrington 200135 Healthy 127 79 2.63 4.53 7 0.79
Herrington 2001 30 45 7.87 4.35 7 1.46
Woodman 200136 Healthy 24 55 6.60 4.06 7 0.71
Lind 200037 Healthy 10 22 7.40 3.55 2 hours 2.19
Lind 2000 10 22 7.40 3.55 21 2.82
Preik 200038 Healthy 8 28 10.60 3.62 20 1.06
Liang 199839 Healthy 30 44 10.80 3.84 18 2.01
Hardie 199740 Healthy 19 36 3.00 3.78 90 4.83
*measured in days, unless stated otherwise, γtrue peak diameter; **peak at 60 seconds
Statistical analysis
Reported measures of FMD reproducibility varied between studies. Many studies presented 
the coefficient of variation (CV) of repeated measurements, although this measure was 
calculated in a number of different ways, precluding direct comparisons. Measures of 
reproducibility included the technical error of the measurement (TEM), Pearson- and intraclass 
correlation coefficients (ICC), and limits of agreement. In order to make valid comparisons 
between studies, we defined as primary outcome measure the typical error of estimate (TEE) 
of FMD, which is calculated as standard deviation of the paired differences/√2.13
Data are presented as mean ± SD or median (range) as appropriate for continuous variables 
and as frequencies for categorical variables. FMD TEE data were highly skewed (Shapiro-Wilk 
test, P<0.0001) and were log transformed prior to the analyses. Relations between log-FMD 
TEE and continuous variables were determined by Pearson correlation coefficients analysis. 
For categorical variables, the statistical significance of differences in FMD TEE between 
different levels were assessed by the Mann-Whitney U test. Significant correlates were 
entered in a multivariate linear regression analyses with backward elimination to identify 
independent predictors of FMD TEE. All analyses were conducted using JMP version 11.0 (SAS 
Institute Inc., Cary, NC, USA).
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Results 
Our systematic search identified 446 potentially relevant publications and an additional 12 
were obtained through review of references of included studies, relevant reviews and meta-
analyses. Twenty-seven studies14-40 with 48 relevant study groups met our inclusion criteria 
and were included in our analysis (Figure 1). Characteristics of the included study groups are 
presented in Table 1. The 48 study groups comprised a total of 1,537 subjects (mean sample 
size 32; range, 8-135) with a mean age of 41.5 years (range, 22-79 years). Eleven study groups 
included subjects with increased CVD risk, i.e. presence of diagnosed CVD, hypertension 
or diabetes. The other remaining 37 study groups consisted of healthy subjects. The time 
between repeated FMD measurements ranged from 25 minutes to 9 months. Mean baseline 
brachial diameter was 3.9 mm (range, 3.5 to 4.7 mm) and mean baseline FMD (i.e. this first of 
the two repeated measurements) was 7.1% (range, 1.8 to 19.9%). The FMD TEE ranged from 
0.33 to 4.83% across study groups, with a mean value of 1.4%. The level of experience for 
each centre at the time of publication of the reproducibility study in question varied widely 
(number of previously published studies on FMD ranging from 0 to 71, median of 3).
Methodology-related factors versus variation in FMD
There was considerable variation in the methodological factors between studies. Adherence 
scores ranged from 2.4 to 9.2, with a mean of 5.3 (out of a maximum of 10). The adherence 
score was inversely correlated with log FMD TEE (adjusted R2=0.36, P<0.01, Figure 2). 
Figure 2. Linear correlation between the Typical Error of the Flow Mediated Dilation Estimate (FMD 
TEE) and adherence to expert guidelines (Adherence Score) in 27 studies (involving 48 study groups) of 
FMD reproducibility.
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To explore the impact of the different aspects of the adherence score on the FMD TEE, we 
compared the FMD TEE between adherence (Yes vs No) to various methodological variables. 
Statistically significant differences in FMD TEE were found for use of the true peak diameter 
to calculate %FMD, continuous brachial artery diameter measurement over the cardiac cycle, 
use of automated edge detection software and smoking cessation prior to measurements 
(Table 2).
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Subject-related factors versus variation in FMD
For the remaining methodology related factors and subject characteristics, there were weak, 
but statistically significant correlations of log FMD TEE with age (adjusted R2= -0.18, P<0.01) 
and with baseline FMD (adjusted R2 0.11, P=0.013). In addition, FMD TEE was significantly 
smaller in the subgroup of studies that applied a stereotactic probe holder, and in studies 
performed by groups with more experience according to number of earlier publications on 
FMD. The %FMD TEE of studies above and below the median duration between repeated 
measurements (7 days) was not significantly different (Table 3), and there was no correlation 
between %FMD TEE and the time between repeated measurements (adjusted R2= -0.02, 
P<0.75).
Table 3. Relationship of subject- and methodology-related characteristics with FMD TEE
Continuous variables Adjusted Pearson R2 P-values
Age (years) -0.18 <0.01
Baseline FMD (%)‡ 0.11 0.01
Baseline diameter (mm) -0.02 0.15
Number of subjects (n) -0.001 0.33
Categorical variables Median (IQR) %FMD TTE
n No n Yes P-values
CVD risk 37 1.15 (0.79-2.01) 11 0.94 (0.85-1.07) 0.31
Distal occlusion cuff 
placement
5 2.01 (0.91-2.6) 43 1.04 (0.79-1.47) 0.17
Stereotactic probe holder 18 1.82 (1.02-2.85) 30 0.92 (0.73-1.22) <0.01
Experienced centre* 23 1.32 (0.88-2.5) 25 0.91 (0.80-1.19) 0.01
Time between repeated 
measurements above 
median†
18 0.94 (0.81-1.72) 30 1.06 (0.71-1.61) 0.77
‡ Baseline FMD refers to the first of the two repeated measurements
*Centre experience was defined as the number of previous studies on FMD published by the principle 
author of each included study. The effect of centre experience was examined by comparing the %FMD 
TEE of studies below (No) and above (yes) the median number of previously published FMD studies.
†The effect of the time duration between studies was examined by comparing the %FMD TEE of studies 
below (no) and above (yes) the median duration of 7 days.
We constructed a stepwise multivariate regression model with log FMD TEE as the dependent 
variable and all factors that significantly influenced FMD TEE based on the individual analyses 
(adherence score, age, baseline FMD, probe holder and previous experience). The stepwise 
multivariate regression model predicted 51% of the variability in log FMD TEE. Adherence 
score (β= -0.16), age (β = -0.01) and probe holder (β = -0.19) remained as statistically 
significant (P<0.05) predictors in the model (Table 4). 
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Table 4. Relation of the adherence score, subject- and methodological factors with the reproducibility 
of the FMD measurement
Stepwise Regression Analysis (model Adj R2=0.51)
Variable β 95% CI P-value
Adherence Score (unit) -0.16 -0.24; -0.07 <0.01
Age (year) -0.01 -0.02; -0.001 0.03
Stereotactic probe holder (yes) -0.19 -0.06; -0.33 <0.01
The regression coefficient β represents the increase in the log FMD TEE per unit increase in each factor. 
Baseline FMD and Centre experience did not remain in the model
Discussion
In the recent years the measurement of FMD in the brachial artery has been associated with 
predictive capacity for future CVD events. Despite this, and the relatively straightforward and 
non-invasive approach to its measurement, the clinical use of the FMD is hampered by its 
sensitivity to variations in methodology. 
Our systematic analysis of previous studies that explored FMD reproducibility provides us with 
a number of novel observations. First, we found considerable variation in the methodology 
applied to measure FMD and consequently, differences between studies in the adherence to 
current expert consensus guidelines. Secondly, these data show a robust inverse association 
between adherence to the guidelines and FMD reproducibility, with higher adherence to 
guidelines being related to smaller variation in FMD. Thirdly, we identified methodological 
factors that were associated with smaller variation in FMD. Specifically, the use of automated 
edge detection software, continuous measurement of brachial artery diameter across the 
cardiac cycle, calculating %FMD by means of the true peak diameter and use of a stereotactic 
probe holder were related to a better reproducibility. Taken together, our study provides 
strong scientific data that highlight the importance of rigorous application of standardized 
contemporary methodology to reduce measurement error of FMD and, consequently, 
improve its use in (pre)clinical studies. 
To our knowledge, no previous study has explored the (relative) importance of adherence 
to expert consensus guidelines for measures of vascular health, including frequently used 
techniques like intima-media thickness, pulse wave velocity, and finger photoplethysmography. 
Taking all studies on the reproducibility of the FMD together, involving 1,537 subjects, we 
found a TEE of 1.4% based on an average FMD of 7.1%. This indicates an overall good-to-
acceptable reproducibility of the FMD. However, significant variation was observed between 
studies, with adherence to the expert consensus guidelines representing an important 
determinant of this variation. Our data suggests that roughly 36% of the variation in FMD 
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reproducibility can be explained through adherence to the guidelines alone. The presence of 
a linear relation between adherence to the guidelines and variation of the FMD suggests that 
measurement error would be further reduced with stricter adherence to the guidelines. Our 
data also indicate that even with full adherence to current expert consensus guidelines, some 
level of measurement error remains present. Nonetheless, a significant amount of variation 
in the FMD can be prevented by strong adherence to guidelines.
Our analysis provides further insight into methodological factors that determine within-
person error of the FMD measurement. For example, we found that taking the true peak 
artery diameter (rather than a fixed time point), continuous diameter measurement and 
automated edge-detection contribute to minimizing measurement error. The importance 
of these methodological factors have already been acknowledged in previous work. For 
example, Black et al. found that the peak diameter following cuff release differs between 
young and older subjects.7 Consequently, calculating the FMD% at an arbitrary time point (e.g. 
60 seconds) may lead to misleading conclusions compared to an approach in which diameter 
of the brachial artery is recorded continuously, allowing for the detection of the true peak 
dilation. Furthermore, previous work demonstrated that the adoption of edge-detection 
software to perform observer-independent analysis leads to smaller variation compared to 
the application of manual calipers, the latter being highly prone to measurement bias.36, 41, 
42 Whilst these studies highlight the importance of considering these factors for valid use 
of FMD, the present study also highlights the importance of considering these factors to 
lower variation. Therefore, our study provides an additional rationale to perform continuous 
assessment of the diameter and the adoption of edge-detection software when performing 
valid and reproducible assessments of the FMD.
Another important observation in our study was that previous experience of a laboratory 
with the FMD resulted in a smaller variation. A potential explanation for this finding is 
that experienced laboratories are more likely to demonstrate better adherence to the 
expert consensus guidelines. Indeed, when all factors were included in the final regression 
analysis (including adherence to the guidelines), previous experience of a laboratory with 
FMD did not emerge as an independent predictor of FMD reproducibility. Another factor 
that contributed to a smaller variation of the FMD was the use of a probe holder. The use 
of such devices is largely dependent on the personal preference of the laboratory and the 
effect on measurement reproducibility is a complex topic, since highly skilled operators with 
years of experience are able to conduct FMD measurements with exceptional reproducibility, 
regardless of the use of a probe holder.19 One may speculate that sonographers’ learning 
curves will likely differ depending on whether a probe holder is used or not and also depending 
on the design and construction of the probe holder itself. Therefore, despite the significant 
inverse association in our analysis, it remains difficult to ascertain whether use of a probe 
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holder leads to a smaller variation in FMD per se. Further studies are needed to confirm the 
importance of using a probe holder to reduce variability of the FMD.
Of the subject-related factors (age, diameter and baseline FMD), only age contributed 
independently to the variation in FMD. Notably, higher age of subjects was associated with 
a smaller variation in FMD. Older age is typically associated with a lower FMD,43, 44 which 
may contribute to a smaller (biological) variation and/or less ability to change in response 
to hemodynamic stimuli, consequently leading to a smaller measurement error. However, at 
least a previous work suggests the presence of larger variability for measurements of vascular 
health in clinical groups. For example, Craiem et al. found that subjects with CVD, despite 
comparable baseline FMD% values, demonstrate a larger coefficient of variation compared to 
healthy controls.22 Our data suggest that the reproducibility of the FMD may differ between 
(clinical) groups. 
Interestingly, the time between repeated measurements did not significantly affect FMD 
reproducibility in our analyses. This might seem counter-intuitive, as poorer reproducibility 
is expected as the time between repeated measurements increases. Indeed, a recent study 
specifically designed to determine FMD reproducibility over short (48 hours), medium 
(3 months) and long (9 months) time frames did find poorer reproducibility at 9 months 
between repeated measurements.15 Reproducibility was comparable for the shorter time 
periods however, which is in agreement with a recent Italian multicentre study which found 
no differences in FMD reproducibility up to 30 days between measurements.16 It should be 
noted that there was a large heterogeneity in time between measurements in the included 
study groups, with the majority ranging between one and 15 days (n = 32) and some up to 30 
(n=11), 90 (n = 4) and 270 days (n = 1). Excluding these last 16 studies from the analyses did 
not appreciably change our findings our findings however (data not shown).
Limitations. An obvious limitation of our systematic review is that the degree of adherence 
to expert consensus guidelines was assessed from information as provided in the papers. 
If a methodological description omitted one or more of the 19 different scoring factors, 
no points were assigned for those factors. As a consequence some studies with sparse 
methodological descriptions received lower scores. Poor methodological reporting might 
therefore have confounded our outcomes. It should also be acknowledged that our 
estimation of the experience of a laboratory with FMD measurements does not necessarily 
reflect the experience of an individual sonographer. However, a laboratory more experienced 
in performing FMD measurements will generally require a level of skill and training for their 
sonographers that will meet at least the standard of their previous work. This highlights the 
importance of the level of experience in performing studies with FMD as an outcome variable. 
Another limitation is that our analysis on the relative importance of individual subject- and/or 
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methodology-related factors could only be based on a between-study comparison of factors 
contributing to the reproducibility of the FMD. Various other factors may have influenced 
this analysis. Therefore, future studies are necessary to further explore the importance of 
(some of) the methodology-related factors, including the effects of factors which we could 
not examine with the current dataset such as the observer/analyst, the time of cuff occlusion 
and changes in baseline brachial artery diameter.
In conclusion, this systematic review shows that adherence to current expert consensus 
guidelines significantly reduces measurement error when assessing brachial artery FMD in 
humans. Moreover, when adopting the guidelines, we found that the use of contemporary 
techniques (i.e. continuous diameter recording, edge-detection and wall-tracking software 
and under some circumstances the use of a probe holder) is crucial to improve reproducibility 
of the FMD measurement. Considering these factors will importantly decrease measurement 
error of the FMD and, consequently, decrease chances for type II errors in studies that rely on 
FMD as their primary outcome parameter. In other words, ignoring current expert-consensus 
guidelines causes significant variability of the FMD and, consequently, may lead to spurious 
conclusions. This study delivers important insight that should be taken into account when 
developing future updates to expert-consensus guidelines.
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Abstract
Brachial artery flow mediated dilation (FMD) is widely used as a non-invasive measure of 
endothelial function. Adherence to expert consensus guidelines on FMD measurement 
has been found to be of vital importance to obtain reproducible data. This article lists the 
literature data which was considered in the development of a tool to aid in the objective 
judgement of the extent to which published studies adhered to expert guidelines for FMD 
measurement. Application of this tool in a systematic review of FMD studies (http://dx.doi.
org/10.1016/j.atherosclerosis.2016.03.011)1 indicated that adherence to expert consensus 
guidelines is strongly correlated to the reproducibility of FMD data.
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Specifications Table 
Subject area Medicine
More specific subject area Vascular Physiology
Type of data Table
How data was acquired Systematic literature survey and expert consensus
Data format Processed 
Experimental factors  Methodological parameters related to valid measurement FMD
Experimental features  Assessment tool based on 33 studies pertaining to the most 
appropriate methods to assess FMD in humans identified from 
literature and expert guidelines for FMD measurement
Data source location  Nijmegen, The Netherlands
Data accessibility Data is within this article
Value of the data 
•  The literature data provided here establishes an evidence base and a physiological 
background rationale for the individual components included in the Adherence Score, 
aiding in the improvement of the practical guidance and technical approaches to FMD 
measurement and analysis.
•  This “Adherence Score” which ranges between 0 (i.e. no adherence) and 10 (i.e. full 
adherence) can conceivably be employed to evaluate the perceived quality of studies 
reporting FMD data, with a higher outcome of this measure being strongly related to 
better reproducibility of the FMD data.
•  This tool may prove useful additional information when pooling, contrasting and 
comparing different studies, e.g. for the purpose of meta-analyses or systematic reviews. 
Data
A tool to enable objective assessment of the level adherence to the FMD guidelines was 
developed. Table 1 presents the 19 different factors that make up the “Adherence Score” 
tool along with citations to the literature data which justify the inclusion of each factor in 
question. 
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Table 1. Scoring tool based on currently accepted guidelines for the assessment of the perceived quality 
of FMD studies
Characteristic Score Ref.
Subject preparation
Fasting state (>6h) Yes  0.2; No  0 1-3
No smoking or any tobacco consumption prior to 
measurement (>6h)
Yes  0.2; No  0 4-6
No habitual exercise prior to measurement (>48h) Yes  0.2; No  0 7-9
No food/beverages that contain alcohol and/or caffeine 
for >12 h
Yes  0.2; No  0 10, 11
No food/beverages that are rich in polyphenols (cocoa, 
tea, fruit juices) for >18 h
Yes  0.2; No  0 12
No vitamins for at least 72h Yes  0.2; No  0 13-15
Vasoactive medications withheld on the morning of the 
study if possible for single measurements; Careful noting 
of the use and timing of any drugs in the case repeated 
measurements
Yes  0.2; No  0 16, 17
Supine position; Rest for at least 15 min prior to 
measurements in a quiet, temperature controlled room
Yes  0.2; No  0 18-20
In female subjects, repetitive measurement should be 
made at the same time of the menstrual cycle (ideally 
on days 1–7)
Yes  0.2; No  0 21, 22
Repeated measurements done in fixed time windows 
(same time of day)
Yes  0.2; No  0 23-25
Image acquisition
Diameter measurements recorded continuously + over 
the heart cycle OR;
Diameter measurements obtained during end diastole 
only
Yes  2;  No  0
Yes  1; No  0
26, 27
Simultaneous acquisition of pulse-wave Doppler velocity 
signal for quantification of shear stimulus
Yes & insonation angle ≤60°  2;
Yes & insonation angle >60°/not 
reported  1; 
No  0
28-30
Image analysis
Analysis using automated edge detection and wall 
tracking software 
Yes & continuous (i.e. time bins of 
≤5 seconds)  2; 
Yes & fixed time points
  1; No  0
31-33
Laboratory information
Use of experienced sonographers reported Yes  1;  No  0
Same sonographers paired to same subjects for 
repeated measurements
Yes  1; No  0
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Experimental Design, Materials and Methods
Based on previous expert-consensus guidelines,34 we devised a scoring system reliant on 
the reporting of 19 different methodological factors related to FMD measurement. These 
factors were identified after critical review and appraisal of published physiological studies 
pertaining to the most appropriate methods to assess FMD in humans. Values were assigned 
to each component proportional to its perceived importance for valid assessment of the 
FMD. This was done through expert consensus discussion within the Working Group (AG, LG 
and DHJT). The “Adherence Score” that any given study can be assigned ranges from 0 to 10 
points depending on how many of the 19 different factors that are reported or referred to in 
the text of the paper in question.
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To the editor
We thank Dr. Sabour1 for his interest in our recent publication.2 In our study we conducted a 
systematic review of studies reporting on the reproducibility of brachial artery flow-mediated 
dilation (FMD). Subsequently, we determined the relation between the adherence of these 
studies to current expert guidelines for FMD measurement and its reproducibility of the FMD. 
Dr. Sabour raises important points around analysis of reliability. More specifically, Dr. Sabour 
strongly supports the use of the intraclass correlation coefficient (ICC) when examining 
reliability. It should be noted, however, that our paper does not necessarily relate to this 
work on reliability. In fact, we have not performed any specific analysis on reliability and/
or reproducibility.  Adopting the ICC approach in our study would have required us to have 
access to the original individual data of the studies identified in our systematic review (which 
we did not). We simply correlated a predefined and standardized measure of reproducibility3 
(that was calculated and presented in previous studies) to a measure of reported adherence 
to guidelines.
The above approach led us to conclude that studies which reported high adherence to 
current expert consensus guidelines and use contemporary techniques for measuring 
brachial artery FMD were related to lower measurement error. As such we would reiterate 
that ignoring current expert-consensus guidelines causes significant variability of the FMD 
and, consequently, may lead to spurious conclusions.
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Abstract
Objectives. Carotid artery reactivity (CAR%), involving carotid artery diameter responses to 
a cold pressor test, is a non-invasive measure of conduit artery function in humans. This 
study examined: 1. the impact of age and cardiovascular risk factors on the CAR% and 2. The 
relationship between CAR% and coronary artery vasodilator responses to the cold pressor 
test. 
Methods. Ultrasound was used to measure resting and peak carotid artery diameters during 
the cold pressor test, with CAR% being calculated as the relative change from baseline (%). We 
compared CAR% between young (n=50, 24±3 years) and older participants (n=44, 61±8 years), 
and subsequently assessed relationships between CAR% and traditional cardiovascular risk 
factors in 50 participants (44±21 years). Subsequently, we compared left anterior descending 
(LAD) artery velocity (using transthoracic Doppler) with carotid artery diameter (i.e. CAR%) 
during the cold pressor test (CPT, n=33, 37±17 years).
Results. A significantly larger CAR% was found in young versus older healthy participants 
(4.1±3.7 versus 1.8±2.6, P<0.001). Participants without cardiovascular risk factors 
demonstrated a higher CAR% compared to those with ≥2 risk factors (2.9±2.9 versus 0.5±2.9, 
P=0.019). Carotid artery diameter and LAD velocity increased during CPT (P<0.001). Carotid 
diameter and change in velocity correlated with LAD velocity (r=0.486 and 0.402, P<0.004 
and 0.02, respectively).
Conclusion. Older age and cardiovascular risk factors are related to lower CAR%, whilst CAR% 
shows good correlation with coronary artery responses to the CPT. Therefore, CAR% may 
represent a valuable technique to assess cardiovascular risk, whilst CAR% seems to reflect 
coronary artery vasodilator function. 
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Introduction
Previous studies have explored the impact of stimulation of the sympathetic nervous system, 
using the cold pressor test (CPT), on coronary artery responses.1-3 Coronary artery responses 
to CPT are suggested to be endothelium-dependent.4 Whilst coronary dilation is observed in 
healthy volunteers, participants with CV risk or disease demonstrate attenuated dilation or 
even constriction during the CPT.2, 4-8 Moreover, CPT-induced constriction of coronary arteries 
independently predicts future cardiovascular (CV) events.9 Non-invasive assessment of 
coronary artery diameter, however, is currently technically challenging, expensive and lacks 
sufficient temporal resolution to assess rapid changes in diameter. 
Similar to coronary arteries, CPT may dilate carotid artery in asymptomatic older participants, 
whereas significant constriction is present in those with coronary heart disease.10 No 
previous study examined whether the magnitude of response (i.e. dilation or constriction) 
of the carotid artery reactivity (CAR%) to the CPT is altered by older age and/or presence of 
cardiovascular risk factors. Furthermore, given similarity in vascular responsiveness between 
coronary and carotid arteries to CPT, with opposite responses between healthy participants 
(i.e. dilation) versus patients with coronary heart disease (i.e. constriction),9, 10 one may 
question whether a correlation exists between coronary and carotid artery responses to the 
CPT, such as described previously for other measures of peripheral vascular function.11-16 This 
would provide the first study to assess whether CAR% directly relates to coronary artery 
vascular function.
This study aims to better understand the potential clinical relevance of CAR% as a putative 
marker of cardiovascular risk and surrogate for coronary artery function. First, we examined 
the hypothesis that older age and increasing number of traditional cardiovascular risk factors 
(e.g. blood pressure, cholesterol, hypertension, diabetes, and smoking) are associated with 
a smaller CAR% in healthy, asymptomatic participants. Secondly, we explored the relation 
between coronary artery and carotid artery responses to the CPT in healthy, asymptomatic 
participants. This work will provide important information to determine if the carotid and 
coronary arteries exhibit similar functional responses in the presence of cardiovascular risk 
factors and disease.
Methods
Participants
We recruited 94 healthy participants without clinical presentation of atherosclerosis. 
Exclusion criteria were a history of cardiovascular disease (i.e. angina, myocardial infarction, 
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and heart failure), presence of Raynaud’s phenomenon, scleroderma, chronic pain and/or 
open wounds on the upper extremities. Written informed consent was obtained from all 
participants prior to participation. Ethical approval was obtained from local Ethics committee 
(Aim 1: Radboud university medical centre, Aim 2: Liverpool John Moores University), in 
accordance with the latest revision of the Declaration of Helsinki.
Experimental design
All participants (n=94) reported to our laboratory for a single visit. Participants were asked to 
abstain from strenuous exercise for 24 hours, fast for ≥6 hours, and to abstain from dietary 
products known to alter endothelial function for ≥18 hours prior to the testing sessions (i.e. 
caffeine, vitamin C) according to guidelines to assess peripheral vascular function.17 Upon arrival, 
weight (kg) and height (cm) were measured and participants rested in the supine position 
for at least 15 minutes on a comfortable bed in a temperature-controlled room. All subjects 
underwent the CPT, involving continuous ultrasonography measurements of the carotid artery 
diameter and velocity as well as haemodynamics at baseline (1-min) and during (3-min) CPT. 
Peak changes in diameter during CPT, presented as the relative change from baseline, represents 
the CAR%. To reduce measurement error, procedures were repeated after 1 h and averaged for 
analyses. For Aim 1 (i.e. relationship CAR% & risk factors), we divided the entire study population 
(n=94) into young (n=50, age range 19-30 years) and older adults (n=44, age range 50-82 years). 
Cardiovascular risk profile was assessed in 50 participants (Radboud university medical centre, 
44±21 years), who were divided in subjects with 0, 1 or ≥2 cardiovascular risk factors. These 
different subgroups are presented in Figure 1. 
For Aim 2 (i.e. CAR% vs coronary artery velocity), we studied a subgroup of 44 participants 
(Liverpool John Moores University), and simultaneously examined carotid artery diameter 
and left anterior descending coronary artery velocity responses using Doppler ultrasound 
during the CPT. Due to technical constraints 11 participants were excluded from analysis. This 
left us with 33 participants to assess the relation between CAR% and coronary artery velocity 
responses to the CPT (37±17 years).  
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Figure 1. Flow diagram
Experimental measures
Cold pressor test. The CPT consisted of a 3-minute immersion of the left  hand in a bucket of 
ice slush (~4.0°C). The parti cipant was positi oned supine on a comfortable bed, facilitati ng 
arm movement of the left  hand into the bucket of ice slush without signifi cant movement of 
the neck to enable assessment of the caroti d and coronary arteries. Aft er a 1-minute baseline 
period, the parti cipant immersed the hand up to the wrist in the ice slush for 3 minutes. The 
parti cipant was instructed not to speak and breathe normally (to prevent hyperventi lati on) 
when the hand was submerged into the ice slush.
Caroti d artery diameter, blood fl ow and shear rate. Parti cipants were positi oned with the 
neck extended to allow assessment of the caroti d artery. Left  caroti d artery diameter 
and red blood cell velocity were recorded conti nuously during baseline (1-minute) and 
CPT (3-minutes) with a 10-MHz linear array handheld probe att ached to a high resoluti on 
ultrasound machine (Terason T3000, Aloka, United Kingdom). When an opti mal image was 
found, the probe was held stable and the ultrasound parameters were set to opti mise the 
longitudinal, B-mode image of the lumen-arterial wall interface. Conti nuous pulsed wave 
Doppler velocity assessments were also obtained and were collected at the lowest possible 
insonati on angle (always <60°). Following a 1-minute baseline assessment of caroti d artery 
diameter and velocity, the hand was immersed for 3-minutes with simultaneous and 
conti nuous assessment of caroti d artery diameter and velocity. 
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Intima-media thickness. Previous studies found carotid artery intima-media thickness (IMT) 
to relate to cardiovascular risk and predict future cardiovascular disease.18 To explore the 
relevance of studying CAR% and IMT, we included measurements of the IMT (mm) of the left 
common carotid artery. According to widely adopted recommendations, we measured the 
IMT approximately 2cm proximal to the bulbus. We recorded the IMT continuously for 10 
seconds, in 2 different perpendicular planes (differing 90º).  From the 2 measurements wall 
thickness was calculated. Analyses were performed with edge-detection and wall-tracking 
software, as described elsewhere.19 
Blood pressure and heart rate. Before and during CPT, we continuously measured blood 
pressure using non-invasive photoplethysmography (Aim 1: Nexfin, BMEYE, Amsterdam, The 
Netherlands, Aim 2: Portapress, Finapres Medical Systems, Amsterdam, Netherlands). 
Cardiovascular risk factors (Aim 1; CAR% vs Risk factors). For the subgroups of 50 participants, 
we performed additional assessment of cardiovascular risk factors. To examine systolic and 
diastolic blood pressure, we performed two assessments of blood pressure using the manual 
approach (sphygmomanometer, on the left arm). Hypertension was defined as systolic 
pressure ≥140mmHg and/or diastolic pressure ≥90mmHg.20 We reported diagnosis of type 
1 or 2 diabetes mellitus and recorded (past and current) smoking habits. We used capillary 
blood to assess total cholesterol, high density lipoprotein cholesterol, low density lipoprotein 
cholesterol and triglycerides (35µL blood, Mission, ACON Laboratories, Inc., San Diego, USA). 
Elevated cholesterol levels were defined as total cholesterol >5.0 mmol/L.21-23 Based on the 
presence of risk factors, these participants were subdivided in; i. 0 risk factors, ii. 1 risk factor, 
and iii. ≥2 risk factors. 
Coronary artery responses (Aim 2; CAR% vs coronary artery). In a subgroup of 33 participants 
(37±17 years), left anterior descending (LAD) coronary artery velocity responses to the CPT 
were examined using transthoracic ultrasound, during simultaneous assessment of the 
CAR. Transthoracic assessment was performed by a highly experienced sonographer using 
a Vivid Q (GE Medical, Horten, Norway), with a 4 MHz phased array transducer. To this end, 
participants assumed a slightly left lateral position to allow access and measurement of the 
proximal end of the LAD from a modified parasternal window. When the vessel was detected 
(using colour flow mapping), the Doppler sample volume was positioned in the vessel, to 
allow for real-time velocity assessment during the cardiac cycle. Acquisition of the coronary 
velocity was obtained at baseline and during CPT.24 
Data analysis
Carotid artery diameter, velocity, blood flow and shear rate. CAR% responses were assessed 
for both diameter and blood flow. Analysis of the carotid artery diameter was performed using 
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custom-designed edge-detection and wall-tracking software, which is largely independent of 
investigator bias, by a single blinded investigator.25 Details of this technique can be found 
elsewhere.26 Baseline diameter, velocity, shear rate,25 and blood flow were calculated as the 
mean of data acquired across the 1 minute preceding the CPT test. After submersion of the 
hand in ice slush, data were calculated as the mean value for 10-second intervals, involving 
8-10 full cardiac cycles. Based on this data we calculated the peak diameter change (i.e. 
the 10-second bin with the highest value, CAR%) and area-under-the-curve for the diameter 
change during CPT (CAR
AUC
). The peak diameter change can refer to a maximum constriction 
or dilation. The direction of this change was determined by a positive (i.e. dilation) or negative 
(i.e. constriction) CAR
AUC
. In keeping with previous work, we also calculated the diameter 
change at 90 seconds (CAR90).
17 Reproducibility (coefficient of variation, CV) of diameter 
responses to CPT was assessed with a 1- and 24-hour interval. Within-day CV for baseline and 
peak diameters was 2.2 and 2.6%, whilst day-to-day CV were 2.3% and 2.7%. Furthermore, 
the CAR% (i.e. maximum change in diameter) showed a within-day reproducibility of 2.6% 
and between-day reproducibility of 2.8%.
Blood pressure and heart rate. Analyses included baseline and peak mean arterial pressure 
(MAP, mmHg), and baseline and peak heart rate (HR, beats per minute). Analyses were 
performed in labchart (LabChart 7, ADInstruments, Colorado Springs, USA) and/or excel. 
Both MAP and HR were averaged per 30 second bins for analyses. All values were averaged 
over the 2 CPTs.  
Coronary artery responses. All images were exported to DVD in raw format, for offline 
analyses.  The coronary blood velocity was analysed using commercially available software 
(EchoPAC Version 7.0; GE Medical, Horten, Norway). Measurements were performed at both 
baseline and during CPT and included peak systolic (S), peak diastolic (D) velocity and the 
velocity time integral (VTI). 
Statistical analysis
All data were presented as mean ± SD unless stated otherwise. Statistical analysis was done 
using IBM SPSS Statistics 20.0 (IBM SPSS, IBM Corp., Armonk, NY, USA).  For Aim 1, we 
examined differences between young and older groups using an independent Students’ t-tests 
(when data were normally distributed, following Kolmogorov-Smirnov tests of normality) or 
Mann-Whitney U tests (when data was not normally distributed). Effects of CPT differences 
between the groups (young vs older, and 0 vs 1 vs ≥2 risk factors) and time (baseline vs 
CPT) was assessed by 2-way repeated measures ANOVAs. Subsequently, 50 individuals with 
assessment of traditional cardiovascular risk factors were categorised into presence of 0, 1 or 
≥2 cardiovascular risk factors. A one-way ANOVA (data normally distributed) or Kruskal-Wallis 
(data not normally distributed) was adopted to examine differences in our primary outcome 
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parameters between groups. A Pearson’s correlation was adopted to assess the relation 
between CAR% (i.e. carotid artery function) and carotid artery intima-media thickness and 
diameter (i.e. carotid artery structure). For Aim 2, we first examined the change in carotid 
artery diameter and LAD velocity in response to CPT using a paired Student’s t -tests. Pearsons’ 
correlation coefficient was used to explore the relation between the change in carotid artery 
diameter (i.e. CAR%) and change in coronary artery velocity (i.e. VTI). 
Results
In healthy young subjects, CPT caused a gradual increase in carotid artery diameter that peaked 
around 90 seconds and, subsequently, returned towards baseline (Figure 2A). Carotid artery 
velocity and blood flow showed a gradual (~15%), but significant increase across the 3-minutes 
of the CPT-response (Figure 2B-C). Interestingly, shear rate remained around baseline levels 
until 90/100 seconds, after which it showed a marginal (~10%) increase (Figure 2D).
Figure 2. The time course adaptations. 
The time course presented during the cold pressor test in a young healthy subpopulation (n=25). A; 
diameter over time (cm), B; flow velocity over time (m/sec), and C; blood flow (ml/min) and D; shear 
over time (s-1). Error bars represent SEM.
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Aim 1: CAR% versus cardiovascular risk factors
Young and older participants. Older participants demonstrated higher weight and BMI, 
but no differences in height (Table 1). Systolic and diastolic blood pressure were higher in 
older compared to young participants (Table 1). Mean arterial pressure was lower in young 
compared to the older group, whilst heart rate was not different between groups (Table 
2). Carotid artery diameter was larger in the older group than in young participants, whilst 
carotid artery shear rate was higher in the young group (Table 2). CPT induced a significant 
increase in heart rate and mean arterial pressure in both groups, with older participants 
demonstrating a larger increase in heart rate and a larger increase in mean arterial pressure 
(Table 2). Both groups demonstrated a significant increase in carotid artery diameter in 
response to the CPT (Table 2). The diameter response during the CPT was significantly larger 
in young compared to older humans when data were presented as the peak diameter change 
(i.e. CAR%), area-under-the-curve across the 3-minute CPT (i.e. CAR
AUC
) and diameter change 
at 90-seconds (i.e. CAR90) (Table 2, Figure 3A). 
Table 1. Subject characteristics.
   Young Older P-value
Sex (% male) 56% 64% 0.452
Age (years) 24±3 61±8 <0.001
Weight (kg) 69±12 77±13 0.003
Height (m) 174±8 172±8 0.100*
Body Mass Index (kg/m2) 23±3 26±4 <0.001*
Systolic blood pressure (mmHg) 118±9 134±19 <0.001*
Diastolic blood pressure (mmHg) 68±8 78±7 <0.001
Subject characteristics for the comparison between young (19-30 years, n=50) and older (>50 years, 
n=44) participants. P-value refers to an unpaired Student’s t-test or *Mann-Whitney U test for the 
comparison between young and older participants.
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Table 2. Carotid artery and hemodynamic baseline characteristics.
Young Older 2-way ANOVA
Rest CPT Rest CPT group CPT Group*CPT
MAP (mmHg) 85±13 95±14 102±15 114±18 <0.001 <0.001 0.063
HR (bpm) 64±12 65±11 59±9 64±10 0.073 <0.001 0.006
Diameter (mm) 6.3±0.5 6.5±0.5 7.1±0.7 7.2±0.8 <0.001 <0.001 <0.001
Shear rate (1/s) 184±43 186±43 143±42 141±47 <0.001 0.905 0.318
Flow (ml/min) 9.2±2.3 10.1±2.6 10.2±2.8 10.3±3.5 0.286 0.001 0.019
Carotid artery reactivity (CAR)
Diameter change 
(CAR%)
4.1±3.7 1.8±2.6 <0.001*
Diameter change
AUC 
(CAR
AUC
)
2.7±2.3 1.0±1.3 <0.001
Diameter change90 
(CAR90)
3.5±2.8 1.4±1.6 <0.001
Carotid artery and hemodynamic baseline characteristics (averaged across a 1-minute period) and 
change during the cold pressor test (averaged across the 3-minute cold pressor test) in young (19-
30 years, n=50) and older (>50 years, n=44) participants. P-values refer to 2-way repeated measures 
ANOVA’s, for within participant comparison (CPT), between group comparison (group), and the 
interaction Group*CPT. *Refers to Mann-Whitney U test.
Cardiovascular risk factors. Cholesterol and LDL levels were highest in those with 1 RF 
compared to 0 or ≥2 RF, whilst no differences between groups were found for any of the 
other parameters (Table 3). We found a significantly different CAR%, CAR
AUC
 and CAR90 across 
the 3 groups (Figure 3B, Table 3), with a smaller carotid artery dilation observed in the 
presence of more cardiovascular risk factors. Specifically, we found that participants with 
≥2 risk factors showed a smaller dilation compared to those without risk factors (Table 3). In 
line with the CAR%, carotid artery diameter, IMT, and IMT ratio (i.e. intima-media thickness/
baseline diameter) were higher in participants with more risk factors (Table 3). However, no 
significant correlation was found between CAR% and carotid artery baseline diameter (r= 
-0.16, P=0.274), IMT (r= -0.09, P=0.524), or IMT ratio (r= -0.06, P=0.678).
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Figure 3. CAR and risk factors
Carotid artery reactivity (CAR%, presented as maximal change from baseline) in a cohort of healthy, 
asymptomatic subjects that were divided based on age (A: 50 young (black bar) versus 44 older humans 
(white bar)) and presence of cardiovascular risk factors (B: 0 risk factors (black bar, n=27), 1 risk factor 
(grey bar, n=11), and ≥2 risk factors (white bar, n=12)). Error bars represent SE. Statistical analysis 
(unpaired Students’ t-test (A) and ANOVA (B)) revealed significant differences in CAR% between groups.
517976-L-bw-van Mil
Processed on: 14-3-2018 PDF page: 110
110
Chapter 4
Table 3. CAR and risk factors.
0 risk factors 
(N=27)
1 risk factor 
(N=11)
≥2 risk factors 
(N=12)
P-value
Sex (% male) 52% 55% 42% 0.794
Hypertension (%) - 9% 17% 0.115
Diabetes (%) - - 8% 0.312
Smoking (%)             Current - 9% 17% 0.139
                               No 89% 64% 58%
                               History 11% 27% 25%  
Cholesterol (mmol/L) 4.25±0.7 6.17±1.4 5.5±1.3 >0.001†
HDL (mmol/L) 1.39±0.3 1.30±0.4 1.24±0.2 0.408
LDL (mmol/L) 2.59±0.7 4.0±1.5 3.4±1.4 0.025
Triglycerides (mmol/L) 1.3±1.0 2.1±1.3 1.9±1.1 0.196
Baseline diameter (cm) 0.64±0.06 0.70±0.04* 0.74±0.08* >0.001
Intima-media thickness (mm) 0.60±0.2 0.75±0.1* 0.82±0.1* 0.001
IMT ratio 0.09±0.02 0.11±0.02 0.11±0.02* 0.036
Carotid artery reactivity (CAR)
CAR% 2.9±2.9 2.3±2.2 0.5±2.9* 0.060
CAR
AUC
1.9±1.6 1.1±1.2 0.5±1.5* 0.034
CAR90 2.5±2.2 1.4±1.4 0.9±1.7* 0.037
Carotid artery reactivity (CAR%, presented as maximal change from baseline) in a cohort of healthy, 
asymptomatic subjects categorised by the presence of cardiovascular risk: 1. 0 risk factors (n=27), 2. 1 
risk factor (n=11), and 3. ≥2 risk factors (n=12).*Post-hoc significantly different from group 1.†Refers to 
Kruskall-Wallis  test.HDL; High density lipoprotein, LDL; Low density lipoprotein.
Aim 2: CAR% versus coronary artery
The CPT caused a significant increase in heart rate, mean arterial pressure, and carotid 
artery flow, velocity and shear rate (Table 4). A significant increase in carotid artery diameter 
was found when presented as CAR%, CAR
AUC
 and CAR90 (Table 4). Furthermore, a significant 
increase in LAD velocity was found during the CPT (Table 4). We found a significant, positive 
correlation between the CAR% and the change in LAD velocity time integral (r=0.486, P<0.004, 
Figure 4). A significant, positive correlation was also found between changes in carotid 
artery velocity and flow, and the change in LAD velocity time integral (r=0.402, P=0.021, and 
r=0.368, P=0.035, respectively). This relation between carotid and coronary artery responses 
was reinforced when data were presented as CAR90, but not for CARAUC (r=0.361 and 0.258, 
P=0.039 and 0.146, respectively). 
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Table 4. CAR and coronary responses. 
 Rest CPT P-value
Mean arterial pressure (mmHg) 87±14 99±16 <0.001
Heart rate (bpm) 60±10 62±10 0.048
CA diameter (cm) 0.66±0.08 0.68±0.08 <0.001
CA shear rate (1/s) 158±46 174±43 <0.001
CA flow (ml/min) 9.1±2.7 10.9±3.4 <0.001
CA velocity (cm/s) 25.8±6.7 29.3±7.1 <0.001
LAD systolic velocity (cm/s) 15±3.5 18±3.4 <0.001*
LAD diastolic velocity (cm/s) 31±7 39±9 <0.001
LAD velocity time integral (cm/s) 17±4 20±4 <0.001
Diameter change (CAR%) 4.5±3.8
Diameter area-under-the-curve (CARAUC) 2.8±2.5
Diameter change at 90 sec (CAR90) 3.6±2.9
Delta VTI (cm) 2.7±2.3  
Coronary artery responses in all participants included for Aim 2 (n=33). P-value refers to a paired 
Student’s t-test. *Refers to Wilcoxon Signed rank test. 
Figure 4. Correlation CAR and coronary artery 
Correlation between the carotid artery diameter response (% maximum change from baseline; i.e. 
CAR%) and coronary left descending artery velocity response (change in the velocity time integral 
(VTI in cm)) during a cold pressor test in a population of healthy, asymptomatic participants (n=33). A 
significant, positive correlation was observed between both measurements. 
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Discussion
In this study we explored the relationship between age, cardiovascular risk factors and CAR% 
and whether carotid artery responses to CPT reflect coronary artery vascular function. We found 
that the CPT induces carotid artery dilation in healthy, asymptomatic young participants, with 
no changes in shear rate. This highlights the ability of the carotid artery to dilate in response 
to the CPT, a functional change that is unlikely to be related to shear-mediated responses, as 
the dilation response of the carotid artery preceded any change in shear. Secondly, the CAR% 
was significantly attenuated in healthy, asymptomatic older participants, whilst presence of 
traditional cardiovascular risk factors was also associated with a smaller CAR%. These findings 
cannot be ascribed to structural characteristics of the carotid artery diameter (i.e. diameter 
or intima-media thickness), given the absence of a significant correlation between CAR% and 
these factors. Finally, a moderate-to-strong correlation was apparent between carotid artery 
dilation (i.e. diameter and velocity) and coronary artery dilator (i.e. velocity) responses to the 
CPT. These observations provide evidence that the CAR%, most likely independent of carotid 
artery structural characteristics, may represent a valuable test to assess arterial function and 
health and that it reflects coronary artery vasomotor function. 
Our study reveals the novel observation that, in a healthy, asymptomatic population, who 
generally demonstrate carotid artery dilation in response to the CPT, the CAR% successfully 
distinguishes between subjects with incremental number of risk factors. Also carotid artery 
IMT and diameter, both predictors for CV risk,18 were different between groups, with a higher 
value for those with ≥2 traditional cardiovascular risk factors. Since we found no correlation 
between CAR% and carotid IMT or diameter, it is possible that CAR% provides information 
that is independent from that of measures of carotid artery structure (i.e. diameter and IMT). 
This observation provides further support that CAR% may represent relevant information on 
CV risk.
Ideally, a test of (peripheral) vascular function related to CV risk should also reflect vascular 
health of coronary vessels, since coronary arteries are prone to the development of 
atherosclerosis and cardiovascular events. Previous studies have explored the relationship 
between measures of coronary and peripheral artery vascular function.14, 16 In line with these 
studies, carotid artery and coronary artery responses to the CPT show a moderate-to-strong 
correlation, a finding that is reinforced by earlier cross-study observations of comparable 
coronary and carotid artery responses to the CPT; dilation in healthy subjects or constriction 
in those with coronary artery disease.2, 4, 10 The ability for marked vasomotion of the carotid 
artery during the CPT is different to peripheral conduit arteries that typically show negligible 
change in diameter.27, 28 This further highlights the potential relevance for studying the carotid 
artery as a surrogate for coronary artery vascular function, since both of these conduit 
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vessels demonstrate similar responses to the CPT. The agreement between the coronary and 
carotid artery responses to the CPT somewhat contrasts with the lack of correlation between 
measures of carotid artery atherosclerosis (i.e. intima-media thickness) and coronary artery 
atherosclerosis (i.e. plaque burden).18 Our data, nonetheless, suggest that functional, rather 
than structural, measures in the two vascular beds may be related.
The ability of the carotid artery to dilate (or constrict) during the CPT raises questions 
regarding the potential underlying mechanisms. Whilst no extant study has examined the 
carotid artery, several studies explored pathways contributing to coronary artery vasomotion 
to the CPT.1, 2, 4, 6-9, 29 First, the diameter change to the CPT may be endothelium-dependent, 
since coronary artery responses to the CPT and acetylcholine (i.e. an endothelium-
dependent stimulus) show similarity in vasomotion.4, 29 To explain diameter response to the 
CPT, an increase in shear stress during CPT may contribute to an endothelium-dependent 
vasodilation.30 However, the increase in shear rate during CPT occurred after occurrence of 
the peak diameter (Figure 2), making changes in shear an unlikely explanation for carotid 
artery dilation. Another possibility is that the increase in blood pressure accounts for the 
diameter response to CPT. Indeed, we found a relation between increase in MAP and CAR%. 
However, the magnitude of increase in MAP did not differ between groups, whilst an increase 
in MAP was also observed in those who demonstrate a decrease in CAR%. This suggests that 
the increase in MAP is unlikely causally linked to carotid diameter changes. This notion is 
further supported when examining the timing of the peak responses, since peak diameter 
precede peak blood pressure responses by ~30 seconds. Nonetheless, we cannot exclude the 
possibility that increases in blood pressure contribute (partly) to the CAR%. Alternatively, the 
release of catecholamines during the CPT may contribute to vasomotion of the carotid artery 
during CPT,31, 32 with some work linking catecholamines (e.g. norepinephrine [NE]) to coronary 
artery dilation in healthy vessels or constriction in diseased arteries.2, 29 More specifically, 
NE may contribute to vasodilation via endothelium-dependent release of vasodilators,1, 33 
whilst a direct impact of NE on smooth muscle cells causes vasoconstriction.34, 35 The balance 
between both effects may ultimately determines the vasomotor response, which could 
be influenced by endothelium dysfunction. Although these mechanisms were explored in 
coronary arteries, comparable mechanisms may be present in the carotid artery during 
the CPT. Further research is required to characterize the physiology of the carotid artery 
responses to sympathetic stimulation using the CPT. 
  
Clinical relevance. Previous studies adopting invasive intracoronary Doppler catheters2, 4, 29 
and quantitative angiography,2, 4, 9, 29 have shown strong predictive capacity of coronary artery 
responses to sympathetic stimuli for future CV disease and/or events.6, 7, 9 Our observation 
of agreement between coronary and carotid artery responses to the CPT, combined with 
the relation of the CAR% with age and cardiovascular risk factors, suggest the potential 
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utility of the CAR% test. This is further supported by the observation that the CAR% provides 
information that seems independent from that of structural measures of the carotid artery, 
i.e. diameter and intima-media thickness. The potential use is further emphasised since it is 
easy applicable, simple, cheap, non-invasive, and requiring a minimum of training.
Limitations. We choose to group the number of cardiovascular risk factors, rather than explore 
the impact of individual risk factors, on the CAR%. Examining all individual risk factors would 
require a markedly larger sample size to properly perform statistical analyses, whilst our aim 
was to explore the relation between cardiovascular risk factors and the newly introduced 
CAR% in asymptomatic subjects. We strongly recommend future studies to explore the 
impact of individual risk factors to better understand how traditional risk factors affect CAR%. 
Secondly, due to technical restrictions, we were unable to collect LAD diameter to correlate 
diameter changes between both arteries. Since changes in diameter will affect measures of 
velocity, we may have underestimated the true correlation between both arteries in response 
to the CPT. Nonetheless, the significant correlation between both vascular beds, including 
the significant correlation between carotid artery and coronary artery velocities, emphasises 
the agreement between coronary and carotid responses to the CPT.
In conclusion, in the present study we found that older age and the presence of cardiovascular 
risk factors is related to a lower CAR%. Therefore, CAR% may represent a valuable technique 
to assess cardiovascular risk, which may be used in addition to structural measures of the 
carotid artery (i.e. diameter and intima-media thickness). In addition, the CAR% shows a 
good correlation with coronary artery responses to the CPT, which suggests that the CAR% 
represents a surrogate for coronary artery vasomotor function. 
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Abstract
Background. Carotid artery (CCA) dilation occurs in healthy subjects during cold pressor test 
(CPT), whilst the magnitude of dilation relates to cardiovascular risk. To further explore this 
phenomena and mechanism, we examined carotid artery responses to different sympathetic 
tests, with and without α1-receptor blockade, and assessed similarity to these responses 
between carotid and coronary arteries.
Methods. In randomised order, 10 healthy participants (25±3 yrs) underwent sympathetic 
stimulation using the CPT (3-minutes left hand immersion in ice-slush) and lower-body negative 
pressure (LBNP). Before and during sympathetic tests, CCA diameter and velocity (Doppler 
ultrasound) and left anterior descending (LAD) coronary artery velocity (echocardiography) 
were recorded across 3-min. Measures were repeated 90-min following selective α
1
-receptor 
blockade via oral Prazosin (0.05mg per kg bodyweight).  
Results. CPT significantly increased CCA diameter, LAD maximal velocity and velocity-time 
integral area-under-the-curve (all P<0.05). In contrast, LBNP resulted in a decrease in CCA 
diameter, LAD maximal velocity and velocity time integral (VTI, all P<0.05). Following α
1
-
receptor blockade, CCA and LAD velocity responses to CPT were diminished. In contrast, 
during LBNP (-30 mmHg), α
1
-receptor blockade did not alter CCA or LAD responses. Finally, 
changes in CCA diameter and LAD VTI-responses to sympathetic stimulation were positively 
correlated (r=0.66, P<0.01).
Conclusion. We found distinct carotid artery responses to different tests of sympathetic 
stimulation, where α
1
-receptors partly contribute to CPT-induced responses. Finally, we found 
agreement between carotid and coronary artery responses. These data indicate similarity 
between carotid and coronary responses to sympathetic tests and the role of α
1
-receptors 
that is dependent on the nature of the sympathetic challenge.
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Introduction
Activation of the sympathetic nervous system (SNS) is an important and clinically-relevant 
prognostic stimulus to examine artery function.1, 2 During the cold pressor test (CPT), a 
potent sympathetic stimulus, the coronary arteries can result in a vasoconstrictor (via α
1
-
receptors) or vasodilatory response (via the α2-, and β-receptors).
3 Vasodilator pathways 
prevail in healthy volunteers,4, 5 whereas experimental studies in patients with coronary 
artery disease demonstrate vasoconstriction during SNS activation.6-8 Coronary artery 
responses to CPT independently predict future cardiovascular events in patients at risk for 
cardiovascular disease,2, 9, 10 which highlights the clinical relevance of this response. However, 
the invasive nature of angiography make these tests impractical for large scale clinical use. 
Interestingly, the carotid artery shows vasodilation during SNS activation in healthy subjects, 
similar to coronary artery responses. This carotid dilation is abolished or even reversed 
to vasoconstriction in those with (increased risk for) cardiovascular disease.11, 12 To date, 
relatively little is known about the underlying mechanisms for the carotid artery reactivity to 
SNS activation. 
Previous studies in peripheral conduit arteries have reported divergent responses to different 
tests of SNS-activation.5, 13-16 To date, no previous study compared vasomotor responses of 
the carotid artery to distinct SNS stimuli. In line with peripheral arteries (i.e., the brachial 
and superficial femoral artery), we expect that distinct SNS stimuli (i.e. CPT and lower body 
negative pressure (LBNP)) lead to distinct carotid and coronary artery responses, as these 
tests mediate sympathetic activation through different pathways. More specifically, CPT 
evokes sympathetic activation via cold stress. The LBNP test gradually decreases central 
blood volume which results in progressive increases in muscle sympathetic nerve activity,17, 18 
which can directly lead to constriction of the carotid diameter. 
No previous study examined the potential underlying mechanisms mediating carotid artery 
vasomotion during SNS activation. Work in both animal and human coronary arteries revealed 
a central role for α
1
-receptors to mediate vasomotor responses during SNS activation.19-21 In 
line with this previous work, we expect that α
1
-receptors, at least in part, contribute to the 
carotid artery responses to CPT and LBNP. Therefore, our first aim is to examine the impact of 
activation of the SNS, either through the CPT (i.e. elevates SNS activity and blood pressure)22, 
23 or LBNP (i.e. elevates SNS activity, with preserved blood pressure)24, 25 on carotid artery 
diameter. Our second aim was to assess the role of α
1
-adrenoreceptors to these carotid 
artery responses by using an oral, selective α
1
-adrenoreceptor blocker (i.e. Prazosin). 
A recent study found good agreement between carotid and coronary responses to the CPT in 
healthy young and older subjects.12 To further explore this relationship, we aimed to compare 
the responses between the carotid artery diameter and left anterior descending coronary 
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artery velocity (LAD velocity) during different SNS stimuli, with and without α
1
-receptor 
blockade. Based on previous work,11, 12 we anticipated that there would be similarity in the 
magnitude and direction of the vascular responses between both the carotid artery diameter 
and LAD velocity, and that these responses would be partly mediated via α
1
-receptors. 
Methods
Ethical approval
This study was approved by the Human Ethics Committee of the University of British Columbia 
and conformed to the standards set by the Declaration of Helsinki. All volunteers provided 
written informed consent.
Participants
We recruited 10 healthy male participants (mean age 25±3 years, height 1.78±0.1m, and 
weight 76±9 kg). Exclusion criteria were a history of cardiovascular disease (i.e. angina 
pectoris, myocardial infarction, heart failure), lung disease (i.e. COPD, lung cancer), brain 
disease (i.e. stroke, dementia), presence of Raynaud’s phenomenon, scleroderma, chronic 
pain and/or open wounds on the upper extremities, obesity (body mass index >30 kg/m2), 
diabetes mellitus type 1 or 2, history of smoking, or elevated blood pressure (systolic >130 
mmHg; diastolic >85 mmHg). 
Experimental design
All participants reported to our laboratory for a single visit. They were asked to abstain 
from strenuous exercise for 24 hours and abstain from dietary products known to affect 
endothelial function for ≥18 hours prior to the testing session (i.e. vitamin C, caffeine and 
alcohol). Moreover, participants were asked to fast for ≥2 hours, adapted from existing 
guidelines to assess peripheral vascular function.26 Participants rested in the supine 
position for >15 minutes on a bed in a temperature-controlled room (23±1°C). Subsequently, 
participants underwent LBNP and two CPT, in a randomly assigned order, with 45-minutes 
rest between tests. All tests involved simultaneous assessment of common carotid artery 
(CCA) diameter and velocity (ultrasound) and left anterior descending (LAD) coronary artery 
velocity (echocardiography) before (across a 1-minute baseline) and during sympathetic 
stimulation. The protocol was repeated 90-minutes after oral administration of Prazosin 
(i.e. α1- adrenergic receptor antagonist that effectively blocks 80% of α1-recepter activity, 
0.05mg per kg body weight).27, 28
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Experimental measures 
Common carotid artery diameter and velocity. Left carotid artery diameter and red blood 
cell velocity were recorded simultaneously and continuously during baseline (1-minute) 
and sympathetic stimuli (i.e. 3-minutes CPT, and ~18-minutes LBNP). Carotid artery image 
acquisition was performed using a 10-MHz multifrequency linear array handheld probe 
attached to a high resolution ultrasound machine (15L4, Terason T3200, Burlington, MA, 
USA). When an optimal image was found, 2-3 cm proximal from the bifurcation, the probe 
was held stable and the ultrasound parameters were set to optimise the longitudinal, 
B-mode image of the lumen-arterial wall interface. Continuous pulsed wave Doppler velocity 
assessments were also obtained and were collected at the lowest possible insonation angle 
(always <60º). Assessment was performed by an experienced sonographer (ACCM), whom 
has an hour-to-hour reproducibility (i.e. coefficient of variation) of CCA baseline diameter of 
0.8% and reproducibility of 0.8% for the peak CCA diameter, in line with previous findings.12
Coronary artery velocity. Before and during both CPT and LBNP, the left anterior descending 
(LAD, cm) coronary artery velocity was examined using transthoracic ultrasound. This 
assessment was performed simultaneously with CCA diameter and velocity responses. 
All echocardiographic measurements were collected by a trained sonographer (MS) on a 
commercially available ultrasound system (Vivid E9; GE, Fairfield, CT) using a broadband M5S 
5 MHz or a 3V 3D-array transducer. In a previous study the Cronbach’s alpha reliability test 
revealed alpha values of 0.81 and 0.89 for both max and mean LAD velocities, respectively, 
suggesting good consistency between LAD velocity measurements.29 Participants assumed 
a left lateral position to allow for data collection. The LAD was imaged using a modified 
parasternal short axis view from the fourth or fifth left intercostal space, and was assessed 
using pulsed-wave Doppler. The transducer was positioned such that a 2- to 3-mm segment 
of the LAD was imaged along the long axis, taking care to align the pulse-wave cursor with the 
length of the vessel. With a sample volume (2.0 mm) positioned over the color Doppler signal 
in the LAD, measurements of the LAD velocity were collected during the sympathetic tests. 
Blood pressure and heart rate. All continuously recorded cardiovascular measurements 
were acquired at 200 Hz using an analog-to-digital converter (Powerlab/16SP ML 880; 
ADInstruments, Colorado Springs, CO, USA) interfaced with a personal computer. Before 
and during CPT and LBNP, systolic and diastolic blood pressure (SBP and DBP, in mmHg, 
respectively), stroke volume (SV, ml), rate-pressure product (RPP, HR x SBP, a reliable indicator 
for myocardial oxygen demand),30 and cardiac output (CO, L/min) were continuously measured 
using non-invasive finger photoplethysmography (Finometer Pro, Finapres medical systems, 
Amsterdam, Netherlands). Heart rate (HR, beats per minute) was recorded using three-
lead electrocardiography, placed in lead II configuration (Bioamp, ML132, ADInstruments, 
Colorado Springs, CO, USA). 
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Sympathetic stimuli
Cold pressor test. The cold pressor tests (CPT) consisted of a 3-minute immersion of the left 
hand in a bucket of ice slush (~4.0°C).12 The participant was positioned in supine position on a 
tilt bed, tilted slightly to the left lateral position (~25-30°), to facilitate arm movement in the 
bucket of slush without significant movement of the body, and provide adequate coronary 
assessment. After a 1-minute baseline period, the participants hand was immersed up to the 
wrist in the ice-slush for 3 minutes.  The participant was instructed to remain quiet during 
the CPT to provide for valid CCA assessment. The partial pressures of end-tidal carbon dioxide 
(P
ET
CO2) and oxygen (PETO2) were clamped at baseline values for the entire duration of the 
protocol to reduce the potential impact of hyperventilation on the vascular responses, upon 
an end-tidal forcing approach described extensively elsewhere.31 To reduce measurement 
error, CPT procedures were repeated twice and averaged for analyses.12
Lower body negative pressure. The participant was positioned in the supine position on a tilt 
bed, and strapped into a custom-made airtight, lower-body suction chamber at the level of 
the iliac crest.32 The LBNP chamber was then moved from supine position into a left lateral 
position (~25-30°) to ensure adequate coronary imaging. The lower body negative pressure 
test consisted of a 5-minute baseline, followed by progressive 2-minute stages, using 
increments of -10 mmHg, to -80 mmHg or until pre-syncope. LBNP was terminated when 
a) pre-syncope occurred, defined by a sustained drop in systolic blood pressure <80 mmHg 
for more than 10 seconds,33 or b) upon participants request due to the onset of subjective 
symptoms (e.g. feelings of dizziness, nausea, faintness). During the Prazosin condition, 
participants were unable to last longer than -40mmHg during the LBNP test. For reliable 
comparison between the control and drug condition, we chose to only include data until 
-30mmHg. 
 
Data analysis
Carotid artery responses. Analyses of diameter (cm), blood flow (ml/sec), blood velocity (cm/
sec) and shear (s-1) were performed using custom-designed edge-detection and wall-tracking 
software, which is largely independent of investigator bias, as was extensively described 
elsewhere.34 Baseline diameter, blood flow, blood velocity and shear were calculated as the 
mean of data acquired across a 1-minute baseline period.34 For the CPT, data were calculated 
for 10-second intervals. LBNP data was calculated per 1-minute intervals. Subsequently, 
offline image analysis involves the identification of the region of interest (ROI), to allow for 
automated calibration on the B-mode image and velocities on the Doppler assessment.35 A ROI 
is drawn around the optimal B-mode image, in which a pixel-density algorithm automatically 
identifies the near- and far wall. Another ROI is drawn around the Doppler waveform, which is 
synchronized with the B-mode diameter ROI. Ultimately, this allows for blood flow and shear 
rate calculations.35 Peak diameter change was calculated relative to baseline diameter. 
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Coronary artery responses. All images were exported for offline analysis using commercially 
available software (EchoPAC Version 13.0; GE Medical, Horten, Norway). All echocardiographic 
values represent an average value of three cardiac cycles representing the clearest of five 
collected images for each experimental stage. The collected waveforms were analyzed to 
determine mean diastolic velocity (LADVmean, cm/sec), peak diastolic velocity (LADVmax, 
cm/sec), and the velocity time integral (VTI, cm).36 Coronary flow velocity reliably reflects 
changes in absolute coronary blood flow,4, 5, 37 suggesting that an increase in flow velocity 
reflects coronary artery dilatation. Using observer-independent software, VTI is calculated as 
the integral of individual velocities across the cardiac cycle. Participants in whom at least 1 
image was suboptimal, were excluded prior to analyses.29
Blood pressure and heart rate. Analyses of systolic and diastolic pressure, heart rate, 
cardiac output, stroke volume, and the rate-pressure product (RPP) were performed in 
commercially available software (LabChart V7.1, ADInstruments, Colorado Springs, CO, USA). 
Measurements were averaged per 10-second bins for analyses for the CPT, and 1-minute bins 
for the LBNP analyses. Baseline CPT was averaged over a 3-minute period. Continuous blood 
pressure measurements were calibrated to automated brachial blood pressure readings 
during baseline (HEM-775CAN, Omron Healthcare, Bannockburn, IL, USA). 
Statistical analyses
All data were presented as mean±SD unless stated otherwise. Parameters were tested 
for normality using a Shapiro-Wilk test. Responses of the CCA (i.e. diameter (cm), blood 
velocity (cm/sec), flow (ml/sec) and shear (s-1)) and LAD (i.e. mean velocity (cm/sec), max 
velocity (cm/sec) and VTI (cm) were assessed during the sympathetic stimulus with paired 
Students’ t-tests (in case of non-parametric variables, a Wilcoxon signed-rank test was 
performed). Changes over time were assessed with 2-way repeated measurement ANOVA’s 
(missing values were only imputed based on previous and consecutive measurements when 
available). We assessed whether CCA and LAD changes in diameter, velocity, flow and shear 
occurred over time (i.e. within factor ‘time’), and whether this differed between conditions 
(i.e. between factor control vs Prazosin) were examined. In addition to the main effects, 
the ‘time’*’condition’-interaction revealed whether the CCA and LAD changes across time 
differed between the control condition and Prazosin. This was done to assess the potential 
role of α-receptors in mediating CCA and LAD responses. The 2-way repeated measurement 
ANOVA’s were performed with Sidak correction to account for multiple comparisons. Data 
were analysed using SPSS 20.0 software (IBM SPSS, IBM Corp., Armonk, NY, USA). Values for 
p<0.05 were assumed to be statistical significant.
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Results
Carotid artery responses: different SNS stimuli.
Cold pressor test. The CPT caused a significant increase in systolic and diastolic blood pressure 
and the rate-pressure product (RPP), whilst no change was found in stroke volume, heart 
rate and cardiac output (n=9, Table 1). Although the diameter (cm) of the CCA increased 
significantly during CPT (P<0.001, Figure 1), CCA velocity (cm/sec), flow (ml/sec) and shear 
rate (s-1) did not change significantly across time during CPT (P>0.05, data not shown). 
Lower body negative pressure. LBNP caused a gradual, but significant increase in heart rate, 
a decrease in stroke volume and diastolic blood pressure, whilst systolic blood pressure and 
cardiac output were preserved (n=9, Table 2). LBNP caused a significant decrease in CCA 
diameter (cm, Figure 2), whereas no changes were found in CCA velocity (cm/sec), flow (ml/
sec) and shear (s-1) (data not shown). 
Figure 1. Responses of the carotid artery and the LAD coronary artery to CPT.
A. Diameter change of the carotid artery over time. B. Percentage change in carotid diameter at 
baseline and during CPT (area under the curve, AUC). C. VTI change of the LAD coronary artery over 
time. D.  Percentage change in LAD coronary artery VTI at baseline and during CPT (area under the 
curve, AUC). Data are presented as mean, error bars represent standard error of the mean (SEM). White 
bars represent baseline measurements, black bars represent peak values.
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Figure 2. Responses of the carotid artery and the LAD coronary artery to LBNP.
A. The diameter change of the carotid artery over time. B. The percentage change in carotid diameter 
at baseline and during LBNP. C. the VTI change of the LAD coronary artery over time. D.  The percentage 
change in LAD coronary artery VTI at baseline and during LBNP. Data are presented as mean, error bars 
represent standard error of the mean (SEM). White bars represent baseline measurements, black bars 
represent peak values.
Carotid artery response to sympathetic activation: role of α1-receptors.
Cold pressor test. Prazosin increased baseline CCA diameter, and decreased shear (0.671±0.05 
to 0.703±0.05 cm, and 185.9±50 to 159.1±40 s-1 respectively, all P<0.05), whilst no changes 
were found in carotid blood flow and blood velocity (10.9±1.8 to 10.8±1.5 ml/sec P=0.405, and 
30.7±6.6 to 27.7±5.2 cm/sec, P=0.051). Prazosin caused an abolished CPT-induced increase 
in diameter (Figure 3). Prazosin attenuated the increase in blood pressure during CPT, and 
resulted in a larger increase in cardiac output, heart rate and RPP during the CPT (n=9, Table 
2). We found no change in stroke volume (Table 2), whilst we also found no change in CCA 
flow, shear and velocity (data not shown). 
Lower-body negative pressure. Baseline CCA diameter, flow and velocity were significantly 
larger following Prazosin administration (0.684±0.05 to 0.706±0.05 cm, 10.2±1.6 to 12.0±2.3 
ml/sec, and 27.6±5.0 to 30.0±5.5 cm/sec, respectively, all P<0.05). All subjects reached pre-
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syncope at -30 or -40 mmHg. Therefore, we compared data between both sessions up to 
-30 mmHg. Prazosin did not alter CCA diameter responses during LBNP (Table 2, Figure 4). 
Prazosin exaggerated the increase in heart rate and RPP during LBNP, whilst blood pressure 
decreased during the Prazosin trial (n=9, Table 2).
Carotid artery responses versus coronary artery responses.
SNS stimulation. Similar to CCA responses, CPT caused a significant increase in LAD maximum 
velocity (n=6, baseline 0.25±0.03 to peak 0.34±0.02 cm/sec, P<0.05) and VTI (P<0.05, Figure 1). 
Due to the suction of the LBNP box, movement of the participants prevented assessment in 5 
participants. Again in agreement with CCA responses, LBNP caused a reduction in LAD maximum 
velocity (n=5, Table 2) and peak VTI (cm, Figure 2). When pooled, a significant correlation was 
found between changes in CCA diameter and LAD peak VTI (n=20, r=0.65, P<0.01). 
α
1
-receptor blockade. Following Prazosin administration, LAD VTI were elevated and Prazosin 
abolished the increases in CCA diameter and LAD peak VTI (Figure 3, Table 2). During LBNP, 
Prazosin did not alter CCA diameter (cm), LAD peak VTI or LAD peak velocity responses (cm/
sec, up to -30 mmHg; Table 2, Figure 4). 
Figure 3. Responses of the CCA and the LAD to CPT, Control versus Prazosin condition.
A. Diameter change of the carotid artery over time. B. Percentage change in diameter. C. VTI change of 
the LAD coronary artery over time. D.  Percentage change in LAD coronary artery VTI at baseline and 
during the CPT. Data are presented as mean, error bars represent standard error of the mean (SEM). 
White bars represent the Control condition, black bars represent the Prazosin condition.  
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Figure 4. Responses of the CCA and the LAD to LBNP, Control versus Prazosin condition.
A. Diameter change of the carotid artery over time. B. Percentage change in carotid diameter at baseline 
and during the LBNP. C. VTI change of the LAD coronary artery over time. D.  Percentage change in LAD 
coronary artery VTI at baseline and during the LBNP. Data are presented as mean, error bars represent 
standard error of the mean (SEM). White bars represent the Control condition, black bars represent the 
Prazosin condition.
Discussion
We present the following findings. First, activation of the SNS using the CPT significantly 
increased CCA diameter, whilst SNS activation using LBNP mediated a decrease in CCA 
diameter. Second, systemic blockade of the α
1
-receptors significantly attenuated the dilator 
response of the carotid during the CPT, whilst these changes were unaltered during LBNP. 
This latter finding suggests the presence of distinct carotid artery responses to different types 
of SNS activation, with a distinct contribution of α
1
-receptors mediating these responses. 
Furthermore, we found good agreement between the direction and magnitude of the 
coronary and carotid artery responses when comparing the different tests of sympathetic 
stimulation, but also regarding the contribution of α
1
-receptors. Taken together, we found 
divergent responses to distinct tests of SNS activation and the role of α
1
-receptors mediating 
these responses, whilst similarity is found between carotid and coronary arteries in the 
magnitude and direction of vascular responses to sympathetic stimulation and blockade of 
α
1
-receptors.
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Carotid artery responses to sympathetic stimulation.
The CPT resulted in a characteristic dilation in the CCA of our healthy subjects, a finding 
observed previously in our laboratory12 and others.11 Interestingly, these dilator responses 
of the carotid artery contrasts with peripheral artery responses, since brachial or superficial 
femoral arteries demonstrate negligible diameter changes during CPT.14, 16 Central, elastic 
arteries (such as the carotid artery) may thus respond differently to SNS activation using 
the CPT compared to muscular, peripheral arteries. This notion is further supported by 
observations of abdominal aorta dilation during the CPT.38 In contrast, LBNP mediated a 
decrease in CCA diameter. The presence of distinct artery responses to different tests of 
sympathetic activation has also been reported in peripheral conduit arteries.14 Both CPT 
and LBNP mediate sympathetic activation through different pathways, leading to distinct 
vascular responses in peripheral and central arteries. The CPT causes an immediate stressor 
response,5, 14 leading to rapid catecholamine release and blood pressure elevation. This 
induces β-receptor mediated vasodilation, and sympathetic blood pressure mediated 
constriction, respectively. The resultant of this response is an increase in CCA diameter, 
due to the outweighing effect of β-receptor mediated vasodilation. In contrast, the LBNP 
mediates a gradual, arterial baroreflex-mediated activation of the sympathetic nervous 
system and thus can directly decrease carotid diameter. Both sympathetic tests demonstrate 
distinct time-dependent changes in circulating catecholamines, with an immediate elevation 
after CPT, and a slower (time- and intensity-dependent) elevation during LBNP.5, 14, 24, 39 This 
data indicates that distinct tests of stimulation of the sympathetic nervous system lead to 
different carotid artery responses.
Role of α1-receptors in carotid artery responses to sympathetic stimulation.
Under physiological conditions, α
1
-receptors mediate vasoconstriction in coronary arteries 
during a sympathetic stimulus.20, 40 Indeed, blockade of α
1
-receptors resulted in an increase 
in baseline CCA diameter and velocity, but also LAD velocity. However, in contrast to our 
hypothesis, α
1
-blockade attenuated the carotid artery dilator responses during the CPT, 
whilst no impact of α
1
-blockade was found during LBNP. One potential explanation is that the 
increase in baseline diameter and/or velocity (induced by α
1
-receptor blockade) prevented a 
further increase in diameter upon additional SNS stimulation. This explanation is supported 
by previous work in peripheral arteries, which found that an increase in baseline diameter 
is associated with a smaller endothelium-(in)dependent vasodilation.41, 42 However, our data 
does not reveal such a relation between resting carotid diameter and peak responses (CPT 
control r=-0.280, Prazosin r=-0.275, LBNP control r=-0.401, Prazosin r=-0.219, all P>0.05). 
Therefore, CCA dilation during α
1
-blockade may not explain the attenuated vasomotor 
responses to CPT or preserved response to LBNP. 
517976-L-bw-van Mil
Processed on: 14-3-2018 PDF page: 131
131
SNS activatioN & ceNtral artery reSpoNSeS
5
An alternative explanation for the attenuated dilator response may relate to the 
pharmacological actions of α
1
-receptor blockers. In healthy coronary arteries, vasoconstriction 
upon sympathetic stimulation is largely mediated via α
1
-receptors, with only a minor role 
for α2-receptors.
43, 44 Previous studies in both animals and humans found that during α
1
-
receptor blockade, SNS activation still mediates coronary constriction through activation 
of α2-receptors.
45-47 Possibly, α
1
-receptor blockade in our study yielded stimulation of α2-
receptors during activation of the SNS using the CPT. Consequently, the vasodilator responses 
may be attenuated by the constrictive actions of α2-receptors. This hypothesis needs 
further exploration. A final reason for the diminished CCA dilation during CPT could reside 
in the attenuated blood pressure responses. However, it is unclear whether blood pressure 
represents the principal contributor to the carotid dilation, especially since peak diameter 
responses precede peak blood pressure values. Moreover, blood pressure rises similarity 
between individuals who demonstrate carotid artery vasodilation versus vasoconstriction.12 
Nonetheless, we cannot exclude a potential role for the blood pressure response to contribute 
to the carotid dilation. 
Carotid artery versus coronary artery.
Our findings provide strong evidence for similarity between the carotid and coronary arteries 
regarding the direction and magnitude of the vasomotor response. Indeed, both carotid and 
coronary arteries demonstrated dilation in response to CPT, but constriction was present 
in both arteries during LBNP. The presence of coronary dilation to CPT,6, 7 but also coronary 
constriction to LBNP5 has been reported in previous studies. This further confirms the 
presence of distinct artery responses to distinct stimuli to activate the sympathetic nervous 
system. Furthermore, α
1
-receptor blockade mediated similar effects between carotid and 
coronary arteries for the LBNP test. During the CPT we observed that α
1
-receptor blockade 
attenuated the carotid responses, whilst the coronary responses were reversed. Agreement 
between arteries was further supported by the presence of a significant and strong correlation 
between both arteries (Figure 5), a finding that is in line with previous work.11, 12 A potential 
limitation of the echocardiographic measurement is the inability to examine blood flow. 
However, strong agreement is present between changes in coronary artery blood velocity 
and blood flow in response to sympathetic stimulation,4, 5, 48 suggesting that the increase in 
LAD velocity can be interpreted as true coronary vasodilation. 
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Figure 5. Correlation between the carotid artery diameter and coronary LAD response
Correlation between the carotid artery diameter response (CAR%) and coronary LAD response (change 
in the velocity time integral (VTI in cm)) pooled for the cold pressor test and lower body negative 
pressure test (n=16).
Despite these similarities in magnitude and direction of vascular responsiveness, it is important 
to emphasise that the mechanisms contributing to vascular control may differ between 
arteries. For example, coronary artery flow and velocity during sympathetic stimulation are 
dependent on both local metabolic and vasodilatory mechanisms sensitive to the rate of 
myocardial oxygen consumption (MVO2).
5 For this purpose, we have calculated the rate-
pressure product, a common used index for myocardial oxygen consumption (RPP, Figure 6). 
The increase in RPP during the CPT suggests that the dilation of the coronary artery is, at least 
partly, related to the increase in myocardial oxygen uptake. Whether similar mechanisms 
are present in the brain to contribute to carotid artery dilation during the CPT is currently 
unknown. For the LBNP, we found no important role for RPP to contribute to the vascular 
responses in our study. When correcting our responses for potential differences for the RPP, 
correlation between LAD VTI and CAR(%) remained present (r=0.66, P<0.05). Future studies 
are required to better understand the mechanisms contributing to the vascular responses 
during sympathetic stimulation in both carotid and coronary arteries.  
Clinical relevance. Coronary artery responsiveness to SNS stimulation, including the CPT, 
has shown a strong predictive ability for future cardiovascular disease and/or events.2, 9, 10 
Similarity in vasomotor responsiveness between coronary and carotid arteries suggests that 
the carotid artery may serve as a alternative measure for coronary vascular responses to SNS 
stimulation. An important advantage of measuring the carotid artery is its easy accessibility, 
high reproducibility and the accuracy of the test. This warrants future studies to further 
explore the potential clinical use of examining carotid responses to SNS stimulation. To further 
explore the similarity between the carotid and coronaries, future studies could be performed 
in a catheterisation laboratory, to simultaneously measure both carotid and coronary artery 
responses during sympathetic stimulation. These studies can be extended by the addition 
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of selective α- and /or β-adrenergic agonist/antagonists, to further resolve the contribution 
of adrenergic receptors to sympathetically-mediated carotid and coronary artery responses. 
Methodological considerations. A strength of our study was that we controlled for end-tidal 
gases at baseline values, during both CPT and LBNP, and the α
1
-receptor blockade condition. 
Fluctations and alterations in P
ET
CO2 are known to directly influence the diameter of the CCA
49 
and LAD VTI.29 Following our α1 blockade, which directly affects mean arterial pressure and 
ventilatory regulation during sympathetic activation, clamping P
ET
CO2 and PETO2 to baseline 
values reduced the possible interference with our carotid and coronary artery responses. 
To summarize, our data demonstrates that the carotid artery demonstrates distinct vascular 
responses to different stimuli to activate the sympathetic nerve system. Additionally, 
blockade of the α
1
-receptors significantly attenuated the dilator responses in the carotid 
artery during the CPT, whilst no changes were found during LBNP, suggesting a potential role 
for α-receptors to contribute to vasomotor responses in carotid arteries. Finally, even though 
α
1
-blockade resulted in disparate responses during CPT, our findings indicate strong similarity 
between carotid and coronary artery reactivity in response to distinct sympathetic stimuli. 
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Table 1. Cold pressor test, hemodynamic responses
Cold pressor test 1 minute CPT 2 minutes CPT
Baseline 10 20 30 40 50 60 70 80  90
Stroke volume 
(ml) Control
105±15 106±17 106±16 105±17 105±17 105±19 105±20 105±21 104±20 104±20
Stroke volume 
(ml) Prazosin
112±14 113±15 114±14 114±15 113±16 112±17 111±16 110±15 111±17 111±16
Cardiac Output 
(L/min) Control
6.2±1.3 6.6±1.2 6.8±1.3 6.6±1.4 6.7±1.6 6.8±1.8 7.0±1.6 6.9±1.6 6.7±1.7 6.6±1.5
Cardiac Output 
(L/min) Prazosin
6.7±0.9 7.4±1.0 7.5±1.2 7.5±1.3 7.7±1.5 7.7±1.6 7.5±1.6 7.6±1.6 7.5±1.4 7.5±1.4
Heart Rate  
(bpm) Control
59±12 63±10 65±11 64±11 64±13 64±12 67±12 66±12 64±13 63±13
Heart Rate 
 (bpm) Prazosin
62±12 69±13 68±11 68±11 71±13 71±14 70±13 71±14 70±15 70±14
Diastolic BP 
(mmHg) Control
79±8 83±6 81±7 84±9 86±8 88±8* 91±8* 92±9* 92±8 92±8
Diastolic BP 
(mmHg) Prazosin
74±9 76±9 74±9 76±9 78±9 80±9 81±10 81±9 81±9 82±8*
Systolic BP 
(mmHg) Control
133±7 139±8 137±10 140±11 142±12 146±13 148±11* 150±12* 150±12* 150±13
Systolic BP 
(mmHg) Prazosin
131±7  136±6* 135±7 136±7 138±6 140±7 141±9 140±7 140±7 140±6
Rate pressure 
product - Control
7927±1754 8787±1449 8963±1654 9028±1804 9160±2048 9483±2096 9901±2047 9978±2093 9619±2114 9549±2097
Rate pressure 
product - Prazosin
8141±1534 9380±1761 9169±1724 9284±1750 9771±1778 9953±2062 9833±2023 9960±2072 9887±2196 9858±2024
LAD velocity  
max Control
0.252±0.03 0.325±0.07 0.304±0.03 0.280±0.05
LAD velocity max 
Prazosin
0.261±0.04 0.312±0.04 0.302±0.07 0.281±0.06
LAD velocity 
mean Control
0.201±0.03 0.256±0.07 0.232±0.03 0.224±0.04
LAD velocity 
mean Prazosin
0.199±0.03 0.25±0.02 0.226±0.03 0.228±0.05
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3 minutes CPT 2-way ANOVA
100 110 120 130 140 150 160 170 180 Time Trial Time* 
Trial
103±20 105±21 106±21 106±21 106±20 106±20 106±20 107±19 107±19 0.450 0.296 0.450
109±17 110±17 110±17 111±17 112±17 111±17 111±18 112±18 112±17
6.3±1.4 6.3±1.5 6.3±1.4 6.3±1.5 6.1±1.6 6.3±1.5 6.3±1.4 6.3±1.5 6.3±1.4 0.200 0.049 0.021
7.5±1.4 7.6±1.3 7.6±1.2 7.4±1.1 7.6±1.1 7.6±1.1 7.6±1.0 7.7±0.9 7.6±1.0
62±12 62±13 61±12 61±13 59±15 61±13 61±12 60±14 59±12 0.107 0.024 0.001
71±14 72±14 72±14* 70±13 71±13* 71±12 71±13* 71±12* 70±13*
93±9* 92±9* 92±9* 92±9* 91±8* 90±8* 90±8* 90±8 89±8* 0.000 0.045 0.031
82±9* 82±8 83±9 80±9 81±9* 82±9* 81±9* 81±9* 80±8*
151±13 150±13 151±12 151±11* 150±12* 149±11* 148±10* 148±11 148±11* 0.000 0.169 0.023
141±8 141±8 141±9 139±9 140±8 141±9* 141±9* 140±9* 140±7*
9458±1931 9253±2024 9212±1982 9166±2045* 8890±2087 9077±2011 8984±1819 8883±2042 8834±1927 0.008 0.307 0.014
10088±2018 10158±2138 10217±2204 9705±1855 9892±1870* 9941±1667* 9981±1580* 9928±1482* 9826±1709*
0.261±0.04 0.266±0.05 0.265±0.05 0.007 0.769 0.594
0.278±0.06 0.284±0.06 0.279±0.05
0.209±0.03 0.215±0.03 0.207±0.03 0.041 0.603 0.400
0.231±0.04 0.231±0.04 0.228±0.04
Hemodynamic and coronary responses during Cold pressor test (averaged per 10 second intervals). 
P-values refer to 2-way repeated measures ANOVA’s, for within participant comparison (time), between 
trial comparison, and the interaction time*trial. *Symbols denote P<0.05 difference to baseline values.
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Figure 6. Mean coronary velocity expressed versus the rate pressure product (RPP). 
∆A. Responses of mean coronary velocity versus RPP during CPT. B. Responses of mean coronary velocity 
versus RPP during CPT with prazosin. C. Responses of mean coronary velocity versus RPP during LBNP. 
D. Responses of mean coronary velocity versus RPP during LBNP with prazosin. Light grey indicates 
individual responses, whilst the black arrows indicate the mean response.
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Abstract
Objective. Patients with peripheral arterial disease (PAD) have increased risk on future 
cerebro- and cardiovascular (CV) events. Our aim was to examine whether the carotid artery 
reactivity (CAR; a novel, simple procedure to examine endothelial function) predicts CV 
events in PAD patients. 
Methods. 172 PAD patients (68±10 years, 67% male) underwent the CAR, which involves 
ultrasound measurement of carotid artery diameter during sympathetic stimulation produced 
by 90sec hand immersion in 4°C ice-water (i.e. cold pressor test). CAR-responses were 
dichotomised into carotid constriction or dilation. We recorded cardiac and cerebrovascular 
events, mortality and clinical progression to percutaneous transluminal angioplasty or loss of 
patency during 12-months follow-up. 
Results. Eighty-two PAD patients demonstrated carotid constriction and 90 patients 
demonstrated dilation. PAD patients with carotid constriction showed more (CV) events 
compared to patients with dilation (Kaplan-Meier Log rank; P<0.05). Cox proportional hazard 
model showed that patients with carotid constriction continued to show higher risk for CV 
events (Hazard Ratio: 4.1, 95%CI: 1.3-12.5) and clinical progression (Hazard Ratio: 2.0, 95%CI: 
1.2-3.3), even after adjustment for other risk factors. Ankle brachial pressure index and 
carotid intima-medial thickness alone did not predict (CV) event or improve risk assessment 
beyond that provided by CAR. 
Conclusion. Carotid vasoconstriction identifies PAD patients with a four-fold increased risk for 
future CV events and two-fold increased risk for clinical deterioration. CAR provides a simple, 
novel strategy to predict CV events and progression in PAD patients.
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Introduction 
Peripheral arterial disease (PAD) is the result of atherosclerotic arterial stenosis and 
occlusions in the larger vessels supplying the lower extremities.1 Patients with PAD have 
a markedly increased risk for future cardiovascular mortality and morbidity.1-4 Endothelial 
dysfunction contributes to the development and progression of PAD.5, 6 Endothelial function, 
often examined as the brachial artery reactivity response to ischaemia, in PAD patients is 
impaired7-9 and relates to future CV events.10, 11 The recent AHA/ACC-guideline on the 
management of PAD highlighted the need for an easy, simple and rapid test of endothelial 
function to predict future adverse events in PAD.12 Although brachial artery reactivity shows 
predictive capacity for future CV events,10, 11 concerns have been raised regarding practical 
limitations that prevents the clinical application of this technique.
Carotid artery reactivity (CAR) testing is a simple, non-invasive procedure to examine 
endothelial function. It involves measuring the carotid artery diameter responses to the 
sympathetic stimulation produced by the cold pressor test (CPT).13, 14 The carotid arteries, like 
coronary arteries,13, 14 dilate in response to the CPT in healthy subjects, whereas this dilation 
is attenuated, or reversed to vasoconstriction, in patients with cardiovascular disease.13-16 
Interestingly, the coronary arteries’ response to CPT is a strong, independent predictor of 
cardiovascular events,17, 18 but it is not clear if the carotid response to CPT (i.e. CAR) also 
predicts future cardiovascular events. This study is to our knowledge, the first to examine 
the prognostic value of the CAR in patients with PAD. We hypothesized that CAR-induced 
vasoconstriction would predict future CV events in patients with PAD, independent of subject 
characteristics and clinical status.
Methods
Participants and study approval
We recruited 172 patients with PAD scheduled for a routine visit at the vascular laboratory 
(Department of Surgery, Radboud University Medical Center, Netherlands) for the study 
(Figure 1). We included PAD patients with present or prior Fontaine classification 2B-3-4, 
age ≥18yr, and the ability to provide informed consent. We excluded patients with Raynaud’s 
phenomenon, chronic pain syndrome, open wounds on the upper extremities, arterial-venous 
shunts, scleroderma, coronary, central and/or peripheral arterial disease interventions within 
the prior <1 week, and unstable angina pectoris, myocardial infarction, stroke or heart failure 
within the prior 3 months. Patients provided written informed consent prior to participation. 
The study was approved by the local Ethics Committee (NL-46109.091.13) in accordance 
with the latest revision of the Declaration of Helsinki. This study was registered as NTR-4117 
(Netherlands Trial Registration).
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Figure 1. Consort diagram 
Experimental design
Pati ents abstained from strenuous exercise for 24 hours, fasted for ≥6 hours, and abstained 
from caff eine and vitamin C, which are known to alter endothelial functi on, for ≥18 hours 
prior to testi ng in accordance with guidelines on assessing endothelial functi on.20
Experimental measures
General characteristi cs. Age and sex were obtained from the electronic pati ent records. A 
physician obtained the history of smoking, hypercholesterolemia, hypertension, diabetes 
and medicati on use. Height (in m), weight (in kg), and waist-hip rati o (WHR) were measured 
by a research nurse. The same vascular surgeon assigned the pati ent’s Fontaine clinical 
classifi cati on. Pati ents with Fontaine stage ≥2 performed walking tests to disti nguish between 
Fontaine stages. Finally, the ankle-brachial pressure index (ABPI) was measured based on 
clinical requirements following recent guidelines.21 The highest systolic pressure in the right 
and left  posterior ti bial or dorsal pedis artery and in the right brachial artery was measured 
twice, and the average of those two measurements was used to calculate the ABPI for 
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each leg. The lowest ABPI of two legs was used for analysis. For the purpose of analysis, we 
compared those above versus below the median ABPI.
Carotid artery reactivity. Patients rested on a comfortable bed in a temperature controlled 
room for at least 5 minutes. Participants were in the supine position with the neck extended 
for assessment of the carotid artery. Left carotid artery diameter was recorded continuously 
for 30-seconds before and for 90-seconds during immersion of the hand up to the wrist in 
ice slush (4 °C). Images were obtained using a L9-3 MHz linear array probe attached to a 
high resolution ultrasound machine. When an optimal image was found, the probe was held 
stable and the ultrasound parameters were set to optimise the longitudinal, B-mode image 
of the lumen-arterial wall interface. Following a 30-second baseline assessment of carotid 
artery diameter, the hand was immersed for 90-seconds with simultaneous and continuous 
assessment of carotid artery diameter. 
CAR% responses were assessed for diameter. Analysis of the carotid artery diameter was 
performed by a single blinded investigator using custom-designed edge-detection and wall-
tracking software, which is largely independent of investigator bias.22 Details of this technique 
can be found elsewhere.23 Baseline diameter was calculated as the mean of data acquired 
across the 30 seconds preceding the CPT test. After submersion of the hand in ice slush, data 
were calculated as the mean value for 10-second intervals, involving 8-10 full cardiac cycles. 
Based on this data we calculated the peak diameter change (i.e. the 10-second bin with the 
highest value, CAR%). The peak diameter change can refer to a maximum constriction or 
dilation. The direction of this change was determined by a positive (i.e. dilation) or negative 
(i.e. constriction) area under the curve. 
Reproducibility (coefficient of variation, CV) of diameter responses to CPT were previously 
assessed with a 1- and 24-hour intervals in 50 subjects. Within-day CV for baseline and peak 
diameters were 2.2 and 2.6%, whilst day-to-day CV were 2.3% and 2.7%. Furthermore, the 
CAR% (i.e. maximum change in diameter) showed a within-day reproducibility of 2.6% and 
between-day reproducibility of 2.8%.14 
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Figure 2. Study set-up 
Set-up of the practi cal performance of the test (A). Screen-shot of the assessment of caroti d artery 
diameter, with the yellow box indicati ng the region of interest within the automated soft ware performed 
analysis of the diameter (i.e. yellow lines on the artery wall) (B). Data from a representati ve subjects 
demonstrati ng caroti d artery diameter dilatati on (C) and constricti on (D) during the cold pressor test. 
Both panels represent the caroti d artery diameter (in cm) across the 30-s baseline (up to the verti cal 
dashed line; the start of the cold pressor test) and 90-s during the cold pressor test. Data were analysed 
in 10-second bins to identi fy presence of dilatati on or constricti on. More detailed fi ndings of this 
procedure is presented in the methods secti on.
Inti ma-media thickness. Caroti d artery inti ma-media thickness (cIMT), a marker for vascular 
structure, is related to future development of PAD.24 To examine whether the CAR relates to 
future CV events, independent of the cIMT, we examined cIMT from the same secti on of the 
artery as the CAR. We obtained conti nuous recordings of the cIMT for 10 seconds. Analyses 
were performed by a blinded researcher, using observer-independent edge-detecti on and 
wall-tracking soft ware.25 For the purpose of analysis, we compared those above versus below 
the median cIMT.
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Follow up and assessment of adverse events
After 12 months of follow-up, adverse events were extracted from medical records and 
verified by a blinded vascular surgeon (MW). The Dutch National Death Registration was 
used to determine mortality. Death certificates of patients who experienced a fatal event 
were obtained when available to categorise death into CV or non-CV related mortality. 
Adverse events were categorised into; 1. Cardio- and cerebrovascular events (“CV events”; 
CV-related mortality, myocardial infarction, coronary revascularisation procedures, 
transcranial ischemic attack, cerebrovascular accident, carotid surgery, major- and minor 
amputations, and ischemic bowel disease), 2. “Clinical progression” that is related to PAD 
(loss of patency (i.e., the presence of restenosis in a previous endovascular reconstructed 
vessel), endovascular reconstructive surgery using percutaneous transluminal angioplasty, 
and worsening in Fontaine-classification), and 3. “All-cause Mortality”. We also grouped 
these 3 categories to capture all adverse events (“Adverse events”). Only the first event was 
included in the analyses for patients who experienced more than 1 event. All indications for 
PTA and revascularisation surgery were discussed prior in a multidisciplinary team of vascular 
surgeons and interventional radiologists, whilst preference of patient and interventional were 
taken into consideration. All involved members of the multidisciplinary team were blinded to 
the outcome of the CAR test. 
Statistical analysis
Prior to our study, we aimed to include 200 PAD patients. This group size is in line with 
previous studies examining the prognostic value of measures of vascular health,10, 19 whilst 
this group size also accounts for potential drop out (10-15%) and access to sufficient PAD 
patients (n=400/annum, 50% inclusion rate). Data are presented as mean±SD or n (%) unless 
stated otherwise. Statistical analysis was performed using IBM SPSS Statistics 21.0 (IBM SPSS, 
IBM Corp., Armonk, NY, USA). Baseline characteristics were assessed for normality with the 
Shapiro-Wilk test. We adopted unpaired Student’s t-tests (Mann-Whitney U-test for non-
normally distributed parameters) to compare subject characteristics, co-morbidities, clinical 
status, and medication use between PAD patients with carotid constriction vs. dilation. We 
used logistic regression to assess if subject characteristics, co-morbidities, clinical status, or 
medication could predict presence of carotid constriction.
Analyses to examine whether presence of carotid constriction could predict future events, 
analyses were performed separately for “CV events”, “Clinical progression”, “All-cause 
mortality” and “Adverse events”. Cumulative event rates of carotid constriction and dilation 
were estimated with Kaplan-Meier survival analyses, and were calculated with the log-rank 
test. Cox proportional hazard models were used to calculate hazard ratios, including correction 
for confounding variables (age, sex, BMI, and WHR). These variables were selected based on 
prior evidence of an association with measures of endothelial function.14, 20 Analyses were 
repeated in subgroups in whom we examined cIMT (n=169) or ABPI (n=142). We examined if 
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these clinical measures were related to increased risk for future events,26 and whether they 
altered the analyses related to carotid measurement.
Results
Subject characteristics, co-morbidities, clinical status and adequate imaging was obtained 
in all 172 PAD patients. Median change in carotid artery diameter was 0.8% (95% 
Confidence Interval -19.3 – 11.6%). Carotid constriction occurred in n=82 patients, whereas 
vasodilation occurred in 90 patients. Seventy patients (41%) experienced ≥1 event, which 
included loss of patency (n=18), increase in Fontaine-classification (n=15), percutaneous 
transluminal angioplasty (n=44), transient ischemic attack (n=1), myocardial infarction (n=4), 
cerebrovascular accident (n=3), coronary revascularisation procedures (n=1), major (n=7) 
and minor (n=1) amputation, and ischemic bowel disease (n=1). Ten PAD patients died; from 
CV-related mortality (n=4), cancer-related mortality (n=2), and unknown cause (n=4). We 
found no baseline differences between PAD patients with carotid constriction versus dilation 
in subject characteristics or co-morbidities. Patients with carotid constriction reported lower 
antiplatelet drugs usage (Table 1). Logistic regression revealed that none of the subject 
characteristics, co-morbidities, clinical status or medication use could predict if a PAD patient 
would demonstrate carotid constriction (backward likelihood ratio analysis, all parameters 
P>0.05). When comparing patients with and without an adverse event, those with events 
showed higher prevalence of hypercholesterolemia. Other factors did not differ between 
groups (Supplemental data 1).
Prognostic value of carotid constriction for future adverse events. 
Kaplan-Meier survival curves demonstrated that PAD patients with carotid constriction report 
a higher incidence of CV events (P=0.007), clinical progression (P=0.005) and adverse events 
(P=0.006) compared to carotid dilation (Figure 3). There were no significant differences 
between groups for all-cause mortality (Log-rank, P=0.417, Figure 3).  
Using a multivariate Cox proportional hazard model, with the fully adjusted model correcting 
for potential confounders (i.e. age, sex, WHR and BMI), PAD patients with carotid constriction 
continued to demonstrate higher risk for CV events (HR 4.1, 95%CI 1.3-12.5), clinical 
progression (HR 2.0, 95%CI 1.2-3.3) and adverse events (HR 1.8, 95%CI 1.1-3.0), but not all-
cause mortality (HR 1.4, 95%CI 0.4-5.1, Table 2).
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Table 1. Baseline characteristics 
Total group CAR 
constriction
CAR dilation P-value
Subject characteristics n=172 n=82 n=90
Age*, y 68±10 71 [43-85] 67 [46-90] 0.223
Sex, males (%) 115 (67) 58 (71) 57 (63) 0.303
Height (m) 1.73±0.09 1.73±0.10 1.72±0.10 0.464
Weight (kg) 79.8±14.6 80.1±14.3 79.6±14.9 0.804
Body-mass index (kg/m2) 27±4 27±4 27±4 0.900
Waist-to-hip ratio 1.01±0.10 1.02±0.10 1.00±0.10 0.210
Smoking, yes n (%) 55 (32) 28 (34) 27 (30)
   History n (%) 97 (56) 45 (55) 52 (58) 0.839
Comorbidities
Hypertension, n (%) 138 (80) 66 (80) 72 (80) 0.936
Hypercholesterolemia, n (%) 133 (76) 61 (74) 72 (80) 0.380
Diabetes Mellitus, n (%) 46 (27) 22 (27) 24 (27) 0.873
Medication use
Antiplatelet drugs, n (%) 136 (79) 59 (72) 77 (86) 0.028
Statins, n (%) 141 (82) 71 (87) 70 (78) 0.133
Beta-blockers, n (%) 89 (52) 40 (49) 49 (54) 0.458
ACE inhibitors, n (%) 59 (34) 26 (32) 33 (37) 0.494
Proton pump inhibitors, n (%) 87 (51) 40 (49) 47 (52) 0.652
Clinical status
Mild ischaemia  
(Fontaine 1-2A), n (%)
62 (36) 25 (30) 37 (41)
Moderate-severe ischaemia 
(Fontaine 2B-3-4), n (%)
110 (64) 57 (70) 53 (59) 0.143
ABPI (n=142) 0.65±0.22 0.65±0.22 0.66±0.21 0.679
ABI left rest (n=135) 0.72±0.22 0.73±0.21 0.76±0.25 0.402
ABI right rest (n=132) 0.73±0.22 0.74±0.25 0.74±0.21 0.978
Carotid IMT* (mm) 0.79 [0.15-2.78] 0.80 [0.15-2.78] 0.78 [0.35-2.06] 0.860
Carotid diameter* (mm) 7.5±1.1 7.7 [4.4-10.5] 7.3 [5.1-10.9] 0.358
Baseline characteristics of patients with PAD with coronary artery constriction (CAR constriction) or 
dilation (CAR dilation) during the CPT. *Indicate Mann-Whitney U test, presented as median [minimum 
– maximum]. P-value indicates difference between vasoconstriction versus vasodilation.
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Figure 3. Kaplan-Meier survival curves for CAR
Kaplan-Meier survival curves for adverse events (A), CV events (B), clinical progression (C) and all-cause 
mortality (D) in PAD patients (n=172) across a 1-year follow-up. We have dichotomised PAD patients in 
those who demonstrate coronary constriction (CAR constriction, dotted line) or dilation during the CPT 
(CAR dilation, solid line). P-values relates to a Log-rank test.
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Table 2. Cox analyses and hazard ratios 
Adverse events CV events Clinical 
progression
All-cause 
mortality
  N events 70 18 61 10
Unadjusted model
  CAR dilation
  CAR constriction
Reference
1.89 (1.17-3.04)
Reference
4.08 (1.34-12.41)
Reference
2.01 (1.20-3.38)
Reference
1.68 (0.47 - 5.94)
Model 1*  
  CAR constriction 1.80 (1.11-2.93) 4.05 (1.33-12.36) 1.92 (1.14-3.24) 1.54 (0.43-5.60)
Model 2§   
  CAR constriction 1.82 (1.12-2.95) 4.10 (1.34-12.53) 1.96 (1.16-3.31) 1.35 (0.36-5.10)
Cox analyses and hazard ratios for adverse events, CV events, clinical progression and all-cause mortality 
in 172 PAD patients across a 1 year follow-up. Data are presented as the hazard ratio and the 95% 
confidence interval (95%CI), with stepwise inclusion of a subject characteristics up to model 2. *Model 
adjusted for Age and Sex. § Model adjusted for Age, Sex, WHR and BMI. 
Added value of clinical measures. In 30 subjects, we were unable to perform a valid ABPI 
because of non-compressible arteries or amputation. We were unable to perform analysis 
of cIMT in 3 participants because of technical problems. Analyses for cIMT (n=169) and ABPI 
(n=142) showed no significant effect using the Kaplan-Meier survival analysis for adverse 
events (Figure 4), CV events (Log-rank P=0.674 and 0.457, respectively), clinical progression 
(Log-rank P=0.484 and 0.153, respectively) or all-cause mortality (Log-rank P=0.198 and 
0.795, respectively). 
The cox proportional hazard models for the carotid constriction (including models 1 and 2) 
were repeated for the subgroups with data on cIMT and ABPI. Adding cIMT or ABPI to the 
fully adjusted model did not alter the HR of carotid constriction for future CV events, clinical 
progression, all-cause mortality or adverse events (Supplemental material 2).
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Figure 4. Kaplan-Meier survival curves for cIMT and ABPI
Kaplan-Meier survival curves for cIMT (A, 169 PAD patients), and ABPI (B, 142 PAD patients) related to 
occurrence of adverse events across a 1-year follow-up. The solid line represents the cIMT and ABPI 
above the median, the dotted line refers to the cIMT and ABPI below the median. P-values relates to a 
Log-rank test.
Discussion
This is the first study, to our knowledge, to examine the relation between the carotid response 
to the cold pressor test and future CV events in PAD patients. We found that patients who 
demonstrated carotid constriction during the cold pressor test had a 4.1-, 2.0- and 1.8-times 
increased risk at 1-year of developing a CV event, clinical deterioration and other adverse 
events, respectively, compared to those with carotid dilation. Importantly, the ability of the 
carotid vasomotor response to predict CV events was independent of subject characteristics 
and more predictive than other common clinical measures such as ABPI and cIMT. This 
suggests that a measure of (generalised) vascular health is more important than the extent 
of the (localised) atherosclerotic lesion in PAD patients. Therefore, a simple and non-invasive 
measure of carotid artery endothelial function can identify PAD patients at increased risk for 
future adverse CV events and clinical progression.
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Dilation versus Constriction
We14, 27 and others13, 15, 16 have demonstrated that the CPT produces a gradual dilator or 
constrictor response. Similarly, normal coronary arteries show an endothelium-mediated 
dilation that is mediated by the CPT-induced catecholamine-release, which exceeds the 
direct constrictor effects of catecholamines on smooth muscle cells.15, 16 However, endothelial 
dysfunction and/or (partial) endothelial damage impedes endothelium-mediated dilation 
leading to vasoconstriction.15 Similar responses in the carotid artery probably explain the 
distinct dilator or constrictor responses we observed in our study. Surprisingly, other subject 
characteristics, co-morbidities and clinical measures did not differ between PAD patients 
demonstrating constriction or dilator responses. This suggests that CV risk factors do not 
contribute to the distinct vasomotion responses between PAD patients, and that the PAD 
disease state, rather than subject characteristics or CV risk factors contributes to carotid 
artery endothelial dysfunction.
Relation between the carotid vascular response and subsequent events
Current CV risk factors do not predict future CV events in patients with PAD.12 This highlights 
the potential utility of the carotid artery vasomotor response in predicting future CV events. 
Others have demonstrated that brachial artery flow-mediated dilation predicts future CV 
events in PAD patients,10, 11 but this technique is more difficult than our approach of simply 
measuring the relatively large carotid diameter (i.e. ~7.5 mm) in response to the CPT. 
Previous studies have also not measured clinical progression, whereas we found that carotid 
constriction had a 2-fold increased risk for loss of patency, endovascular reconstructive 
surgery and/or worsening in Fontaine-classification. This knowledge may allow clinicians to 
treat more aggressively in those patients at risk for clinical deterioration.
Others have found that the coronary artery response to CPT predicts future CV events.17, 
18  Results from the present study suggest that the carotid artery response to the CPT is a 
surrogate for coronary arteries. This is supported by our previous within-subject observation 
that a subject’s carotid and coronary response to the CPT are similar.14, 27 This observation 
also supports the concept that atherosclerosis is a whole body, generalised disease of the 
endothelium, such that an abnormal response in one vascular bed is likely also present other 
vascular beds. Consistent with this concept is the observation that abnormal brachial artery 
dilator responses to endothelial stimulation using increased flow6 or acetylcholine28 are 
associated with abnormal coronary artery responses to endothelial stimulation.
ABPI is useful in both the diagnosis of PAD29 and predicting the need for revascularisation.2, 
30, 31 Examining cIMT has also been useful in predicting atherosclerotic risk in some, but 
not all, studies of the general population.24, 32 We found no relation between either ABPI 
or cIMT and future CV events, clinical progression or adverse events. Furthermore, adding 
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these clinical measures to the statistical model did not alter the relationship between carotid 
artery reactivity and future (CV) events. The finding that ABPI and cIMT are not related to 
future events contrasts with previous work performed in the general population,2, 30, 31 but is 
largely in agreement with studies performed in PAD.12, 33 Abnormal ABPI and cIMT indicate the 
presence of atherosclerosis, whereas coronary responses to CPT reflect endothelial function. 
This suggests that in individuals with known CVD, the impact of the atherosclerotic process 
on the endothelium is more important than the atherosclerotic lesion in predicting CV events. 
A potential limitation of our study is that we did not include other biomarkers, such as high-
sensitive C-reactive protein, which are demonstrated to have potential prognostic value in 
PAD for future CV events.37, 38 Unfortunately, we did not assess these biomarkers to examine 
the potential added value of combining these markers with the CAR, which may be relevant 
since these biomarkers may provide additional information to our in vivo measure of 
endothelial function.
Clinical relevance. The carotid artery reactivity to CPT procedure is easy to perform, low-
cost, non-invasive, and requires minimal time and equipment. The simplicity of the test is 
supported by an excellent reproducibility.14 Moreover, in contrast to the majority of subject 
and/or disease characteristics, the carotid artery vasomotor response to CPT identified 
subjects with an increased risk for future events. The clinical relevance of the CAR may 
relate the identification of PAD patients who are more vulnerable to non-adherence and/
or complications during surgery. For example, although symptomatic PAD should all be on 
drug therapy, compliance to therapy is relatively poor.34-36 The CAR-test may help to identify 
individuals in whom it is of special importance to maintain compliance to drug therapy. 
Additionally, cardiovascular co-morbidity in PAD patients is associated with increased 
perioperative cardiovascular risk. Future studies are needed to assess the potential added 
value of the CAR to estimate perioperative risk in PAD patients.  
In conclusion, our study provides the first evidence that carotid artery reactivity, independent 
of subject characteristics and clinical measures such as cIMT and ABPI, predicts future 
adverse (CV) events and clinical progression in PAD patients. The presence of carotid artery 
constriction during the CPT is associated with a 4-fold increased risk for future CV events 
and 2-fold increased risk for clinical progression. These observations suggest that the carotid 
artery reactivity should be further evaluated for its ability to predict future risk in patients 
with PAD.
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Supplemental material
Supplemental table 1. Baseline characteristics of patients with PAD, with and without a cardiovascular 
event during the 12-month follow-up.*Indicate Mann-Whitney U test, presented as median [minimum 
– maximum]. P-value indicates difference between no events versus events. 
Total group 1  year follow-up
No adverse events Adverse events P-value
Subject characteristics n=172 n=102 n=70
Age, y 68±10 67±10 70±10 0.056
Sex, males (%) 115 (67) 66 (65) 49 (70) 0.469
Height (m) 1.73±0.09 1.73±0.10 1.72±0.10 0.593
Weight (kg) 79.8±14.6 80.4±13.7 79.1±15.9 0.582
Body-mass index (kg/m2) 27±4 27 [17 – 39] 26 [17 – 40] 0.416*
Waist-to-hip ratio 1.014±0.098 1.00±0.10 1.03±0.10 0.067
Smoking, yes n (%) 55 (32) 36 (35) 19 (27)
   History n (%) 97 (56) 54 (53) 43 (61) 0.497
Comobidities
Hypertension, n (%) 138 (80) 82 (80) 56 (80) 0.949
Hypercholesterolemia, n (%) 133 (80) 73 (72) 60 (86) 0.030
Diabetes Mellitus, n (%) 46 (27) 28 (27) 18 (26) 0.350
Medication use
Antiplatelet drugs, n (%) 136 (79) 82 (80) 54 (77) 0.607
Statins, n (%) 141 (82) 83 (81) 58 (83) 0.803
Beta-blockers, n (%) 89 (52) 55 (54) 34 (49) 0.490
ACE inhibitors, n (%) 59 (34) 33 (32) 26 (37) 0.516
Proton pump inhibitors, n (%) 87 (51) 51 (50) 36 (51) 0.854
Clinical status
Fontaine 1-2A, n (%) 62 (36) 52 (84) 10 (16)
Fontaine 2B-3-4, n (%) 110 (64) 50 (45) 60 (55) <0.001
ABPI (n=99) 0.65±0.2 0.68±0.21 0.60±0.18 0.068
ABI left rest (n=92) 0.72±0.22 0.75±0.21 0.68±0.23 0.572
ABI right rest (n=93) 0.73±0.22 0.75±0.23 0.69±0.21 0.335
Carotid IMT (mm) 0.79 [0.15-2.78] 0.78 [0.35–2.78] 0.81 [0.15–2.06] 0.315*
Carotid diameter (mm) 7.5±1.1 7.5±1.1 7.6±1.1 0.648
CAR% 0.8 [-19.3 - 11.6] 1.3 [-9.5 – 11.6] -1.2 [-19.3 – 9.6] 0.068*
Constriction/Dilation 
(% constriction)
82/90 (48%) 40/62 (39%) 42/28 (60%) 0.007
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Supplemental table 2. Cox analyses and hazard ratios for adverse events, CV events, clinical progression 
and all-cause mortality in 169 PAD patients across a 1 year follow-up. Data are presented as the hazard 
ratio and the 95% confidence interval (95%CI), with stepwise inclusion of subject characteristics, with 
the inclusion of cIMT in model 3. 
Adverse events CV events Clinical 
progression
All-cause mortality
  N events 70 18 61 10
Unadjusted model
  CAR dilation
  CAR constriction
Reference
1.92 (1.19-3.11)
Reference
4.15 (1.37-12.60)
Reference
2.05 (1.22-3.44)
Reference
1.70 (0.48 – 6.03)
Model 1* 
  CAR constriction 1.84 (1.13-2.99) 4.10 (1.34-12.49) 1.95 (1.16-3.30) 1.52 (0.42-5.49)
Model 2†  
  CAR constriction 1.85 (1.14-3.00) 4.13 (1.35-12.62) 1.99 (1.18-3.36) 1.36 (0.36-5.10)
Model 3‡ 
  CAR constriction 1.85 (1.14-3.00) 4.14 (1.35-12.67) 1.99 (1.18-3.36) 1.47 (0.39-5.52)
*Model adjusted for Age and Sex. † Model adjusted for Age, Sex, WHR and BMI. ‡ Model adjusted for 
Age, sex, WHR, BMI and cIMT. 
Supplemental table 3. Cox analyses and hazard ratios for adverse events, CV events, clinical progression 
and all-cause mortality in 142 PAD patients across a 1 year follow-up. Data are presented as the hazard 
ratio and the 95% confidence interval (95%CI), with stepwise inclusion of subject characteristics, with 
the inclusion of ABPI in model 3. 
Adverse events CV events Clinical 
progression
All-cause mortality
  N events 54 12 45 9
Unadjusted model
  CAR dilation
  CAR constriction
Reference
1.84 (1.07-3.16)
Reference
2.52 (0.76-8.38)
Reference
1.98 (1.09-3.60)
Reference
1.55 (0.42-5.77)
Model 1* 
  CAR constriction 1.78 (1.02-3.08) 2.31 (0.69-7.74) 1.88 (1.02-3.44) 1.54 (0.39-6.09)
Model 2†   
  CAR constriction 1.78 (1.03-3.09) 2.29 (0.68-7.78) 1.90 (1.04-3.47) 1.08 (0.24-4.81)
Model 3‡
  CAR constriction 1.78 (1.03-3.08) 2.32 (0.68-7.86) 1.89 (1.03-3.46) 1.01 (0.22-4.54)
*Model adjusted for Age and Sex. † Model adjusted for Age, Sex, WHR and BMI. ‡ Model adjusted for 
Age, sex, WHR, BMI, and ABPI. 
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The general aim of this thesis was to improve performance of the “older” measures of 
endothelial function and to explore “newer” indices. In this chapter, the findings of the 
preceding individual chapters are summarized and discussed in relation to the contemporary 
literature. Finally, I provide a future perspective and highlight remaining knowledge gaps 
surrounding the assessment of endothelial function in humans. 
Flow-mediated dilation guidelines, a walk through time
Part I of my thesis deals with the “older”, traditional measure of endothelial function, the 
flow-mediated dilation (FMD). The origin and development of FMD dates back to 1992 and 
the milestone study of Celemajer et al. that introduced assessment of conduit artery diameter 
responses to an increase in blood flow, induced by 5-minute cuff occlusion (Figure 1).1 Based 
on the promising results from initial studies, its apparent simplicity and low costs, the number 
of studies adopting the FMD methodology rapidly multiplied. Studies demonstrated that FMD 
may be used as a surrogate measure of coronary endothelial function.2, 3 Others explored the 
potential prognostic value of FMD in different populations.4-12 Unfortunately, many follow-up 
studies deviated from the original protocol, which contributed to significant between-study 
differences in methodology. Indeed, a meta-analysis from 2005 acknowledged the presence 
of wide variation in baseline FMD between studies, with resting FMD between 0.2% to 19.2% 
in healthy individuals, and -1.3% to 15% in diseased individuals.13 Several technical aspects 
were identified that may contribute to the variation between studies, such as the occlusion 
site and occlusion duration. Variation in the protocol may contribute, at least partly, to the 
heterogeneity in baseline FMD values. It was suggested that uniform methodology would 
facilitate more reliable between-study comparisons.13
Although Corretti published their guidelines in 2002,14 these guidelines left many questions 
unanswered. The most recent guidelines date from 2011, when Thijssen et al. collaborated 
with international groups to improve the practical guidance and technical approaches for 
valid FMD assessment.15 These guidelines focussed on the technical issues involving duplex 
ultrasound, measurement methodology (i.e. continuous assessment of at least 180sec post-
deflation, and relevance of baseline diameter), and data analyses (i.e. using edge-detection 
software, and shear normalisation). Nonetheless, despite using these guidelines, variation 
within and between studies remains (Chapter 2 and Chapter 3). This raises the question 
about the utility of the FMD as a valuable tool for (clinical) assessment of vascular function.
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Figure 1. FMD ti meline
A ti meline of the development of the fl ow mediated dilati on technique, including key papers and 
discoveries. 
FMD, clinical uti lity, research tool, or both?
In 2010, the American College of Cardiology (ACC) and the American Heart Associati on (AHA) 
published new guidelines for the assessment of cardiovascular risk in asymptomati c adults, 
including discussion of various strategies and tests (e.g. caroti d inti ma-media thickness, 
pulse-wave velocity).16 Their classifi cati on of recommendati ons and the level of evidence is 
provided in Figure 2. 
The ACC-AHA taskgroup ranked the evidence available for specifi c methodologies and tests 
to either the level A (multi ple randomized controlled trials and/or meta-analyses published), 
level B (single randomized trial or non-randomized studies), or level C (limited literature 
available, based primarily on consensus opinion of experts). Additi onally, methods are 
graded on their proven benefi t, which resulted in a fi nal recommendati on (Figure 2). Their 
recommendati on was that FMD is not recommended for cardiovascular risk assessment in 
asymptomati c adults (Class III, no benefi t, evidence level B).
Their recommendati on that measuring FMD was not benefi cial was based on 2 reasons; 1) 
technical diffi  culuti es resulti ng in considerable variability between studies, and 2) the modest 
evidence regarding the prognosti c value in asymptomati c adults and when controlling for 
traditi onal risk factors. Below, I have discussed both reasons, taking our own fi ndings into 
considerati on. 
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Figure 2. ACC-AHA recommendations
Adapted from the ACC-AHA guidelines 2014, Greenland et al.16 
Technical difficuluties and between-study variability; what can we do?
In this thesis we identified several technical factors that independently contribute to FMD 
variability, including baseline diameter, operator experience, and use of a stereotactic probe 
holder. These factors will be further considered below, and I will provide recommendations 
to improve future FMD assessment.  
Baseline diameter. FMD is negatively associated with the baseline diameter, meaning 
that a smaller baseline diameter likely leads to a larger FMD, and vice versa.1, 17, 18 Studies 
involving between-group comparisons (e.g. healthy versus diseased) are urged to report 
their absolute diameter changes, to account for between-subject variability.19-21 Between-
subject comparisons are more susceptible to differences in baseline diameter and incorrect 
assessment of the true endothelial function. This emphasises the importance of normalising 
the FMD for baseline diameter.11, 12, 17 A possible method of normalising FMD for baseline 
diameter can be achieved by allometric scaling, which accounts for the absolute diameter 
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changes in respect to the logarithmic/linear slope between peak and baseline diameter.17 
Within-subject comparisons are easier to perform, as baseline diameter is comparable. 
However, in the case of longer time lapses between repeated measurements, biological 
variability (aging) and environmental factors (e.g. exercise training results in arterial 
remodelling, reducing initial functional improvement back to baseline),22-24 differences in 
baseline diameter need to be accounted for by scaling accordingly. 
Level of experience. To our knowledge, our work (presented in Chapter 2) represents the first 
evidence that laboratory experience importantly affects reproducibility of the FMD. Despite 
the deceptively simple appearance, FMD assessment is technically challenging and requires 
proper training before active data collection.14 Nonetheless, qualifying ‘proper’ training 
remains difficult. Since ‘sufficient level of training’ is a sensible path to follow when performing 
FMD work, studies often present a brief statement regarding involvement of experienced 
sonographers without further specifications of operator training and/or reproducibility.19, 
25, 26 Previous described specific instructions included hands-on training by an experienced 
individual, and making at least 100 scans annually to maintain competency.14 Another study 
choose to incorporate a formal training programme; one was eligible to scan when 10 
repeat scans were performed with <2% variability.27 Others followed with a similar training 
protocol, consisting of 20 supervised scans, resulting in a quality certification following 5 
consecutive scans with variation <2%.28 Due to a steep learning curve in the FMD assessment, 
some talented operators will obtain the desired level within a short period of time (e.g. 2-4 
months), whilst others require a more extensive period (up to 6 months and longer). This 
should be taken into consideration when designing a new study.  
Since previous FMD training and operator experience is seldom reported (Chapter 3; 307 of 
376 publications did not report reproducibility), extensive disclosure of operator- and analyst 
training and reproducibility is vital. We recommend reporting the inter-operator coefficient 
of variation. When this is <2% variation within repeated measurements, the operator 
is considered skilled enough to validly assess FMD. Additionally, we advise the ability to 
perform repeated scans (e.g. 5 consecutive scans) with <2% variation at any given moment, 
maintaining the desired level of scanning. 
Probe holder versus handheld. The use of a probe-holder has been a point of discussion since 
the beginning of the FMD era.14, 15 Beux et al. described that using a probe-holder improved 
FMD reproducibility, as the holder allows for fine adjustments through small movements 
(using micrometer screws).29 These findings were supported by others, demonstrating that 
using predefined settings for a stereotactic probe holder is feasible and yields reproducible 
results.19, 28 None of these studies, however, provided evidence that using a probe-holder 
results in better reproducibility compared to the hand-held approach. Findings from Chapter 
3 indicated that use of a probe holder was associated with lower FMD variation between 
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studies. Nonetheless, in line with our findings from Chapter 2 and others,30 it is possible that 
highly skilled operators are able to conduct FMD measurements with high reproducibility, 
regardless of the use of a probe holder. The discussion concerning superiority of the method 
is still undecided. Future studies are warranted to directly compare the stereotactic probe-
holders with the hand-held approach. 
To briefly summarize, the factors mentioned above independently contribute to the wide 
variation between studies. To improve FMD reproducibility, I recommend 1) reporting 
absolute baseline diameter (and scaled accordingly when differences between groups occur), 
2) describing operator training and experience (preferably as coefficient of variation), and 
3) direct comparison between hand-held and probe-holder use to determine superiority. 
Combining these recommendations with adherence to expert-consensus guidelines will 
reduce between-study variability. 
Adherence to the guidelines and the prognostic value
Expert-consensus guidelines have contributed tremendously to the standardization of 
technical approaches and set minimum standard requirements for FMD measurements.14, 
15, 31 However, this thesis described large variation in the adherence to guidelines between 
studies (2.4 to 9.2, Chapter 3), whilst almost every paper refers to using these guidelines. In 
Table 1 we take a closer look into several prognostic FMD studies, specifically exploring how 
well these studies adhered to FMD guidelines using the previously described scoring tool 
(Chapter 3). Interestingly, the average score of the studies in Table 1 is 3.4 points, and varies 
between 0 and 5.6 out of 10. In other words, none of the studies examining the prognostic 
value of the FMD for future CV events meet the minimum required level of adherence of 6 
(since studies with adherence >6 showed acceptable-to-good reproducibility in Chapter 3). 
Although most of these studies were published before the latest revision of the methodological 
guidelines by Thijssen et al., it is striking that even recent studies do not comply to these 
guidelines. For example, a recent study describing predictors of endothelial dysfunction in 
patients with rheumatoid arthritis, measured FMD with upper arm occlusion.21 Moreover, a 
detailed description of the methodology is absent, leading to an adherence score of only 0.4. 
The FMD for their healthy control group is ~11±0.5%, and 6±2% in patients with rheumatoid 
arthritis. These values are remarkably high, especially when comparing these with our 
previous analysis of 109 healthy participants which resulted in a FMD of 6.6±2.8%, meaning 
that only 10% of our population had an FMD of 11% or higher. 
The potential impact of not following the FMD guidelines becomes apparent from another 
recent example, where FMD was assessed in non-alcoholic liver disease in postmenopausal 
women.20 Whilst this study reported adherence to the published guidelines, detailed 
inspection revealed that the researchers do not clearly describe the included control group, 
and details on operator training are missing, leading to an adherence score of 3.6. This study 
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demonstrated a remarkably high resting FMD of ~15% in the healthy control group. Based on 
our previous work and the work performed in Chapter 3, this again seems highly remarkable 
and may be caused by not following the guidelines. 
Table 1. FMD studies and their scores
First Author Year N Age Group FMD% Baseline diameter Score
Patient population       
Neunteufl 2000 73 51 Chest pain 5.7±4.8% 4.0±0.7 2.4
Gokce 2003 199 67 PAD 6.6±4.7% 3.9±0.7 2
Brevetti 2003 131 64 PAD 7.6% [5.3; 9.9] 2.2
Fathi 2004 444 58 CAD 5.2±6.1% 3.3 2.6
Frick 2005 398 54 Chest pain 7.6% 4.3 2.4
Patti 2005 136 63 CAD 7.0% 4
Kitta 2005 141 65 PCI 3.5-7% 1.6
Suzuki 2008 377 67 MS 5.26±3.7 4
Skjold Ulriksen 2009 223 54 Chest pain 4.7±2.7% 2.6
Tarro Genta 2013 71 65 HF 6.5±4.0% 3.7±0.7 5
Pugh 2014 34 48 NAFLD 4.8% [4.1;5.4] 4.2 [3.9;4.6] 7.4
Paine 2016 156 56 HF 4.6±3.4% 5.6
Kubo 2016 80 69 Chest pain 4.2% 3.8
Hamid 2016 78 54 MI 5.9±3.1% 0
Healthy population       
Yeboah 2007 2792 79 asymptomatic 2.7% 4.5±0.9 5.4
Rossi 2008 2264 54 asymptomatic 6.3% 3.9±0.6 3.4
Shechter 2009 435 54 asymptomatic 11.7±3.2% 5.8 ± 0.9 6.6
Yeboah 2009 3026 61 asymptomatic 4.4±2.8% 4.3±0.8 5.4
Lind 2011 921 70 asymptomatic 4.7±3.6% 4.0
Shechter 2014 618 55 asymptomatic 12.0±3.2% 5.7±1.0 5.8
Prognostic value of the FMD, in patient- and healthy populations. Adapted from Green et al 2011. 
CAD; coronary arterial disease, PAD; peripheral arterial disease, CAG; coronary angiography, MS; 
metabolic syndrome, PCI; percutaneous coronary intervention, HF; heart failure, NAFLD; non-alcoholic 
fatty liver disease, MI; myocardial infarction. Either expressed as mean ± standard deviation, or median 
[interquartile range].4-6, 8, 10-12, 32-44 
Regardless of the various expert-consensus guidelines, many current studies do not comply 
with these guidelines.14, 15, 31, 45 This contributes to questionable FMD outcomes, and leads 
to high variability within and between studies. Therefore, I believe that studies with poor 
adherence scores (i.e. <6, and application of continuous diameter recording, edge-detection 
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and wall-tracking software is mandatory) should not be published and/or taken into 
consideration in (meta-analytical) reviews, as the risk of measurement error and over/under 
sampling will result in ambiguous findings and more between-study variability. Our newly 
proposed scoring tool to assess the level of adherence (Chapter 3B) could serve as a guide 
to aid researchers in standardizing the FMD approach. Preferably, authors should report 
their individual adherence score to the guidelines using the tool we published previously, or 
improve their applied methodology and publication accordingly. 
We also observed significant variation in FMD between studies in Table 1, even when 
comparing similar patient populations. For example, the study from Neunteufl et al. reported 
a FMD of 12.6±6.7%,8 whilst Kubo et al. reported a FMD of 4.2%,35 both in patients with 
chest pain. The substantial disparity in FMD is also visable when comparing asymptomatic 
participants with clinical groups. For instance, our previous analysis of 109 healthy participants 
resulted in a FMD of 6.6±2.8%, which is remarkably lower than reported by the study from 
Brevetti et al. in patients with peripheral arterial disease (average FMD of 7.6%).4 This implies 
that any FMD value could refer to supra-normal, normal or sub-normal values, dependent 
on the laboratory and protocol that was followed. The construction of reference values (and 
following current guidelines) could assist in the more accurate interpretation of FMD, thus 
lessening the between-study variability.
 
Flow mediated dilation, lessons learned
In summary, I believe we have reached a turning point in the research involving the “old” 
FMD technique. To meet the AHA-ACC required guidelines for assessment of CV risk, we 
should adhere to the above-mentioned recommendations and expert-consensus guidelines, 
achieving at least a score of 6 out of 10 related to the adherence score. Studies with poorer 
adherence should not be taken into consideration when making evidence-based conclusions 
based on literature searches. This will mitigate the variation between and within studies. 
Moreover, this also relates to the FMD’s true prognostic value in clinical populations. 
Additionally, reference values for the FMD (when adopting the guidelines) are necessary for 
correct interpretation of an FMD value. Having these reference values for several populations 
(i.e. young versus old, healthy versus disease), will positively contribute to reducing 
measurement variability. 
Carotid artery reactivity, a new step forward?
The second part of this thesis focusses on the development and validation of a newly 
introduced test of vascular health; the carotid artery reactivity (CAR) test. Given the 
novelty of the CAR and lack of studies exploring the mechanisms for carotid dilation during 
sympathetic nervous system activity, many questions regarding the physiological mechanism 
are currently unanswered. However, similarity in responsiveness between the carotid and 
coronary arteries was previously suggested.46 Therefore, to provide an initial overview on 
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the potential mechanisms underlying carotid dilation during sympathetic activity, I will first 
discuss studies that provided mechanistic insights into coronary artery responsiveness to 
sympathetic stimulation. Specific information on carotid artery reactivity is provided when 
available. Whether all assumptions on coronary reactivity can be applied to the carotid artery 
is currently unknown and warrants further evaluation.   
Coronary arteries and sympathetic stimulation. The coronary circulation is highly responsive 
to sympathetic stimulation, such as demonstrated by Folkow et al., who reported the 
innervation of the coronary vasculature by sympathetic adrenergic fibres (Figure 3).47, 48 In 
a subsequent study, Feigl demonstrated that generalized sympathetic stimulation results in 
an increase in myocardial blood flow.49, 50 Several mechanisms seem to contribute to this 
increase in blood flow, including an increase in metabolic demand, changes in flow, and 
neuro-hormonal stimuli.51-53 Importantly, the involvement of these mechanisms to coronary 
vasodilation seem to relate to immediate sympathetic stimulation (i.e. following a stress-
response). A known test to provoke sympathetic activity, is the cold pressor test (CPT).54 
CPT increases catecholamine release55 and coronary flow, which can be mediated by a local 
increased metabolic demand, blood flow (or shear stress)-mediated dilation and/or neural 
factors.52, 56-59 The neural component refers to an adrenergic-mediated vasoconstriction, 
to maintain a uniform transmural blood flow distribution in the cardiac muscle.49, 50 The 
metabolic, flow-mediated and neural vasoactive responses together mediate a vasodilator 
response of coronary arteries, whilst current work is unable to untangle the exact contribution 
of these various vasoactive pathways that closely work together.
Interestingly, a study in 1986 found that removal of the coronary endothelium in dogs 
resulted in abolished vasodilation responses to sympathetic provocations (infusion with 
norepinephrine), whilst intact endothelium resulted in pronounced vasodilation.60, 61 This 
implies, to some extent, a role for the endothelium. The importance of functionally intact 
endothelium was further verified by multiple studies. For example, it was shown that 
infusion of acetylcholine, a strong endothelium-dependent vasodilator, mirrored the effect 
of sympathetic stimulation; vasodilation in intact coronary arteries.56, 58, 62, 63 Schächinger et al. 
examined whether responses to both acetylcholine and CPT could independently predict the 
occurrence of future cardiovascular events and disease in CV patients.57 Later also confirmed 
by others, Schächinger found that coronary vasoreactivity measured with both acetylcholine 
and CPT, could predict long-term atherosclerotic disease progression and cardiovascular 
events.57, 64, 65 
Carotid arteries and sympathetic stimulation. When examining peripheral arteries as a 
potential surrogate for the coronary circulation, sympathetic activation does not necessarily 
lead to similar peripheral artery responses as observed in coronary arteries.59, 66-69 More 
specifically, previous work found no change or a small constriction of peripheral arteries upon 
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sympathetic stimulation. However, a previous observational study found that the carotid artery 
shows marked dilatation in response to CPT.46 This implied similarity between carotid and 
coronary artery responses to CPT, supposedly the result of the balance between adrenergic 
vasoconstriction and endothelium-mediated vasodilation.46 In this thesis, we followed up on 
this observation and confirmed similarity in responses between the carotid and coronary 
arteries (Chapter 4). These studies suggest that the carotid artery shows arterial responses 
that reflect those observed in the coronary circulation. Given the easy access of the carotid 
artery, this raises several questions about the potential use of this physiological phenomenon. 
Considering the previous established AHA-ACC guidelines,16 a test for cardiovascular health 
assessment should 1) have a strong empirical literature background, 2) requires a technical 
achievable methodology, and 3) be beneficial for risk assessment independent of risk factors. 
These AHA-ACC criteria are further discussed below in relation to the CAR.
Figure 3. CAR timeline 
A timeline of the development of measuring coronary and carotid reactivity to sympathetic stimulation, 
including key papers and discoveries.
Strong empirical background
Similarity in responses between the coronaries and carotid. Ideally, a test of vascular function 
that predicts coronary events should reflect the vascular health of the coronary arteries, which 
are particularly susceptible for endothelial dysfunction and atherosclerosis. The carotid shows 
similar responsiveness as the coronary artery responses to CPT.46 When we combine data from 
Chapters 4 and 5, we have obtained measurements of coronary artery function in 49 participants. 
These include measures from both the CPT test and the lower body negative pressure test 
(LBNP). We found a significant correlation of 0.59 for CPT and LBNP results combined (Figure 4). 
This further strengthens our earlier findings (Chapters 4 & 5), demonstrating similarity between 
carotid responses and coronary flow responses to sympathetic stimulation. Moreover, these 
findings suggest the CAR may serve as a surrogate measure of coronary vascular health.
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An important limitation of these previous observations must be discussed. Whilst measuring 
carotid artery diameter and velocity is feasible, measuring coronary velocity and diameter 
with non-invasive echo Doppler techniques is currently technically not feasible. However, 
coronary flow velocity is documented to reliably reflect changes in absolute coronary 
blood flow. Several studies have adopted coronary flow velocity (measured as the velocity 
time integral, cm) as a model to non-invasively assess coronary dilation.59, 70-72 Since this 
is still an indirect measure of coronary artery blood flow, we would ideally reproduce the 
similar responses between the carotid and coronary arteries using invasive, gold standard 
techniques. Such studies are recommended to better understand the CAR-test and should be 
done in a catheterisation laboratory, which allows for direct and simultaneous comparison 
of both vessel responses. Finally, it is essential that these findings are reproduced in patient 
populations as well.  
Figure 4. Correlation CAR and coronaries
Correlation (Pearson) of carotid artery reactivity, percentage dilation (CAR%) and coronary artery flow 
velocity in n=49 participants, expressed as the velocity time integral (VTI) in cm.
The eliciting stimulus. To further understand the empirical background of CAR, it is important 
to understand the underlying mechanisms contributing to the vasomotor response of the 
carotid artery to sympathetic stimulation. In Chapter 4, I discussed the potential role for 
shear stress and blood pressure as mediating factors for carotid vasomotor responses. The 
slower increase in both shear rate and blood pressure compared to the diameter change 
make these stimuli unlikely as the primary triggers that mediate carotid artery dilation. In 
addition, no relation was found between changes in blood pressure or shear stress and 
carotid artery diameter changes. Furthermore, despite the presence of increases in blood 
pressure, some participants demonstrated a decrease in carotid artery diameter. This makes 
it unlikely that the carotid artery diameter response represents a shear- and/or pressure-
driven vasomotor response. 
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Metabolic demand. As discussed earlier in the Discussion, several mechanisms contribute 
to the sympathetically mediated increase in coronary flow. These mechanisms include an 
increase in local metabolic demand, endothelium mediated vasodilation, and neural mediated 
vasoreactivity. Berne et al. previously acknowledged the key role of coronary metabolic 
activity (i.e. myocardial oxygen consumption) in mediating coronary flow.53, 73 Feigl reported 
that a significant decrease in coronary sinus oxygen was present, when changes in coronary 
metabolism were absent (blunted by propranolol).74 This suggested that myocardial oxygen 
uptake was not only regulated by myocardial demand, but also by coronary sympathetic 
activity. The contribution of adrenergic receptors in mediating coronary oxygen uptake was 
confirmed by Mohrman et al. who found that α-blockade caused a decrease in coronary 
oxygen uptake.75 Finally, Di Carli et al. examined coronary flow in transplant patients, 
where both denervation and regional re-innervation of cardiac segments could be studied 
simultaneously. It was demonstrated that increases in coronary flow in response to CPT 
were larger in areas in re-innervated areas, which suggests that coronary flow is regulated 
to larger extent by adrenergic mechanisms than via metabolic regulation. Taken together, 
as was also nicely summarised in a recent review from Barbato et al., increases in cardiac 
metabolism and coronary sympathetic vasodilation are involved in adrenergic vasodilation. 
Since it is challenging to study these factors independently, it remains unclear to what extent 
the metabolic and adrenergic components interact and contribute to coronary vasomotion 
during sympathetic activation.
Endothelium-mediated dilation and role of NO. The pivotal role of the endothelium in the 
coronary responses to sympathetic stimulation was examined by assessing coronary responses 
to sympathetic stimuli in healthy and atherosclerotic and/or (pharmacologically) denuded 
coronary segments (in animals).56, 58, 60, 61, 63 Several studies demonstrated that both CPT and 
acetylcholine induced vasoconstriction in atherosclerotic coronary segments, whilst infusion 
with nitroglycerin (a potent endothelium-independent vasodilator) induced vasodilation. 
The preserved vasodilation in response to nitroglycerin in atherosclerotic arteries suggests 
the importance of the integrity of the endothelium.56, 58, 63 Tousoulis et al. demonstrated 
that coronary vasodilator responses to CPT could be reduced by inhibition of NO synthase 
(L-NMMA). Inhibition of NO synthase not only attenuates the NO-mediated dilation, but may 
also potentiate adrenergic mediated constriction,76, 77 demonstrating the strong interaction 
between adrenergic and endothelial control mechanisms. 
α- and β-receptors. CPT produces sympathetic release of catecholamines (e.g. norepinephrine 
and epinephrine),55 which are both present on the luminal (i.e. circulating) and abluminal 
side, that influence coronary vasomotion through stimulation of adrenergic receptors, 
present on both coronary endothelial and vascular smooth muscle cells. Below, the roles 
of the α- and β-receptors are discussed. Both α- and β adrenergic receptors are involved 
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in coronary vasomotion in response to activation of the sympathetic nervous system (Table 
2).51 The β-receptors induce vasodilation, which results in an increase in coronary blood flow. 
The α-receptors concurrently induce minor vasoconstriction to limit the metabolic demand. 
This is to ensure maintenance of blood flow in the inner layers of the ventricles. This results 
in a delicate balance between α-mediated vasoconstriction and β-mediated dilation. If the 
endothelium is dysfunctional, dilation evoked by sympathetic stimuli is abolished, partly 
due to endothelial β-receptor failure, impaired endothelium-mediated NO-release, and/or 
enhanced α-receptor responsiveness.51, 56, 63, 76
α-receptors. The α-receptors (both α-subsets, Table 2) are predominantly responsible for 
coronary vasoconstriction. Stimulation of α1-receptors, which are located on the vascular 
smooth muscle (VSM) cells, cause vasoconstriction.51, 78, 79 In healthy subjects, infusion of α1-
agonists does not influence coronary vasomotion.80 This is due to the β-mediated dilation 
through the functionally intact endothelium, counterbalancing the α1-mediated constriction. 
In diseased participants (i.e. those with coronary stenosis), however, infusion of α1-agonist 
(i.e. methoxamine and phenylephrine) resulted in augmented constriction.51, 58, 63 
Stimulation of α2-receptors on the VSM cells mediates neural-mediated constriction, whilst 
receptors located on the endothelium cause dilation through NO-release during sympathetic 
stimulation (Table 2).51, 60, 81, 82 Selective α2-adrenergic agonists can cause endothelium-
dependent relaxation in the coronary arteries of healthy subjects,82 whilst concurrent 
stimulation of α2-receptors on the VSM cells demonstrated microvascular constriction.80, 
83 In contrast, intracoronary infusion of selective α2-agonists induced vasoconstriction in 
patients with atherosclerotic coronaries. This possibly results from a loss of endothelial α2-
receptors. Normally endothelial α2-receptors contribute to luminal vasodilation, whilst VSM 
cell-mediated α2-receptors facilitate abluminal constriction. The net result of endothelial 
dysfunction could result in enhancement of VSM cell mediated α2-vasoconstriction.80, 84-86
β-receptors. β-receptors are predominantly present on the coronary endothelium, causing 
vasodilation during sympathetic activation (Table 2). There are 3 subtypes, located on either 
the endothelium or the VSM cells, and the vast majority corresponds with the β2-receptor 
subtype. In healthy participants, infusion of a β2-receptor agonist (salbutamol) induces 
dilation. Interestingly administration of selective β-receptor blockades in healthy participants 
(e.g. infusion with propranolol),56 partly inhibited vasodilator responses to CPT. Since β2-
receptors are more strongly antagonized by propranolol than β1-receptors, possibly β1-
receptor activation contributed to the remaining dilation.87 It is possible that the paradoxical 
constriction of coronary arteries in patient groups results from disturbed β-receptors, due to 
endothelial dysfunction. Indeed, intracoronary infusion of a β2-receptor agonist (salbutamol) 
showed an impaired vasodilator response in atherosclerotic coronary arteries.56 
Carotid artery. In summary of the discussions above, the exact contribution of both 
adrenergic receptors during CPT to coronary vasoreactivity remains to be further clarified. 
More importantly, scientific work on the adrenergic innervation of the carotid artery is scarce 
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and reliant on animal work.88 Accordingly, future studies are necessary to explore the roles 
of the endothelium and adrenergic innervation of the carotid artery during sympathetic 
activation. We saw in Chapter 5 that administration of Prazosin, a selective α1-receptor 
antagonist, resulted in an attenuated carotid dilator response in healthy participants, whilst 
one would expect a more pronounced vasodilation. This can possibly be attributed to 
concurrent adrenergic α2-receptor activity on the VSM cells. These findings warrant further 
investigation into adrenergic activation of the carotid artery.  Similarly, the precise role of the 
carotid endothelium needs to be investigated. 
Table 2. α- and β-receptor types
Receptor Location Cell affinity Role
α-receptors   
α1 larger vessels VSM cells Vasoconstriction
α2 microcirculation VSM cells  
and endothelium
vasoconstriction  
and vasodilation
β-receptors   
β1 epicardial coronaries endothelium and VSM cells Vasodilation
β2 Arterioles endothelium and VSM cells Vasodilation
β3 Arterioles endothelium Vasodilation
Subsets of α- and β-receptor types in the coronary circulation. VSM; vascular smooth muscle
Technical achievable methodology
The AHA-ACC guidelines require a technical achievable methodology before further 
recommendation as a useful vascular test. Major problems with the current techniques to 
assess endothelial function, relate to 1) technical difficulties, and 2) methodological variability 
and adherence to guidelines. 
Technical difficulties. The CAR test is in some ways analogous to FMD, as both tests use pulsed 
wave Doppler and ultrasound techniques to assess endothelial function. As both tests are 
reliant on vascular function, subject preparation (e.g. 15 minutes of supine rest, fasted state, 
measurements at the same time of the day) and data analyses (e.g. continuous assessment, 
using semi-automated edge-detection software) are performed in a similar fashion.15 However, 
some of the factors that significantly influenced the FMD, are less likely to influence CAR. This 
supports the concept that CAR is a robust test of endothelial function. For example, baseline 
diameter is not related to CAR, as we already saw in Chapter 4. This is further supported by 
combining our data in healthy participants (n=189, r=0.12, P>0.05). This indicates that CAR 
is independent of measures of carotid size, and between-study variability is not influenced 
by baseline diameter. Second, CAR is easy to perform, as the carotid is a larger and more 
superficial artery, making the operator training less tedious. We demonstrated a within-day 
517976-L-bw-van Mil
Processed on: 14-3-2018 PDF page: 180
180
Chapter 7
coefficient of variation (CV) of 2.6% and between-day CV of 2.8% for CAR in Chapter 4. This 
indicates the CAR is highly reproducible. 
Methodological variability. When assessing Chapters 4 and 5, CAR methodology is 
corresponding very well with the adherence scoring tool for FMD, scoring a 9.2 on both 
papers. Differences in the methodology (e.g. time immersed, temperature of the water, 
Chapter 4 and 5) are to be incorporated in guidelines to assure for uniform methodology 
between studies. Therefore, I recommend that when performing CAR tests, adherence to the 
expert-consensus guidelines for peripheral vascular assessment as described in this thesis 
is necessary, to keep methodological variability at a minimum. Factors contributing to CAR 
variation (similar to Chapter 2) can be explored to optimise the methodology. Accordingly, 
the methodology described in our Chapters 4 and 5 need to be incorporated to provide a 
similar expert-consensus guidelines and scoring tool for the CAR test specifically.
Risk assessment and risk factors, the prognostic value of CAR
Risk factors. The key prerequisite of the AHA-ACC guidelines for a new test to assess 
cardiovascular health, is that the test needs to be beneficial for risk assessment. A series 
of longitudinal studies, preferably from various laboratories, is required to obtain detailed 
insight. Obviously, this is currently not available and we will discuss the limited evidence and 
experiences from our laboratory. First, we explored whether CAR relates to the presence 
of established cardiovascular disease risk factors. We showed in Chapter 4 that older 
participants had a significant lower CAR% than their younger peers. We also found that 
participants with more cardiovascular risk factors had a lower CAR%. To further substantiate 
these latter findings, we performed a study in 85 healthy octogenarians (average CAR% 2.9±2) 
who participated in the Nijmegen Four Days Marches of 2016. When assessing the relation 
between risk factors and CAR, we found no differences in CAR between those with 0, 1 and ≥2 
risk factors (2.7±1.7, 3.3±2.1, and 2.4±1.5, respectively, P=0.183). This is not in line with our 
previous findings. Possibly, this finding can be explained by the group we included. Previous 
work found that, although CVD prevalence does not markedly attenuate in octogenarians, 
traditional risk factors do not identify those who will develop future CV events.89 This may 
contribute to the observation that CAR does not relate to CV risk factors in this population. 
Average CAR in the octogenarians was relatively high (i.e. 2.9%) and even higher than the 
healthy older group from Chapter 4 (i.e. 1.8±2.6%). Moreover, no vasoconstriction was 
reported in these healthy octogenarians, whilst 25% of the healthy older group from Chapter 4 
reported constriction. A possible explanation is that our octogenarians were physically active, 
since they all participated in the four days marches, and therefore demonstrated favourable 
vascular health.  To support the possible relation between level of physical fitness and CAR, 
preliminary data from our laboratory in 18 participants with increased CVD risk showed that 
12-weeks of exercise training significantly improved CAR (data not presented). Moreover, six 
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patients who showed vasoconstriction prior to training were reversed to vasodilation after 
exercise training. This implies that CAR can be improved by exercise training, with a (larger) 
dilation being related to improved physical fitness. 
Intima media thickness. A known risk factor and independent predictor of CV events is 
the carotid intima-media thickness (cIMT). The cIMT is a frequently used clinical test,90, 91 
classified as an IIa class test by the AHA-ACC guidelines,16 whilst its clinical value is still being 
debated.91-93 Since both CAR and cIMT relate to the carotid artery, it seems sensible that 
the CAR should exceed the prognostic and discriminative value of the carotid artery wall 
thickness. We saw in Chapter 4 that CAR was not related with cIMT in healthy participants. 
When all data from Chapters 4-5-6 as well as additional testing in the octogenarians on 
CAR and cIMT were combined (n=296), we still found no association between CAR and 
cIMT (r=0.04, P>0.05, Figure 5). Moreover, findings of Chapter 6 demonstrated that carotid 
artery wall thickness did not predict outcomes or contributed to the hazard models for the 
CAR. A logical explanation for the lack of relation, despite that both tests involve the carotid 
artery, is that CAR examines functional characteristics and cIMT addresses structural aspects. 
Therefore, CAR provides novel, additional information since information derived from CAR 
seems independent of carotid artery structure. This seems the case for both asymptomatic 
participants and patients with cardiovascular disease. These observations highlight the 
potential (clinical) relevance of measuring both CAR and cIMT. 
Figure 5. Correlation CAR and cIMT
Carotid artery reactivity, percentage dilation (CAR%) versus the intima-media thickness (cIMT) in n=296 
participants, demonstrating a non-significant correlation (P>0.05). 
Prognostic value. Ideally, the CAR test would be able to predict future cardiovascular events and 
disease, independent of traditional risk factors. In Chapter 6, we found that PAD patients with a 
vasoconstrictive response to the CPT had a 4-fold higher risk for future CV events, 2-fold increased 
risk for clinical progression, but no increased risk for all-cause mortality. More importantly, these 
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findings were independent of traditional risk factors (i.e. age, sex, waist-to-hip ratio, and body 
mass index). A potential follow-up study could include asymptomatic participants (i.e. for primary 
prevention) or groups at increased risk for secondary events (i.e. coronary artery disease). Another 
study could assess whether changes in CAR across a given time period (i.e. increase or decrease in 
CAR) would relate to subsequent development of CV events. 
Chapter 6 described the prognostic value of CAR for (CV) events and clinical progression, but 
CAR could not predict (CV) mortality in PAD patients. In 2016, we performed the CAR test in a 
group of healthy octogenarians who participated in the Nijmegen 4-Day Marches (n=85, aged 
84±2). Using the Dutch National Death Registration, we obtained information on 75 participants 
(n=10 could not be found) and found that 8 participants have died. We found that those still 
alive had an average CAR of 2.6±1.6, whilst CAR was significantly higher in group that died across 
the 1year follow-up (5.8±2.7, P<0.01). The finding that CAR did not relate to all-cause mortality, 
is in line with our observations in Chapter 6, where also no relation was found for CAR versus 
all-cause mortality. Interestingly, although being underpowered, in Chapter 6 we found that 
CAR was lower in those with CV-related mortality compared to the other PAD patients. Possibly, 
CAR relates to occurrence of CV-related mortality rather than all-cause mortality. Future studies 
are required to better understand this link, including our study in octogenarians.
Future perspectives for the CAR
The new CAR test provides a novel test that seems to reflect vascular health, which may 
fit with AHA-ACC criteria. First, the empirical background and physiological mechanism for 
CAR currently relies on literature on coronary responses to sympathetic stimulation. Studies 
in this thesis provide the first evidence for similarity between carotid and coronary artery 
responses to sympathetic stimulation. To further divulge the similarity between the carotid 
and coronaries and their physiological origin, future studies should be performed in a 
catheterisation laboratory, directly analysing endothelial function and sympathetic responses 
of both vessels. At least, our work provides early indication that the CAR represents a 
surrogate measure for coronary vascular health. Secondly, CAR is a feasible, short test (i.e. 
4 minutes), supported by good reproducibility. Since many technical aspects of CAR are 
similar to FMD assessment, I recommend adherence to the expert-consensus guidelines 
for peripheral vascular assessment as described in this thesis when performing CAR tests. 
Additionally, the adopted methodology and technical aspects mentioned in this thesis can 
add to specific expert-consensus guidelines and a scoring tool for the CAR test. Finally, we 
have seen that CAR independently predicts cardiovascular events, but not all-cause mortality, 
in PAD patients, and is independent of structural measures. It is essential to confirm these 
findings in other (clinical) populations, to explore clinical and pre-clinical potency of CAR for 
evaluation of cardiovascular health. At least, data in this thesis warrant further exploration. 
Exploring carotid reactivity in response to ice may only be the tip of the iceberg.    
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SUMMARY
Chapter 1 introduced the old and new measurement of endothelial function, and vascular 
health. The first part of this thesis focussed on the “old” flow-mediated dilation measurement, 
introduced in 1992, which relies on brachial artery vasodilation after a hyperaemic stimulus 
(e.g. after occlusion of a pneumatic cuff), and the susceptibility of the FMD measurement to 
variability. 
In Chapter 2 we sought for factors that might help to improve the reproducibility of the FMD 
measurement. We performed an analysis including 672 participants with repeated FMD. 
Overall we found an acceptable reproducibility, with 33% of the FMD measurements showing 
an excellent-to-moderate reproducibility. We identified several factors that independently 
increased the variation of the FMD, including the presence of hypertension, a lower resting 
FMD%, a larger baseline artery diameter, a longer time between subsequent measurements, 
and less laboratory experience with the measurement. Future studies should take these 
factors into consideration, as certain measures may lower variability of the FMD or more 
subjects should be included in individual studies when variation relates to non-modifiable 
factors. 
Unfortunately, we also found that a large proportion of our study population demonstrated 
a moderate-to-poor reproducibility, despite all included studies adhered to expert-consensus 
guidelines. In Chapter 3, we described the relation between adherence to the expert-
consensus guidelines and reproducibility of the FMD. In this meta-analysis, we combined 
data from twenty-seven studies, comprising 48 study groups, with a total of 1537 subjects. 
Adherence to expert guidelines was inversely related to the measurement error and adopting 
the guidelines (with specific notification of the use of a stereotactic probe-holder, continuous 
diameter recording and the use of automated wall-detection and analysis software) was 
crucial for improving the reproducibility of the FMD.
The second part of this thesis introduced the “new” carotid artery reactivity (CAR) 
measurement, which depends on carotid artery vasomotor responses following sympathetic 
stimulation (e.g. after a cold pressor test, CPT). The carotid artery appears to mirror coronary 
responses to CPT, as it shows dilation in healthy participants, whilst those at risk demonstrate 
a constriction. In this thesis, we sought to understand the relation of CAR with risk factors, and 
the similarity with the coronary responses. An attempt was made to unravel the underlying 
physiological mechanism of CAR. Finally, the prognostic value of CAR was examined in 
peripheral arterial disease patients, to further investigate to clinical potential of the CAR test. 
In Chapter 4 we explored the relation of CAR with cardiovascular risk, followed by assessing 
the similarity in response to sympathetic stimulation between the carotid artery and 
coronary arteries. We first compared CAR between 50 young and 44 older participants 
to assess relationships between CAR and traditional cardiovascular risk factors. We found 
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that CAR was lower in participants with ≥2 risk factors, compared to those with lesser risk 
factors. Secondly, we compared left anterior descending (LAD) artery velocity with carotid 
artery diameter in a subgroup of 33 participants, to assess similarity between coronary and 
carotid artery responses. We found that CAR correlated well with coronary artery velocity. 
This implies that CAR is related to increased CV risk and may represent a surrogate measure 
for coronary vascular health. 
In Chapter 5, the physiological mechanism underlying the CAR was further explored, by 
examining carotid artery responses to different sympathetic stimuli (e.g. the cold pressor test 
[CPT] and the lower body negative pressure test [LBNP]), exploring the role of α
1
-receptors, 
(nor) epinephrine receptors contributing to vasoconstriction, and assessing similarity 
between carotid and coronary arteries. First, 10 participants underwent both sympathetic 
tests in randomized order, whilst concurrently measuring CAR and coronary artery velocity. 
We found distinct carotid artery responses to different tests of sympathetic stimulation (e.g. 
dilation in response to CPT, and constriction following LBNP). Second, when measurements 
were repeated following α
1
-receptor blockade by Prazosin, we found α1-receptors partly 
contributed to CPT-induced responses. Finally, we found agreement between carotid and 
coronary artery responses, during both types of sympathetic nerve stimulation as well as 
during α1-receptor blockade. These data indicate strong similarity between carotid and 
coronary responses to sympathetic tests and the role of α1-receptors.
Since the CAR test was newly introduced, the prognostic value of the test remained unknown 
and this question is highly relevant to understand its clinical utility. Therefore, in Chapter 
6, we examined whether CAR predicts (cardiovascular) events in patients with peripheral 
arterial disease. A total of 172 PAD patients were included, and we recorded cardiac and 
cerebrovascular events, mortality and clinical progression to percutaneous transluminal 
angioplasty or loss of patency during a 12-months follow-up. We found that patients with 
carotid constriction showed a four-fold higher risk for cardiovascular events and two-fold 
increased risk for clinical deterioration, even after adjustment for other risk factors. This 
indicates that CAR provides a simple, novel strategy to predict CV events and progression in 
PAD patients, which has stronger prognostic value than current techniques.
Chapter 7 summarizes, discusses, and explains the findings of these studies, and aims to 
provide recommendations and implications. We discuss future prospects, and provide 
perspective for future vascular health assessment.  
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SAMENVATTING
Hoofdstuk 1 geeft een introductie in een oude en nieuwe meetmethode van de endotheel- 
en vaatfunctie. Het eerste gedeelte van dit proefschrift richt zich op de oudere methode, 
bloedstroom-gemedieerde vasodilatatie (FMD), welke afhankelijk is van een hyperemische 
prikkel (na afknelling) en in hoeverre deze meting ontvankelijk is voor variabiliteit. 
In hoofdstuk 2 hebben we de reproduceerbaarheid van deze FMD meting onderzocht. Voor 
deze studie zijn 672 proefpersonen met herhaalde metingen geïncludeerd. Ongeveer 33% van 
de FMD metingen resulteerden in een excellente-tot-gemiddelde reproduceerbaarheid. We 
hebben enkele factoren geïdentificeerd die onafhankelijk de variatie beïnvloeden, waaronder 
aanwezigheid van hypertensie, een lagere rust FMD, een grotere basis vaatdiameter, een 
langere periode tussen herhaalde metingen en minder ervaring met het uitvoeren van 
de FMD. Toekomstige studies zouden deze factoren in overweging moeten nemen om de 
variabiliteit van de FMD te verminderen. 
Helaas vonden we ook dat een groot gedeelte van onze studiepopulatie een gemiddelde-
tot-lage reproduceerbaarheid toonden, ondanks dat alle geïncludeerde studies de door 
experts-opgestelde richtlijnen volgden. In hoofdstuk 3 onderzochten we de relatie tussen 
het volgen van de richtlijnen en de reproduceerbaarheid van de FMD. Hiervoor hebben we 
een meta-analyse uitgevoerd, met data van 27 studies, 48 groepen en 1537 proefpersonen. 
Wij vonden dat het volgen van de richtlijnen omgekeerd evenredig was met de meetfout. 
Het continu meten van de vaatdiameter, gebruik van automatische vaatwand detectie 
systemen en het gebruik van een probe-houder zijn essentieel voor het verbeteren van de 
reproduceerbaarheid van de FMD.
In het tweede gedeelte van dit proefschrift is een nieuwe meting geïntroduceerd, de carotis 
arteriële reactiviteit (CAR). Deze test meet de reactie van de carotis arterie (verwijding dan 
wel constrictie) na sympathische stimulatie (bijvoorbeeld de ijswater test, CPT, waarbij de 
linkerhand kort wordt ondergedompeld in ijswater om een sympathetische reactie uit te 
lokken). We hebben getracht het onderliggende fysiologische mechanisme te ontrafelen, 
welke terug te vinden zijn in de verschillende studies. Uiteindelijk hebben we de prognostische 
waarde van de CAR test bekeken in een patiëntengroep met perifeer vaatlijden, om de 
klinische waarde van de CAR verder te onderzoeken.
In hoofdstuk 4 hebben wij onderzocht of de coronair arterie (de gouden standaard om 
de vaatgezondheid te bekijken) en de carotis arterie hetzelfde reageren na sympathische 
stimulatie. Bij 50 jongere en 44 oudere proefpersonen hebben wij de CAR gemeten. 
Vervolgens hebben we de associatie tussen CAR en traditionele risicofactoren bekeken. 
Ten slotte hebben wij de vergelijkbaarheid tussen de carotis en coronair arterie bekeken. 
We vonden dat de carotis meer verwijdt in jongere proefpersonen (hogere CAR), dat 
proefpersonen zonder risicofactoren een hogere CAR hebben dan mensen met 2 of meer 
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risicofactoren en dat de CAR goed relateert aan de coronair arteriën. Dit impliceert dat de 
CAR een waardevolle techniek is om het cardiovasculaire risico te evalueren. 
In hoofdstuk 5 hebben we het onderliggende fysiologische mechanisme verder verkend. 
Hiervoor hebben we de reactie van de carotis op andere sympathische stimuli (ijswater 
test en negatieve druk), de rol van α
1
-receptoren (receptoren voor vasoconstrictie na een 
sympathische stimulatie) en de overeenkomst tussen de carotis en coronair arteriën bekeken. 
10 proefpersonen hebben beide testen uitgevoerd, waarbij tegelijkertijd de carotis en 
coronair arteriën zijn gemeten. Deze metingen werden herhaald terwijl alle proefpersonen 
α
1
-receptorblokkers hadden gebruikt. We vonden dat de carotis onderscheidend reageert op 
verschillende sympathische stimuli (dilatatie bij de ijswater test, constrictie bij de negatieve 
druk test), terwijl α
1
-receptoren alleen een rol spelen bij de ijswater test. Tot slot vonden 
we sterke overeenstemming tussen de carotis en coronair arteriën, wat duidt op sterke 
vergelijkbaarheid tussen beide vaten in reactie op sympathische stimuli.
In hoofdstuk 6 onderzochten we of de CAR test cardiovasculaire events (bijvoorbeeld een 
myocard infarct) kan voorspellen in patiënten met perifeer vaatlijden. In totaal zijn 172 
patiënten geïncludeerd. Gedurende 12 maanden hebben we het optreden van cardio/
cerebro vasculaire events, mortaliteit en klinische progressie gemonitord. We vonden dat 
patiënten met een CAR constrictie vier keer meer risico hadden op cardiovasculaire events 
en twee keer meer klinische achteruitgang, zelfs na correctie voor risicofactoren. Hieruit 
concluderen wij dat de CAR een simpele, nieuwe strategie is die cardiovasculaire events en 
ziekte progressie kan voorspellen in patiënten met perifeer vaatlijden.
Hoofdstuk 7 vat de resultaten van dit proefschrift samen, bediscussieert deze en tracht deze 
te verklaren. Ook geven wij aanbevelingen en implicaties van deze nieuwe test, waarmee wij 
ook een perspectief schetsen voor toekomstig vaatfunctie onderzoek. 
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PORTFOLIO
Name PhD candidate: ACCM van Mil
Department: Physiology
Graduate School: Radboud Institute for Health Sciences
PhD period: 1-5-2014 – 1-7-2017
Promotor(s): Prof. Thijssen, Prof. 
Hopman and Prof. Green
Co-promotor(s): Dr. Ellen Dawson
Year(s) ECTS
TRAINING ACTIVITIES
a) Courses & Workshop
- Liverpool John Moores University Vascular sonography summerschool 2014 1.5
- Radboudumc Introduction day 2015 0.5
- Radboud lnstitute for Health Sciences lntroduction course for PhD students 2015 1.5
- Vascular Function and Angiogenesis in Health and Lifestyle related disease 2015 5.0
- BROK (Basiscursus Regelgeving en Organisatie voor Klinisch onderzoekers) 2015 1.4
- Biometrics course 2015-2016 6.0
- Scientific Integrity 2016 0.6
- PhD Organisation Nijmegen, course InDesign 2016 0.5
- Management voor Promovendi 2016 3.0
- Education in a Nutshell 2016 3.0
b) Seminars & lectures
- Radboud Research Rounds 2014-2017 0.5
- Prof. Paul Thompson (Lecture: Can [too much] exercise hurt your heart?) 2015 0.1
- Prof. Duck-Chul Lee (Lecture: ‘Health benefits of physical activity & fitness:  
What type of physical activity is best for health?’)
2017 0.1
- Prof. Bo Fernhall (Lecture: Inflammation, exercise and arterial function) 2017 0.1
c) Symposia & congresses
- ARTERY Maastricht 2014 0.5
- Radboud Research Round – vascular damage theme (Oral) 2016 0.3
- Dutch Endothelial Biology Society, Biezenmortel (Oral) 2016 1.3
- Okanagan Cardiovascular and Respiratory Symposium, Canada (Study 
collaboration)
2016 1.3
- Radboud Into Frontiers (Poster) 2016 1.0
- RIHS PhD retreat (Oral) 2016 1.0
- European College of Sport Science, Essen (Oral) 2017 1.3
d) Other
- Vascular Damage theme meetings 2014-2017 0.5
TEACHING ACTIVITIES
e) Lecturing
- 5O103: Beweging en sturing (practica) 2014-2016 0.3
- HM03 - Clinical Exercise Physiology (Lectures, practica) 2015-2017 1.5
- Minor10 – Practica echografie 2016-2017 0.3
- 1Mbe1 – beweging (werkgroepen) 2016-2017 0.3
- LC circulatie-respiratie 2016-2017 0.6
- Echo practica demo carrousel afdeling 2014-2017 1.0
f) Supervision of internships / other
- Machteld van Erk (Master BMS) - Reproducibility of the carotid vasoreactivity 
test? 
2015 1.0
- Ralf Weijs (Bachelor BMW) -  The effect of lifelong exercise participation on 
the protective effect of ischemic preconditioning on brachial artery ischemia-
reperfusion injury in healthy older men
2015 1.0
- Frederieke van Oorschot (Honours student Dick Thijssen) – daily supervision 2015 0.3
- Nikki Bax (Master GNK Dick Thijssen) – daily supervision 2015 0.3
- Jelmer Wilbrink (Master GNK Dick Thijssen) – daily supervision 2016 0.3
- Thijs Kerstens (Honours student Dick Thijssen) – daily supervision 2016 0.3
TOTAL 38.2
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DANKWOORD
Nou, daar zit je dan, na 3 jaar ploeteren en direct doorgaan in een nieuwe functie, aan de 
eerste regels van je dankwoord. Het meest gelezen (en dus wellicht het belangrijkste?) stuk 
van het boekje. En een stuk gaat het worden, want wat hebben een hoop mensen met mij 
mee geleefd de afgelopen jaren. Samen met hen heb ik zware downs, maar gelukkig veel 
meer mooie ups meegemaakt. Want zo voelt promoveren wel een beetje, als een vrije val 
attractie, met grote hoogtes en diepe dalen. Ik had dit echt niet kunnen doen zonder de hulp 
en bijdrage van mijn collega’s, vrienden en familie.
Prof. Thijssen, Dick. Zonder jou had ik hier vandaag echt never nooit gestaan. Onze eerste 
directe samenwerking was tijdens de PhD round. Tijdens mijn stage in Cardiff kwam ik erachter 
dat ik de vaten en vaatmetingen toch echt heel leuk vond en ik zocht jou op om te vragen of 
je mij wilde begeleiden bij een promotietraject. Helaas, uiteindelijk hebben we de PhD round 
verloren, maar tijdens mijn diploma uitreiking hintte jij al op mooie dingen in het vooruitzicht. 
To be fair, dat is bij mij het ene oor in en andere uit gegaan en jouw belletje een paar weken 
later omtrent het TIFN project kwam voor mij dan ook als donderslag bij heldere hemel. 
Daarna heb jij er voor gezorgd dat mijn tijdelijke project kon worden uitgebreid naar een 
volledige promotie, in samenwerking met LJMU. Jouw passie voor onderzoek, je motivatie 
en manier van relativeren zijn enorm inspirerend en aanstekelijk. In de chaoot die ik ben/kan 
zijn, gaf jij richting en rust. Wanneer er deadlines gehaald moesten worden, kreeg ik mailtjes 
met feedback tot diep in de nacht. Dick, dank. Dank voor de kansen die je hebt gecreëerd, 
dank voor het mentorschap, en dank voor het vertrouwen dat je mij hebt gegeven. 
Maria, toen van mijn tijdelijke project een promotie werd gemaakt, werd ook jij steeds meer 
betrokken. In het begin moest ik je echt overtuigen van mijn projecten. Dank daarvoor! 
De kritische vragen die je stelde en hoe jij met een volledig andere invalshoek mij dwong 
om kritisch naar mijn project te kijken, hebben mij enorm gemotiveerd om er zelf steeds 
meer en meer uit te halen. Jij vond het altijd bijzonder hoe ik alle ballen in de lucht leek te 
houden, ook al waren ze soms misschien net een klein beetje van de grond. Je mateloze 
wetenschappelijke interesse en kennis zijn bewonderingswaardig. Maria, dank voor je 
kritische blik en bevlogenheid voor het onderzoek. Het heeft mij enorm veel geleerd. 
Danny, I know we haven’t discussed most articles in person, but you’ve played a significant 
role in my PhD project. I’ve once had the honour to meet you, the vascular physiology legend, 
and that afternoon is still well-printed in my brain. Thank you for all the constructive feedback 
and suggestions on my articles, whilst you were always at least a couple of oceans away. 
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Eric, I don’t know whether you expected to be in here somewhere, but I believe you deserve 
your own paragraph. Because if it wasn’t for you, I would have never dreamed of pursuing a 
PhD in the first place. Your enthusiasm on research, on basic physiology and the damn why-
question, have inspired me as a last-year master student. While we discussed science and life 
over beer, wine, cocktails and cheese, you made me believe that if you work hard enough, 
you can do anything. Please, whatever happens with science in Wales, or life in New York, or 
wherever you are, never change. It has always been, and will always be, a pleasure to discuss 
life with you, even better when there is Erdinger. 
Ellen, my most important co-promotor. In the end, I haven’t been based in LJMU for a longer 
period, but that never really mattered. Every time when I was in Liverpool, you’ve made me 
feel so welcome and appreciated. Thank you for your ability to put everything in perspective, 
and you constructive feedback on my papers. And next time when I’m in Liverpool, make sure 
you take public transport to LJMU, then we can finally go for that well-deserved pint at the 
Ship.
Michiel, al in het eerste jaar van mijn traject begon onze samenwerking en wat hebben we 
mooie dingen gepubliceerd sindsdien. Het moeten beoordelen van 200 patiëntendossiers 
was soms niet ideaal gepland, maar je was altijd bereid om mijn nieuwsgierige vragen te 
beantwoorden. Dank voor je prettige samenwerking. 
Het gehele TIFN en Maastricht Universiteitsteam, Arno, Peter, Marianne, Ronald, Koen, en 
Lorenzo, dank voor de fijne samenwerkingen en mogelijkheden tijdens mijn promotietraject. 
And also everyone from Liverpool John Moores University, Cardiff Metropolitan University 
and UBC Okanagan, thank you for all the measurements, discussions and awesome 
experiences. En uiteraard dank aan alle deelnemers aan de verschillende studies, zonder wie 
dit boekje niet mogelijk was geweest.
Promoveren is echt een zware klus, maar wel een klus die je samen doet. Graag wil ik (ruim) 
de tijd nemen om iedereen die mij de afgelopen jaren heeft geholpen/bijgestaan, met mij 
heeft gehuild en met mij heeft gelachen, bedanken. 
Nathalie, Joost, Femke, Thessa, Thalijn, Matthijs, en alle collega’s van ION en OSMO, 
bedankt voor al jullie gezelligheid op de afdeling. Milène, dankjewel voor je baan en wijsheid! 
Tim, dank voor je memes, humor en keep on RickRollin. Pascale, dank voor je luisterend oor 
en goede adviezen als weer eens alles in de soep loopt. En alle studenten die mij gedurende 
mijn promotie hebben bijgestaan (Yaïra, Ralf, Machteld, Jelmer, Frederieke en Thijs), 
dankjulliewel voor jullie bijdrage aan dit boekje. 
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Lisa, Thijs, Geert, Carlijn, Cindy, de nieuwe garde. Jongens, heel veel succes met jullie 
prachtige projecten. Het zijn mooie samenwerkingen en prachtige uitdagingen. Geniet ervan, 
het is voorbij voordat je er erg in hebt. 
Bregina, de absolute (lachende) kracht van de afdeling. Een stabiele factor, waar je altijd 
terecht kan voor een goed gesprek, of voor een heerlijk verhaal. Dank voor het prachtige kaftje 
van dit boek en alle wijze adviezen en goede gesprekken J Thijs, gedurende mijn promotie 
hebben wij eigenlijk bar weinig samengewerkt. Enorm leuk om nu met het onderwijs weer 
veel samen te werken. Jouw ambitie en motivatie werken aanstekelijk. Veel succes met al 
je komende projecten, studenten en natuurlijk je mooie gezin! Silvie, je wetenschappelijke 
kennis, kritische houding en organiserend vermogen zijn bewonderingswaardig. Heel veel 
succes met je onderzoeksprojecten in Wageningen en uiteraard ook met je prachtige 
(groeiende) gezinnetje.
Lando, Orlando, nu een tijdje bezig en ook niet meer weg te denken van de Fysiologie. Altijd 
in voor een geintje en je neemt jezelf ook niet al te serieus. Briljant hoe verwonderd jij kan 
zijn om niet-stadse of Arnhemse gebruiken. Veel succes met je mooie project! Eline, wat 
een rust en organisatie straal jij uit. Hoe jij jouw enorme project plant en uitvoert, verdient 
absoluut een applaus. Je werkt snoeihard voor je onderzoek en dadelijk weer terug de kliniek 
in voor je opleiding. Laat maar weten wanneer je begint met schrijven, dan kom ik met Disney 
muziek weer lekker bij jou op de kamer zitten! Hugo, the Boss. Wat krijg je mij gemakkelijk op 
de kast he. Je bent altijd in voor een geintje en ook super sportief als wij jou een keertje tuk 
hebben. Al is dat laatste niet heel vaak het geval. Heel veel succes met alle echometingen, 
echopack, op en neerfietsen voor Zazu en je boekje. Rebecca, Bex, mijn nieuwste roomie. De 
eigenlijke senior van de afdeling en samen met Bregina, die met de meest aanstekelijke lach. 
Met onderwijs hoef ik niet bij je aan te komen, maar je scherpe comments en klinische passie 
zijn fantastisch. Ondanks dat je bijna klaar bent, hoop ik nog heel veel filmpjes van Hannah te 
zien! Succes met de laatste loodjes, ik zal zorgen voor een extra Bounty. 
Esmeé, Es, Bakker(tje), #vetkleponderzoeker. Wij hebben ook niet lang bij elkaar op de kamer 
gezeten, maar wel lief en leed gedeeld. Dat deden we al toen jij nog student was op de 
afdeling, met een fles wijn. Nu ben jij de uitdaging aangegaan om ook een duaal project te 
doen in Liverpool. Met je enorme bevlogenheid voor het onderzoek en de mooie projecten 
die je al hebt gedaan, moet dat helemaal goed komen. Geniet van al je successen! Vincent, 
Vincenzo, Vince, Dr. Aengevaeren. Work hard, play hard. Ik ken weinig mensen die zo veel 
weten en hard werken als jij. Je staat altijd klaar voor een ander met metingen of voor 
onderwijs en ook discussieer je graag mee. Al wacht je met de discussies wel het liefste tot 
vrijdagmiddag 17u, voor de Aesculaaf. Vince, ik hoop dat wij nog veel wijnen gaan proeven 
samen! Succes met je prachtige high-impact project, jij komt er wel. 
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Coen Bongers, CB, balie Bongers, Koene Coen. Daar zitten we dan, beide ein-de-lijk klaar en 
nu dankwoorden schrijven. We kennen elkaar al lang en ik zei het al bij onze bachelorstage, 
van mij kom je niet meer af. Jij had als eerste je project bij Fysiologie, maar ik zat je altijd op 
de hielen. Het moest zo zijn dat wij beide aan de slag gingen bij Fysiologie. En nu ook voor het 
eerst roomies (dus nu mag ik genieten van het foute uur, waarvoor dank). Gelukkig vind je het 
onderwijs niet net zo leuk als de wetenschap! Heel veel succes met je komende projecten en 
uiteraard je Australië avontuur! Yvonne, Yfke, Yvo, druif, meis hoe heb ik je niet genoemd. Mijn 
allereerste pseudo-student! Vanaf het eerste moment al mijn extra werkende rechterhand, 
als ik zelf 2 linkerhanden had. En die heb ik regelmatig gehad, met excel, graphpad, en SPSS. 
Ging het niet over werk, dan waren we wel aan het ouwehoeren. Dat doen we nog en het 
liefst onder genot van kasteel Rouge en/of andere speciaal biertjes. Meis, succes met je 
awesome project! Dominique, Do, Ten Haaf. Mijn ex-roomie en pepermuntsupplier. Wat 
hebben we al een hoop slap gekletst toen we nog roomies waren, en wat kletsen we nog 
steeds heerlijk slap. Maar ik kan bij jou altijd terecht, ook voor een goed gesprek. Wel het 
liefste met witte wijn EN borrelnootjes. Je bent er maar druk mee, korfbal, carnaval, borrelen 
met alle collega’s, met alle familie, de fabriek en Daan. Veel succes met de laatste loodjes van 
jouw promotie. Ik zal er zijn om je aan te moedigen!
Martijn, Mister Maessen, Smaessie, Messias Maessen, Martie, Smartie, en ga zo maar door. 
Mijn maatje op de afdeling, wat zijn we lang roomies geweest. De afgelopen 2 jaar zat je veilig 
bij Thijs op de kamer waar je waarschijnlijk wat productiever was dan bij mij op de kamer. Hey, 
I just met you, and this is crazy, maar dat is alweer 7 jaar geleden. Wat hebben we een hoop 
meegemaakt, met als hoogtepunt natuurlijk jouw promotie (waar ik je paranimf mocht zijn, 
heuj!). Ik ben heel blij dat je je eigen weg gaat volgen, met je nieuwe uitdaging bij VGZ. Ik ga je 
enorm missen, maar anders bel ik wel weer vanuit de auto als je in de trein zit. En uiteraard, 
de groetjes aan Maud!
Niet alleen collega’s hebben mij door de afgelopen jaren heen geloosd, maar alle afleiding 
van vrienden hebben daar ook enorm aan bijgedragen. Sander, dank voor je wijze adviezen 
en verhalen. Ik ben heel blij dat ik altijd bij jou even alle sores kwijt kon. Nu jouw boekje nog! 
Laura, dank voor je luisterend oor, wijn en Harry Potter, wanneer gaan we verder? David (The 
best man), Guido, Maarten, Cees, Machiel, Anne, Paul en Marga, dank jullie wel voor alle 
nonsens, feestjes, spelletjes, weekendjes weg, slappe klets en goede verhalen. Dank voor een 
super studententijd!
Renée, Linda en Nicole, mijn paranimfen! Wat ben ik blij en trots dat ik deze dag met jullie 
mag delen. Nicole (Nol/Nolbol/Snollie), we kennen elkaar al zo lang (veel langer dan 7 jaar) en 
hebben al zo veel meegemaakt. Dank dat je er altijd bent en mijn geouwehoer wilt aanhoren. 
Renée, chocolademonster en mama-in-spé, ik weet dat David en ik je soms helemaal gek 
kunnen maken, dank voor je geduld en je heerlijke relativering. Ik ben heel blij dat ik altijd bij 
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je terecht kan. Linda (Bandi), het organisatorische talent en mijn naamgenoot (Heuj!). Dank 
voor al je gezelligheid en goede gesprekken. Het is heerlijk bij je te kunnen venten en klagen! 
Op naar het volgende feestje!
Mijn sinds recentelijk officiële schoonfamilie, hartelijk dank voor het warme bad waarin ik 
door jullie terecht kwam. Bedankt voor alle gezelligheid!
Rob en Essie, broer en schoonzus, dank jullie wel voor Netflix de afgelopen jaren J Veel 
succes met jullie mooie huisje en toekomst plannen. Komen jullie binnenkort weer eens eten?
Mama en papa, wat ben ik enorm trots en dankbaar dat ik jullie dochter ben. Dank voor de 
prachtige kansen die jullie mij hebben gegeven. Jullie hebben mij altijd aangemoedigd om 
mijn dromen na te jagen en kijk waar dat mij heeft gebracht. Dank voor jullie eeuwige geduld, 
rust, steun en liefde. 
Dennis, mijn alles. Je hebt mijn promotietraject heel actief mee beleefd en mij enorm 
gesteund. Jij houdt mij met 2 benen op de grond, als ik weer eens een keer laat thuis was of 
deadlines niet haalde. En, zoals altijd, was promoveren met jou een stuk leuker. Want schatje, 
jij maakt immers alles leuker. Ik hou van je. 
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Anke van Mil werd op 27 oktober 1989 geboren te ’s-Hertogenbosch. Na haar middelbare 
schoolperiode aan het Rodenborch College te Rosmalen, begon zij in 2008 met de opleiding 
Biomedische Wetenschappen, met als specialisatie Human Movement Sciences, aan de 
Radboud Universiteit te Nijmegen. Tevens heeft Anke de aanvullende master getiteld 
‘Reflections on Science; the wider implications of cognitive neuroscience’ aan de Radboud 
Honours Academy gevolgd. Tijdens haar eerste onderzoeksstage kwam zij in aanraking met 
de afdeling Fysiologie. Onder begeleiding van Dr. Thijs Eijsvogels en Dr. Walter ter Woerds 
bekeek zij de effecten van warmte op de peri- en postoperatieve uitkomstmaten bij patiënten 
met totale heupvervangingen. In het afstudeerjaar van haar master heeft zij voor negen 
maanden in Cardiff, Wales gestudeerd en gewoond. Onder begeleiding van Dr. Eric Stöhr en 
Prof. Dick Thijssen heeft zij de effecten van warmte op hart- en vaatfunctie onderzocht. Deze 
stage heeft uiteindelijk de basis gelegd voor haar interesse in vaatfunctie metingen, waar 
haar verdere promotietraject zich grotendeels op heeft gericht. In mei 2014 is zij gestart 
met een onderzoeksproject in een samenwerkingsverband tussen de afdeling Fysiologie 
van het Radboudumc en de afdeling Humane Biologie van de Maastricht Universiteit. Dit 
project is verder uitgebreid tot een duaal promotietraject in een samenwerking tussen het 
Radboudumc en Liverpool John Moores University, het Verenigd Koninkrijk. Tijdens deze 
periode werden verschillende studies uitgevoerd naar de reproduceerbaarheid van de flow-
gemedieerde vaatfunctie meting. Tevens is in deze periode de basis gelegd voor een nieuwe 
vaatfunctie test, de carotis arteriële vasoreactiviteit. De focus van het laatste jaar van haar 
promotie lag op de klinische relevantie en toepassing van deze nieuwe test. Tijdens haar 
periode als promovendus heeft zij meerdere bachelor- en masterstudenten begeleid en was 
zij betrokken bij het onderwijs van Geneeskunde en Biomedische Wetenschappen aan de 
Radboud Universiteit. Momenteel is Anke werkzaam op de afdeling Fysiologie als docent en 
studentcoördinator Fysiologie. 
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